Ammonia, infection and inflammation in hepatic encephalopathy. by Shawcross, D.L.
2809586172
REFERENCE ONLY
UNIVERSITY OF LONDON THESIS
Degree  Year  ^ 0   Name of Author  C C-OS^
COPYRIGHT
This is a thesis accepted for a  Higher Degree of the University of London.  It is an 
unpublished  typescript  and  the  copyright  is  held  by  the  author.  All  persons 
consulting this thesis must read and abide by the Copyright Declaration below.
COPYRIGHT DECLARATION
I  recognise  that  the  copyright of the  above-described  thesis  rests with  the  author 
and that no quotation from it or information derived from it may be published without 
the prior written consent of the author.
LOANS
Theses  may  not  be  lent  to  individuals,  but the  Senate  House  Library  may  lend  a 
copy to approved libraries within the United Kingdom, for consultation solely on the 
premises  of  those  libraries.  Application  should  be  made  to:  Inter-Library  Loans, 
Senate House Library, Senate House, Malet Street, London WC1E 7HU.
REPRODUCTION
University  of  London  theses  may  not  be  reproduced  without  explicit  written 
permission from  the Senate  House  Library.  Enquiries should  be addressed  to the 
Theses Section of the Library.  Regulations concerning reproduction vary according 
to the date of acceptance of the thesis and are listed below as guidelines.
A.  Before 1962.  Permission  granted  only upon  the prior written  consent of the 
author. (The Senate House Library will provide addresses where possible).
B.  1962-1974.  In  many cases the author has agreed  to permit copying  upon
completion of a Copyright Declaration.
C.  1975-1988.  Most  theses  may  be  copied  upon  completion  of  a  Copyright
Declaration.
D.  1989 onwards.  Most theses may be copied.
This thesis comes within category D.
This copy has been deposited in the Library o f_______f  I  L-
This copy has been deposited in the Senate House Library, 
Senate House, Malet Street, London WC1E 7HU.JLmmonia, Infection and 
Inflammation in Hepatic 
(Encephalopathy
(By
(De66ie L. Shaw  cross
1 Thesis submitted  for the degree of  (Doctor of FhiCosophy
Liver FaiCure (Jroup 
Institute ofJCepatoCogy 
(Royal Free  Vniversity CoCCege London Medical  School 
"University CoCCege London
Submitted  September 2006 
(RevisedJune 2007UMI Number: U592373
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted.  Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U592373
Published by ProQuest LLC 2013.  Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved.  This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml  48106-1346‘There are in fact two things, science and opinion; the 
former 6egets knowledge, the latter ignorance ’
!Hippocrates‘This thesis is dedicated to ad the mem6ers and 
coda6orators of the Liver TaiCure Qroup, past and 
present, whose support and  friendship w id never Se
forgotten.I declare that the work presented in this thesis is my own and that no conflicts of 
interest exist.
4ABSTRACT
For over a century, we have known that ammonia is important in the pathogenesis 
of hepatic  encephalopathy.  Studies  in  patients  with  acute  liver  failure  have  shown  rapid 
progression  to  severe  encephalopathy  in  those  patients  with  evidence  of  a  systemic 
inflammatory  response,  suggesting  a  possible  link  between  inflammation  and 
encephalopathy.  In  view  of the  growing evidence  to  support  the  role  of inflammation  in 
increasing  the  susceptibility  of  the  brain  to  the  effects  of  hyperammonemia  in  liver 
disease,  3  hypotheses  were  explored:  1:  Inflammation  and  infection  are  important  in 
hepatic encephalopathy. 2:  Inflammation and infection act synergistically with ammonia. 
3: Ammonia makes the immune system more susceptible to infection.
In  the  first  of  2  clinical  studies,  inflammation  was  shown  to  be  an  important 
determinant of the presence and severity of minimal  hepatic encephalopathy.  In  a second 
study, significant deterioration of neuropsychological test scores in patients with cirrhosis 
following  induced  hyperammonemia  during  the  inflammatory  state,  but  not  after  its 
resolution,  suggested  that  inflammation  may  be  important  in  modulating  the  cerebral 
effect  of  ammonia  in  liver  disease,  supporting  the  first  hypothesis.  Ammonia  and 
inflammation  were  shown  to  be  synergistic  in  the  bile  duct  ligated  rat  which  showed 
increased brain water and astrocyte swelling exacerbated  by endotoxin  and  accompanied 
by  a  rise  in  nitric  oxide  and  brain  nitrotyrosine,  but  not  in  plasma  ammonia,  suggesting 
nitric  oxide  may  play  an  important  synergistic  role  in  the  pathogenesis  of  hepatic 
encephalopathy.
Ammonia  was  shown  to  impair  neutrophil  function  by  reducing  phagocytosis, 
inducing  spontaneous  respiratory  burst  and  cell  swelling.  The  p38'M APK  pathway  was 
shown to be important and a p38‘M APK agonist prevented neutrophils  from swelling in the 
presence of ammonia and  improved phagocytosis.  While cultures of muscle  cells were  a 
potentially  interesting  direction  to  take  to  investigate  the  effect  of inflammation  on  the 
muscle  uptake  of  ammonia,  unfortunately  the  resulting  data  demonstrated  a  low 
glutamine  synthetase  activity.  In  conclusion,  these  studies  illustrate the  important  factors 
that  modulate  the  manifestation  of symptoms  of hepatic  encephalopathy  in  cirrhosis,  the 
most  important  of  which  is  the  synergistic  role  of  inflammation  and  ammonia. 
Furthermore,  the  ammonia-induced  impairment  of  neutrophil  function  may,  in  part, 
account  for  the  increased  susceptibility  to  infection  found  in  patients  with  cirrhosis.CONTENTS
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261.1  THE FOUNDATION STONES OF HEPATIC
ENCEPHALOPATHY
The word ammonia was derived  from  Amen,  an  Egyptian God  described  in 
Egyptian mythology  (1) (Figure  1.1).  To the Greeks,  Amen was  known as Ammon 
whose temple and oracle were situated at an oasis in the Libyan desert near Memphis. 
Camel  urine  was  collected  in  a  cesspool  close  to  the  temple  and  it  was  widely 
believed  that  "man  and  all  life  rose  spontaneously  from  a  sea of ammonia";  camel 
urine,  soot  and  sea  salt  were  heated  together  to  from  sal  ammoniac  (or  "salt  of 
Ammon") (2).
Figure 1.1
Image obtained from aol Egypt Art images
Amen - Egyptian  Mwliical Cod
27Heating of sal ammoniac with alkali  resulted  in the  production  of ammonia 
gas leading the Swedish chemist Tobem Olaf Bergman to coin the term "ammonia” in 
1782.  Ammonia was  subsequently  widely  used  as the  active  ingredient of smelling 
salts used to revive ladies of that period who were "faint of heart and light of head".
In  the  1890's,  Marcel  Nencki  was  chief chemist  at  the  Imperial  Institute  of 
Experimental Medicine in St Petersburg. Ivan Pavlov was a physiologist in the same 
institution. Pavlov was awarded the Nobel Prize in 1904 for developing the concept of 
the ‘conditional reflex’ in the classic experiment in which he trained a dog to salivate 
at  the  sound  of  a  bell.  Pavlov  was  a  great  manager  and  thinker  rather  than  an 
experimentalist  per  se,  and  coordinated  a  hugely  successful  laboratory  enterprise 
nicknamed ‘Pavlov’s Physiology Factory’. (3) But as is often the case in science, the 
contribution of Nencki  in the development of this hypothesis was overshadowed by 
the  more  well-renowned  and  established  Ivan  Pavlov.  Nevertheless,  the  ‘Nencki 
Institute of Experimental Biology’ was set up in  1918 in Poland and stands in honour 
to this great man’s work where neurobiology and biochemistry research continues on 
even to this day. (Figure 1.2).
Marcel Nencki 
1847  1901
Ivan Pavlov 
1849  1936
Figure 1.2
Nencki image obtained from Bioanalytical.com calendar 2000.
Pavlov image obtained from Twisted History (Copyright 2000 Armour Van Horn).
28Their  first  published  collaborative  work  in  1893  described  the  physiological 
consequences  of a  portacaval  shunt  in  dogs,  a  surgical  procedure  first  described  by 
Eck in  1879 (‘Eck's fistula’). (4) Such dogs developed neurobehavioral changes in  10 
days  to  6  weeks  post-surgery;  symptoms  included  aggression,  irritability,  ataxia, 
convulsions  and  coma.  Symptoms  worsened  after  feeding  of  meat  but  not  after 
ingestion  of  milk  or  bread  leading  the  investigators  to  coin  the  phrase  "meat 
intoxication  syndrome".  They went  on  to perform  nitrogen  balance  studies  in  which 
they discovered an excess of "carbamin saere" (carbamic acid [H2NC(=0 )0 H]) in the 
urine. (5) Carbamic acid is a hypothetical acid that exists only in the form of its esters 
and  salts,  mainly  the  salt  ammonium  carbamate.  Subsequently  they  showed  that 
normal dogs administered  "carbamin saere"  developed neurobehavioral  symptoms in 
a  dose-dependent  fashion.  Portacaval  shunted  dogs  given  relatively  small  doses  of 
"carbamin  saere"  developed  profound  neurobehavioral  changes  associated  with 
increased  urinary  ammonia  excretion.  Similar  findings  were  observed  following  a 
meal  of meat.  They concluded  that  ammonia  is metabolized to urea by the  liver but 
this  process  is  impaired  in  dogs  with  a  portacaval  shunt.  Studies  in  the  Pavlov 
laboratory  were  repeated  in  1896  (6)  and  the  following  is  a  copy  of their  original 
abstract  published  in  german  in  The  Archives  of  Experimental  Pathology  and 
Pharmacology followed by the English translation:
29ORIGINAL ABSTRACT FROM THE PA VLOV LABORATORY
Die  nachfolgenden  Untersuchungen  bilden  eine  Vervollstdndigung  und  bis  zu 
gewissem Grade einen Abschluss der im XXXII.  Bande des Archives von M.  Hahn,  O. 
Massen,  M.  Nencki  und J.P  Pawlow  publicirten  Untersuchung  iiber  die  Eck'sche 
Fistel zw'ischen  der  unteren  Hohlvene  und  der  Pfortader  und  ihre  Folgen  fur  den 
Organismus.  Wir zeigten dort,  dass nach  erfolgreicher Anlegung der  Venenfistel bei 
den  Hunden  friihestens  nach  10  Tagen,  meistens  erst  nach  einigen  Wochen  sich 
charakteristische  Krankheitssymptome  einstellten,  wobei  wir  folgende 
Stoffwechselveranderungen constatirten:
1.  Eine  Verminderung  der  Harnstoffausscheidung  bei  Hunden,  denen  die 
Venenfistel angelegt und ausserdem die Leberaterie unterbunden war.
2.  Eine vermehrte Ammoniakausscheidung im Ham und Unvermogen aus der in
den Magen eingefiihrten Carbaminsdure Harnstoff  zu bilden.
3.  Die  willkiirliche  Hervorrufung  der  Vergiftungssymptome  durch  reichliche 
Zufuhr stickstoffhaltiger Nahrung oder Ammoniaksalzen.
4.  Eine Vermehrung der Harnsaiire im Ham.
30ENGLISH TRANSLATION
The following  investigations  complete  and,  to  a  certain  degree,  conclude  the 
study, published in  Vol.  XXXII of the Archives,  by M.  Ham,  O.  Massen,  M.  Nencki 
and J.P Pavlov on an Eck ’ s fistula between the inferior vena cava and the portal vein, 
and its consequences for the organism.  There we demonstrated that, after successfully 
constructing the venous fistula in dogs,  characteristic disease symptoms occurred at 
the  earliest  10  days,  but  more  often  after  several  weeks,  which  resulted  in  the 
following metabolic changes:
1.  A decrease of urea excretion in dogs in which the fistula had been constructed 
and the hepatic artery had been ligated.
2.  An increased excretion o f ammonia in the urine and an inability to form urea 
from carbamic acid which had been infused into the stomach.
3.  The arbitrary inducement of symptoms of  poisoning through a plentiful supply 
o f nitrogen-containing food or of  salts of ammonia.
4.  An increase of uric acid in the urine.
31A  summary  of the  results  of each  of these  original  experiments  translated  from  the 
1896  publication  (6)  to  include  a  calculation  of the  blood  ammonia  (mmol/L)  are 
shown in Table 1.1  (7)
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32Table 1. Continued
Expt
no.
Experimental
condition
Time after  Organ/blood vessel 
Animal  eating (h)  measured
Blood ammonia 
(mmol/***!)
Tissue ammonia 
(mg/100 g)
14 2-day fast Dog Gastric mucosa 21.5
Intestinal  mucosa 16.2
Muscle 4.6
15 Vegetables Rabbits Gastric mucosa 8.5
Gastric contents 3.2
Liver 4.2
Muscle 5.3
Carotid artery 0.85
16 Hay Sheep Liver 13.9
Kidney 8.6
Muscle 3.5
Ported vein 2.01 5.9
Inferior vena cava 1.77
Carotid artery 0.67
Brain white/grey
17 Hay Horse Matter 5.9/8.3
Liver 21.6
18 Pe formed by Prof Cybulski Portal vein blood flow 2.35-2.7 cc/s(9090cc/h)
in Cracow
19 Oesophagostomv and Dog Gastric mucosa 25.69
gastrostomy Gastric juice 2.44
3.35
20 Portacaval fistula Dog Carotid artery
Gastric mucosa 42.6
Liver 20
Muscle 15.6
Brain 20.9
Kidneys 19.2
Urine 127.42Nencki  and  Pavlov  were  able  to  conclusively demonstrate that  in  the  fasting 
state, arterial ammonia was unchanged but following a high protein meal the ammonia 
in the portal vein (and its tributaries) rose 3 - 4  fold higher than that of the systemic 
circulation. The ammonia content of the blood and tissues depended on protein intake 
(higher  after  meat  than  vegetable  protein).  In  addition  to  the  liver,  all  organs,  in 
particular  the  muscles  had  higher  ammonia  contents  than  blood  from  the  systemic 
circulation.
In  the portacaval  shunted dog,  the  arterial  ammonia only  rose after a protein 
meal  and  this  was  accompanied  by  increased  urinary  excretion  of ammonia.  After 
ammonia ingestion, the dog became comatose and died. This was associated with the 
arterial ammonia concentration approaching that normally found in the portal vein and 
the  ammonia  content  of the  brain  was  four times  that  of normal  which  led  them  to 
attribute  the  behavioural  symptoms  to  ammonia.  This  is  likely  to  be  the  first  ever 
description  of  a  link  between  ammonia  and  the  different  stages  of  hepatic 
encephalopathy, progressing from full wake fullness through to stupor to coma.
Interestingly,  they  also  measured  the  ammonia  content  within  the  gastric 
mucosa and intestinal mucosa and gastric juice. They showed that even in a prolonged 
fasted  state the ammonia content within  the gastric mucosa was high.  They  found  it 
difficult to interpret these findings at the time but in the light of current research these 
early  observations  were  also  highly  significant.  This  may  be  related  to  the  fact  that 
ammonia  inhibits gastric  acid  secretion  and  may  be  important  in  its modulation,  (8) 
but could also be related to the fact that over 80% of dogs are infected with H. pylori, 
an  organism  known  to  hydrolyse  urea  to  produce  ammonia  (9).  Although  recent 
studies (10) suggest that the  H.  pylori  infection  is  not a  major contributing  factor to 
fasting  blood  ammonia  levels  or  parameters  assessing  minimal  hepatic
34encephalopathy in cirrhosis, this may account for their findings, but could also signify 
that  the gastric  mucosa  is  a passive  ammonia  trap  from  the  blood  rather than  being 
obtained directly from the food.
351.2  INTERORGAN AMMONIA METABOLISM
Recent studies have complemented the work of Nencki and Pavlov, suggesting 
that  the gut produces  ammonia which  is  metabolised  in the  liver and  that  almost  all 
organ systems are involved in ammonia metabolism (Table  1.2).
Early clinical and experimental literature suggested that colonic bacterial flora is 
the  main  source  of ammonia  production  in  the  body.  (11)  Colonic  bacteria  produce 
ammonia by splitting urea and possibly amino acids. (12) However, this hypothesis does 
not  explain  hyperammonemia  and  hepatic  encephalopathy  in  germ-free  dogs  with  a 
portacaval shunt, (13) the high portal-venous ammonia concentration in germ-free rats or 
hyperammonemia in germ-free hepatectomized rats. (14) The alternative explanation is 
that  hyperammonemia  in  germ-free  animals  is  the  result  of intestinal  breakdown  of 
amino acids, especially glutamine. (15) The intestines have a high glutaminase activity, 
predominantly located in the enterocytes, and only a little glutamine synthetase activity, 
making it a major glutamine-consuming organ.
In  1960, Owen et al. (16) demonstrated that the kidney is an important source of 
blood  ammonia  in patients with  liver disease,  and  Webster and Gabuzda  in  1958  (17) 
demonstrated  that  ammonia  was  taken  up  by  the  muscle  and  brain  in  hepatic  coma. 
Lockwood  et  al.  (18)  were  then  able  to  confirm  the  initial  finding  of Nencki  that 
ammonia  is  metabolised  in muscle.  Owen  et al.  (19)  and  Dejong et al.  (20) were  then 
able  to confirm  Nencki’s  initial  observation  that  ammonia  is  raised  in  the  kidney  in  a 
portacaval shunted animal model.  Olde Damink et al. (21) determined the contribution 
of  the  main  ammonia  producing  and  consuming  organs  to  whole  body 
ammoniagenesis.
36Table 1.2
The translation of the different pathophysiological observations of 
Nencki and Pavlov into actual therapy of Hepatic Encephalopathy.
A.  Interorgan Ammonia Metabolism
Nencki, Pavlov, Zaleski Observation: Current/Proposed
Treatment:
1. Portal venous ammonia is greater than arterial ammonia. Lactulose and 
antibiotics
2. Ammonia is metabolised in the muscle. L-omithine L- 
aspartate
3. The ammonia concentration is raised in the gastric mucosa 
even in the fasting state.
?? H. Pylori 
eradication therapy
4. Ammonia is raised in the kidney of the portacaval shunted 
dog compared to a healthy one.
Volume Expansion 
Gut Lavage
B.  Animal Behaviour and Brain Ammonia
Nencki, Pavlov, Zaleski Observation: Proposed
Mechanisms:
C u rren t/Proposed 
Treatment:
1. The blood brain barrier ammonia 
concentration is four times as high as that 
in the systemic circulation.
2. Similar arterial concentrations cause 
HE in portacaval shunted dogs, but not in 
control animals.
1. Direct ammonia 
toxicity (cerebral 
energy failure).
-
2. Astrocyte 
swelling.
Hypothermia
3. Ammonia- 
glutamine-brain 
swelling hypothesis.
Mannitol 
Hypertonic saline
4. Altered gene 
expression.
Hypothermia
5. Increased cerebral 
blood flow.
Hypothermia
37Fasted,  metabolically  stable  patients  with  cirrhosis  who  underwent  transjugular 
intrahepatic  portosystemic  shunt  (TIPSS)  portography  were  studied.  The  results 
suggested that hyperammonemia was mostly due to portosystemic shunting and renal 
ammonia  production.  Skeletal  muscle  removed  more  ammonia  than  liver.  However, 
the amount of nitrogen that was taken up by skeletal muscles in the form of ammonia 
was much less than the amount of nitrogen that was released in the form of glutamine. 
Glutamine released from skeletal muscle can be taken up in the portal drained viscera 
and  in  the kidneys,  where  it can  be metabolised  to ammonia,  thereby  abolishing the 
effect  on  muscle  ammonia  uptake  on  whole  body  ammonia  removal.  Increased 
hepatic urea synthesis, urinary ammonia excretion, and probably increased peripheral 
breakdown of arginine were the only ways in which the body removed ammonia.
Upper  gastrointestinal  bleeding  in  cirrhosis  is  associated  with  enhanced 
ammoniagenesis.  Olde  Damink  et  al.  (22)  also  reported  the  results  of a  study  to 
evaluate  interorgan  metabolism  of  ammonia  following  a  ‘simulated’  upper 
gastrointestinal  bleed  by  the  administration  of an  amino  acid  solution  that  mimics 
haemoglobin amino acid composition  in patients with cirrhosis and a TIPSS.  During 
the simulated bleed arterial concentrations of ammonia increased significantly. There 
was  no  change  in  ammonia  production  from  the  portal  drained  viscera  but  renal 
ammonia production increased  6-fold. In contrast to an unchanged ammonia removal 
by  the  liver,  a  significant  increase  in  muscle  ammonia  removal  was  observed.  In 
another  study,  cirrhotics  with  an  acute  upper  gastrointestinal  bleed  that  underwent 
TIPSS  insertion  were studied.  Ammonia was only produced by the  kidneys and  not 
by  the  splanchnic  area,  suggesting  that  enhanced  renal  ammonia  release  played  an 
important role in the hyperammonemia that followed an upper gastrointestinal  bleed 
in  patients  with  cirrhosis.  During  the  hyperammonemic  state,  the  muscle  was  the
38major site of ammonia removal. (22) Figure  1.3 illustrates the inter-organ trafficking 
of ammonia in a normal individual and one with cirrhosis.
Some  50  years  later  after  Nencki  and  Pavlov’s  initial  observation  in  dogs, 
Gabuzda et al.  (23) noted that patients with  cirrhosis and ascites treated with  cation- 
exchange  resins  that  absorbed  sodium  but  released  ammonium  ions  developed 
episodic  hepatic  encephalopathy.  Phillips  et  al.  (24)  then  went  on  to  describe  the 
behavioural alterations and a syndrome of impending hepatic coma in cirrhotics given 
certain  nitrogenous  substances.  The  severity  of  hepatic  encephalopathy  was  then 
shown to broadly relate to the blood ammonia level in 2 large studies. (25;26)
39Inter-organ trafficking of Ammonia
Normal Cirrhosis
Ammonia mmoma
Glutamine Glutamine
Figure 1.3 
Inter-organ trafficking of ammonia in health and in cirrhosis
In  healthy  individuals,  the  liver  removes  ammonia  by  detoxification  into  urea.  In 
patients  with  cirrhosis,  the  metabolic  capacity  of  liver  is  reduced,  resulting  in 
hyperammonemia.  The  muscle  then  becomes  an  important  organ  of  ammonia 
detoxification by trapping it in glutamine.  Glutamine acts as a temporary buffer that 
can both regenerate ammonia in the enterocytes and excrete ammonia via the kidneys.
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Figure 1.4
The cell that is most important in the pathogenesis of hepatic encephalopathy  is the 
astrocyte. This diagram illustrates that acute and chronic liver dysfunction both result 
in  increased  brain  water and  that  an  acute  insult  on  a  background  of chronic  liver 
disease  can  result  in  acute  cerebral  oedema  and  raised  intracranial  pressure  (NH3:  
ammonia; ICP:intracranial pressure).
421.4  NEUROPATHOLOGY
In  acute  liver  failure,  astrocytes  swell  and  patients  develop  cytotoxic  brain 
oedema  (Figure  1.5a).  This  observation  has  been  replicated  in  cultured  astrocytes 
exposed  to high concentrations of ammonia.  (32)  In chronic  liver disease, astrocytes 
show  the  characteristic  morphological  features  of Alzheimer  Type  II  astrocytosis. 
Astrocytes  exhibit  a  large  swollen  nucleus,  prominent  nucleolus,  margination  of the 
chromatin  pattern  and  marked  enlargement  of  the  cytoplasm  associated  with  a 
proliferation  of cytoplasmic  organelles  which  has  also  been  replicated  in  astrocytes 
exposed chronically to ammonia.  (33) (Figure  1.5b) There is also an alteration in the 
expression  of  key  astrocytic  proteins  including  an  increase  in  ‘peripheral-type’ 
benzodiazepine  receptors,  (34)  a  decrease  in  glutamate  transporters  (35)  and  a 
decrease in glial acidic fibrillary protein. (36)
The  central  nervous  system  neurovascular  unit  is  a  dynamic  structure 
consisting  of vascular endothelial  cells,  pericytes,  and  closely juxtaposed  astrocytes 
and  neurons.  Contact  and  communication  between  these  cells  modulates  cerebral 
blood flow and influence permeability properties of the blood brain barrier. (37) The 
blood brain barrier remains anatomically intact in hepatic encephalopathy but studies 
using  positron  emission  tomography  reveal  an  increase  in  the  permeability-surface 
area  to ammonia with  increasing severity  of disease.  (38)  A  recent  study has  shown 
that the removal of astrocytes from culture resulted in increased permeability to small 
tracers  across  the  brain  endothelial  cell  monolayer  and  an  opening  of  the  tight 
junctions  which  was  not  accompanied  by  the  loss  of tight junction  proteins  such  as 
claudin and occludin. (39)
43(a)
Figure 1.5
(a)  Electron micrograph of the brain from a patient dying from acute liver failure 
showing a swollen astrocyte (A) (M:mitochondria).
(b) Histopathology  of  the  brain  from  a  patient  dying  from  cirrhosis  showing 
evidence  of type  II  astrocytosis  (Alz)  and  a  normal  neuron  (n)  from  Kato, 
Hughes, Keays & Williams,  1992. (40)
441.5  PATHOGENESIS OF HEPATIC ENCEPHALOPATHY
Ammonia  has  been  thought  to  be  central  in  the  pathogenesis  of  hepatic 
encephalopathy  for  the  past  100  years  and  most  of the  current  therapies  are  based 
around  modulating  the  circulating  levels  of  this  neurotoxin.  Disturbances  in 
neurotransmission  due  to  increased  y-aminobutyric  acid  (GABA)  (increased 
neuroinhibition) (41), reduced glutamate (reduced neuroexcitation) (42) and increased 
endogenous  benzodiazepines  and  neurosteroids  (43;44)  have  been  thought  to  be 
important but current data suggest that at least some of these effects may be mediated 
by ammonia. (45) Altered cerebral blood flow is thought to be important but it is not 
clear  whether  this  is  mediated  through  ammonia  or  secondary  to  superimposed 
inflammation.  There  is  emerging  literature  suggesting  that  inflammation  and  its 
mediators may be important in the pathogenesis of hepatic encephalopathy.
1.5.1  THE AMMONIA HYPOTHESIS
Important direct  evidence  showing  that  ammonia  is  taken  up  by  the brain  in 
patients  with  liver  disease  and  hyperammonemia  was  provided  by  Lockwood  et  al. 
(46)  Using  positron  emission  tomography  with  I 3N-Ammonia,  he  elegantly 
demonstrated  that  uptake  of  ammonia  into  the  brain  of  patients  with  hepatic 
encephalopathy  was  significantly  higher  than  in  healthy  volunteers  and  that  the 
arterial  concentrations of ammonia may  increase the uptake of ammonia  in the brain 
through an increase in the permeability of the blood brain barrier to ammonia. (38) In 
experimental  animals with  acute  liver failure,  brain  ammonia  flux  may be up  to 45- 
fold higher than normal.  (47) These observations support  those  in  acute  liver failure
45patients where arterial ammonia levels of >150 pmol/L predict a greater likelihood of 
dying from brain herniation. (48)
1.5.1.1 AMMONIA-GLUTAMINE BRAIN SWELLING HYPOTHESIS
In  the presence of liver dysfunction,  urea  synthesis is  impaired and the brain 
acts  as  a  major  alternative  ammonia  detoxification  pathway.  Astrocytes,  which 
provide  physical  and  nutritional  support  for neurons  also  eliminate  ammonia  by  the 
synthesis of glutamine through amidation of glutamate. Accumulation of glutamine in 
astrocytes,  induced  by  hyperammonemia,  produces  osmotic  stress  and  causes  the 
astrocytes  to  swell.  (49)  Evidence  of an  increase  in  brain  water  in  minimal  hepatic 
encephalopathy  has  been  provided  in  humans  through  studies  using  magnetic 
resonance  imaging  which  show  decreased  magnetization  transfer  ratio  indicating 
increased brain water. This was shown to correlate with neuropsychological  function 
and  the  abnormality  was  reversed  by  liver  transplantation.  (50)  More  recently, 
hyperammonemia  induced  by  the  oral  administration  of an  amino  acid  solution  in 
patients  with  cirrhosis  was  shown  to  result  in  significant  deterioration  in 
neuropsychological  function, an  increase in brain glutamine levels and a reduction in 
the  magnetic  transfer  ratio  suggesting  an  increase  in  brain  water.  (51)  This  study 
provided further support for the ammonia-glutamine brain water hypothesis of hepatic 
encephalopathy.  The  effect  of hyperammonemia  is  likely  to  be  determined  by  the 
ability  of the  astrocytes  to  maintain  osmotic  equilibrium  by  losing  osmolytes  like 
myo-inositol  in  response  to  the  ammonia-induced  increase  in  glutamine.  (52) 
Therefore, patients with co-existing hyponatremia (53) or chronic hyperammonemia,
46which resulted in depleted myo-inositol stores, may be more sensitive to the effects of 
induced hyperammonemia (Figure  1.6.1  &  1.6.2).
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Figure 1.6.1
A diagrammatic representation of the ammonia-glutamine-brain swelling hypothesis. 
Astrocytes are the site of ammonia detoxification in the brain and eliminate ammonia 
by  the  synthesis  of glutamine  through  amidation  of glutamate.  The  glutamine  is 
retained and its osmotic effect within the astrocyte causes it to take up water causing it 
to swell.
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Figure 1.6.2
A  diagrammatic  representation  to  show  the  role  of  myo-inositol  as  an  osmotic 
regulator within the astrocyte.  As glutamine accumulates within the astrocyte, myo­
inositol exits to try to redress the osmotic balance within the cell and prevent cerebral 
oedema.
491.5.1.2  DIRECT AMMONIA TOXICITY
Ammonia, when present in high concentrations, has the potential to adversely 
affect  the  central  nervous  system  particularly  through  modulation  of inhibitory  and 
excitatory neurotransmission. (54)
In acute liver failure, the manifestation of hyperammonemia may be excitatory 
in  nature  and  result  in  seizures  associated  with  increased  synaptic  release  of 
glutamate. Glutamate is the major excitatory brain neurotransmitter and results in the 
subsequent  overactivation  of  the  ionotropic  glutamate  receptors,  the  N-methyl-D- 
aspartate  receptors.  Acute  exposure  to  ammonia  in  astrocyte  cultures  results  in 
cytosolic  alkalinization  leading  to  calcium-dependent  release  of  glutamate. 
Furthermore, a deregulation of glutamate release  from astrocytes by ammonia could 
contribute  to  glutamate  dysfunction  consistently  observed  in  the  animal  models  of 
acute hepatic encephalopathy. (55)
In  chronic  liver  disease  however,  there  appears  to  be  shift  in  the  balance 
between  inhibitory  and  excitatory  neurotransmission,  towards  a  net  increase  in 
inhibitory  neurotransmission.  This  may  be  due  to  a  down-regulation  of glutamate 
receptors  resulting  in  decreased  glutamatergic  tone.  In  patients  with  hepatic 
encephalopathy,  cerebral  glutamate  is  decreased  and  down-regulation  of glutamate 
binding sites on the postsynaptic neurons and astrocytes occurs, resulting in decreased 
neuroexcitation.  (56)  Furthermore,  chronic  hyperammonemia  inactivates  the 
glutamate transporter (GLT-1)  in astrocytes.  (57)  For over 25  years now,  it has been 
observed  that  there  is  increased  GABAergic  tone  in  patients  with  hepatic 
encephalopathy.  GABA  is  the  predominant  inhibitory  neurotransmitter  in  the  brain 
and it was hypothesised that GABA accumulated in liver failure and crossed the blood
50brain barrier. (41)  This hypothesis has not been confirmed in some of the more recent 
studies. Recent hypotheses suggest that hyperammonemia may modulate the observed 
increase  in  GABAergic  tone  in  liver disease.  Hyperammonemia  has  been  shown  to 
inhibit astrocytic GABA uptake, increase neuronal chloride currents by a direct action 
on  the  GABAa  receptor  complex,  to  potentiate  the  binding  of GABAa  and  central 
benzodiazepine  receptor  agonists  to  the  GABAa  receptor  complex.  (43;58)  Recent 
studies  have  suggested  that  alterations  in  brain  GABA  content  or receptor  complex 
function may not be as important as the presence of neurosteroids with GABA agonist 
properties  which  may  explain  the  increased  GABAergic  tone  in  hepatic 
encephalopathy. (59)
In rat models of chronic liver failure and hyperammonemia, it has been shown 
that ammonia impairs the glutamate-nitric oxide-cGMP pathway which is activated by 
the NMDA  receptor and  is  important  in  learning.  Moreover,  chronic  treatment with 
sildenafil, an  inhibitor of the phosphodiesterase that degrades cGMP, normalises  the 
function of the pathway and restores learning ability in rats with portacaval shunts or 
with  hyperammonemia.  This  may  at  least  in  part,  offer  an  explanation  as  to  why 
patients with minimal hepatic encephalopathy have impairment in short term memory. 
(60)
1.5.1.3  AMMONIA AND BRAIN METABOLISM
Ammonia  at  millimolar concentrations  also  has  the  potential  to  impair brain 
energy  metabolism,  particularly  as  it  is known  to  inhibit the  tricarboxylic acid  cycle 
enzyme  ketoglutarate  dehydrogenase.  (61)  However,  brain  energy  metabolism  does 
not  appear  to  be  impaired  in  chronic  liver  disease  until  the  very  late  stages  when
51isoelectric  electroencephalography  traces  become  abnormal.  (62)  Nevertheless, 
cerebral  spinal  fluid  lactate is increased in patients with hepatic encephalopathy (63) 
and  in  animal  models  of  chronic  liver  disease  and  ammonia  precipitated 
encephalopathy (64). These contrasting observations may simply reflect the limitation 
of isoelectric electroencephalography  as a tool  to monitor hepatic encephalopathy  in 
chronic liver disease.
However,  using  nuclear  magnetic  resonance  studies  in  the  hepatic 
devascularised rat model of acute liver failure, Zwingmann et al. (65) demonstrated 2 
to 4.5 fold increase in total brain glutamine and lactate in the early pre-coma stages of 
hepatic encephalopathy. In the more severe coma stage associated with brain oedema 
there  was  a  further  significant  increase  in  brain  lactate.  I3C  isotopomer  analysis 
showed  a  selective  increase  of de  novo  synthesis  of lactate  from  [ 1  - 1 3C]  glucose 
resulting  in  a  2.5  fold  increased  fractional  l3C  enrichment  in  lactate.  [2-l3C] 
Glutamine, synthesised through the astrocytic enzyme pyruvate carboxylase increased 
10  fold  in  the  pre-coma  stages  of hepatic  encephalopathy  but  there  was  no  further 
increase  in  the  coma  stages.  l3C-label  incorporation  into  [4-l3C]  glutamate, 
synthesised  mainly  through  neuronal  pyruvate  dehydrogenase,  was  selectively 
reduced in the coma stages whilst brain GABA synthesis remained unchanged. These 
observations  indicate  that  increased  brain  lactate  synthesis  and  impaired  glucose 
oxidative pathways are important  in the pathogenesis of brain  oedema in acute  liver 
failure.
521.5.1.4  ALTERED GENE EXPRESSION
Acute  liver failure  results  in  altered  expression  of several  genes  in  the  brain 
which code for important proteins involved  in brain  function. These are summarized 
in  Table  1.3.  These  proteins  include  the  glucose  (GLUT-1)  and  glutamate  (GLT-1) 
transporters,  the  astrocytic  structural  protein  glial  fibrillary  acidic  protein,  the 
‘peripheral-type’  benzodiazepine receptor and aquaporin IV which is a water-channel 
transmembrane protein. Loss of expression of GLT-1  results in increased extracellular 
glutamate.  The  monoamines  serotonin  and  noradrenaline  are  also  increased 
extracellularly following post-translational modifications to their receptors.  (6 6) This 
altered  monoaminergic  function  may  also  be  responsible  for  the  early 
neuropsychiatric symptoms of hepatic encephalopathy. (67) The increased expression 
and activation of the ‘peripheral-type’ benzodiazepine receptor results in altered brain 
excitability. As a mitochondrial protein, it plays an important role in the maintenance 
of astrocytic energy metabolism and uptake of cholesterol resulting in the synthesis of 
neurosteroids which have potent neuroinhibitory properties. (6 8) Increased expression 
of aquaporin  IV  may  be  important  in  regulation  of water  transport  and  hence  alter 
brain  water  (69)  and  aquaporin  knockout  mice  show  reduced  brain  oedema  and 
improved  neurological  outcome  compared  to  wild  type  mice  in  models  of  brain 
oedema. (70) Portacaval anastomosis in the rat results in increased gene expression of 
the  constitutive  neuronal  isoform  of nitric  oxide  synthase  in  the  brain.  This  may 
contribute to altered mental state through disturbances in cerebral blood flow. (71)
53Table 1.3
A summary of the main astrocyte genes which are up and down-regulated in
acute liver failure
Up-regulation Down-regulation
‘Peripheral-type’ benzodiazepine receptor 
(PTBR)
GLT-1  (Glutamate transporter)
GLUT-1  (Glucose transporter) Glial fibrillary acidic protein 
(GFAP)
Neuronal nitric oxide synthase (nNOS) GLYT-1  (Glycine transporter)
Aquaporin IV
541.5.2 AMMONIA AND CEREBRAL BLOOD FLOW
Cerebral blood flow is closely coupled to neuronal activity and is modified by 
afferent projection fibres that release vasoactive neurotransmitters in the perivascular 
region,  principally  on  the  astrocyte  endfeet  that  outline  cerebral  blood  vessels 
enabling  cerebral  blood  flow  autoregulation.  Cerebral  vasoconstriction  induced  by 
increased  calcium  in  astrocytic  endfeet  is  generated  through  the  phopholipase  A2- 
arachidonic  acid  pathway  generating  2 0-hydroxyeicosatetraenoic  acid  production.
(72)
In  acute  liver  failure,  there  is  a  loss  of  cerebral  autoregulation,  altered 
reactivity  to  carbon  dioxide  and  cerebral  hyperemia.  Arterial  concentrations  of 
ammonia,  its  delivery  to  the  brain  and  its  metabolism  are  significantly  higher  in 
patients  with  acute  liver  failure  and  intracranial  hypertension  confirming  the 
important role of ammonia in the pathogenesis of intracranial hypertension, although 
the  underlying  mechanisms  are  unclear.  (73)  The  development  of increased  blood 
brain  volume  leads  to  a  rise  in  intracranial  pressure  and  this  may  facilitate  the 
movement of water across the blood brain barrier in an osmotically altered brain. (74) 
As the astrocyte is involved in the normal coupling of neuronal activity with cerebral 
blood  flow,  (75)  alterations  in  astrocyte  function  either  directly  or  indirectly  by 
increased  brain  ammonia  concentrations  are  likely  to  affect  cerebral  blood  flow. 
When methods are introduced to inhibit brain  glutamine synthesis, such as using the 
glutamine  synthetase  inhibitor methionine  sulfoximine,  (76)  a  rise  in  cerebral  blood 
flow  is  prevented.  This  observation  supports  the  view  that  increased  cerebral  blood 
flow may be important in initiating brain swelling in this model.  However, in humans 
with  acute  liver failure, the  increase  in  cerebral  blood  flow  is  a  later event.  Patients
55with  acute  liver  failure  that  have  severe  encephalopathy  and  mildly  increased 
intracranial  pressure  often  have  normal  cerebral  blood  flow.  Marked  increases  in 
intracranial  pressure  are  associated  with  a  concomitant  rise  in  cerebral  blood  flow.
(73)
In  contrast,  in  chronic  liver  disease,  the  predominant  picture  is  of cerebral 
vasoconstriction.  (77)  Regional  differences  in  cerebral  blood  flow  are  also  seen. 
Regional  cerebral  blood  flow  corresponds  to  functional  impairment  of  the  frontal 
cortex and cingulate gyrus. (78) Administration of an oral amino acid load to patients 
with  cirrhosis  that results  in  increased  ammonia  results  in  reduced  regional  cerebral 
perfusion  in  the  temporal  lobes,  left  superior  frontal  gyrus  and  right  parietal  and 
cingulate  gyrus,  and  deterioration  in  memory  tests.  (79)  These  results  attest  to  the 
intimate relationship that ammonia has with cerebral blood flow.
561.6  THE ROLE OF INFLAMMATORY MEDIATORS IN 
MODULATING THE MANIFESTATION OF HEPATIC 
ENCEPHALOPATHY
As  is  clear  from  the  previous  discussion,  there  is  overwhelming  evidence 
supporting  the  ammonia hypothesis  of hepatic  encephalopathy.  However,  in  clinical 
practice a consistent correlation  between  the  concentration  of ammonia  in  the blood 
and  the  symptoms  of  hepatic  encephalopathy  cannot  be  confirmed.  Sepsis  is  a 
frequent  precipitating  factor  for  the  development  of  hepatic  encephalopathy  in 
patients  with  cirrhosis  supporting  the  view  that  additional  inflammation  may  play  a 
role  in  the pathogenesis  of hepatic  encephalopathy  (Figure  1.7).  There  is a  growing 
body of evidence supporting the role of inflammation as being important in increasing 
the  susceptibility  of the  brain  to  the  effects  of hyperammonemia.  This  concept  and 
current views on its pathophysiologic basis will now be reviewed.
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Figure 1.7
A diagrammatic representation of the relationship between inflammation and cerebral 
blood  flow  on  the  development  and  manifestation  of  hepatic  encephalopathy. 
Astrocytes  are  the  site  of ammonia  (NH3)  detoxification  in  the  brain  and  eliminate 
ammonia by the synthesis of glutamine through amidation of glutamate. The resultant 
astrocytic  swelling  leads  to  increased  brain  water  and  raised  intracranial  pressure 
(ICP).
581.6.1 CYTOKINES, ASTROCYTES AND THE BLOOD BRAIN BARRIER
Astrocytes are considered to be the key cells involved in the pathogenesis of 
hepatic  encephalopathy,  as  they  have  been  found  to  be  the  cells  that  are  most 
commonly seen to be affected histopathologically. Astrocytes secrete a full repertoire 
of  cytokines  and  neurotrophic  factors  to  neurons,  consistent  with  their 
neurosupportive role.  As the astrocytes are  one of the main  components  involved  in 
the formation of the blood brain barrier and  in controlling cerebrovascular tone,  it  is 
conceivable  that  astrocyte  swelling,  which  is  a  feature  of hepatic  encephalopathy  is 
likely to affect the function of the blood brain barrier.
There is considerable evidence that the peripheral  immune system can signal 
the  brain  to  elicit  a  response  during  infection  and  inflammation.  This  response 
involves the expression of proinflammatory cytokines such as IL-ip, TNF-a and IL-6, 
both  in  the periphery and  the brain.  This  can  occur through  direct entry of cytokine 
into  the  brain  across  the blood  brain  barrier by  a  storable  transport  mechanism,  the 
interaction of cytokine with circumventricular organs such as the orgnum vasculosum 
of the lamina terminalis and area postrema (80) and activation of afferent neurons of 
the  vagus  nerve.  (81)  Sharshar et  al.  (82)  showed  that  in  patients  dying  with  septic 
shock, neuronal and glial apoptosis occurs within the brain autonomic centres, which 
are strongly associated with  iNOS expression in the endothelial cells. This may alter 
glutamatergic  neurotransmission  (83)  and  increase  the  number  of  ‘peripheral-type’ 
benzodiazepine  receptors  which  may  alter  cellular  osmotic  homeostasis.  (84) 
Cytokines  may also modulate  ammonia diffusion  and  it  has been  shown  that TNF-a 
and  IL-6 increase fluid phase permeability and ammonia diffusion in central nervous 
system-derived endothelial cells. (85) Brain endothelial cells have receptors for IL-ip
59and  TNF-a.  These  can  transduce  signals  which  can  culminate  in  the  intracerebral 
synthesis of nitric oxide and prostanoids. (80) Perivascular cells of macrophage origin 
may be a target for these cytokine effects. (8 6 )
In  the  brain  activated  microglial  cells  and  astrocytes  produce  cytokines  in 
response  to  injury  or  inflammation.  One  of  the  early  cytokines  to  be  released  is 
tumour necrosis alpha (TNF-a).  TNF-a  is  involved  in the  induction of the cytokines 
interleukin  1   (IL-1) and interleukin  6 (IL-6 ).  (87)  It has been shown in  vitro that the 
integrity  of the  blood  brain  barrier  is  compromised  by  IL-1 (3,  mediated  through  the 
cyclooxygenase  pathway  within  the  endothelial  cells.  (8 8 )  In  addition,  the  effect  of 
TNF-a on human brain microvesicular endothelial cell permeability has the potential 
to  compromise  the  blood  brain  barrier  function.  (89)  Furthermore,  in  astrocyte 
cultures,  interferon  gamma  (IFN-y)  upregulates  inducible  nitric  oxide  synthase 
(iNOS). (90)
Stimulation  of astrocytes  in  culture  with  lipopolysaccharide  also  results  in 
upregulation of iNOS  that culminates in  increased production of nitric oxide.  (91) A 
similar  phenomenon  is  observed  with  ammonia.  Schleiss  et  al.  have  provided 
evidence of protein tyrosine nitration in ammonia-treated cultured astrocytes and also 
in vivo in brains of rats treated with an ammonia load. (92)  Furthermore, the addition 
of  ammonia  to  astrocyte  cultures  generates  reactive  oxygen  species,  a  process 
involving  the  synthesis  of glutamine.  Treatment  of astrocytes  with  glutamine  also 
increases free radical production. (93) If phosphate-activated glutaminase is inhibited 
free radical production is blocked, suggesting that ammonia released by the hydrolysis 
of glutamine  may  be  a  factor.  (94;95)  As  most  of the  glutamine  in  astrocytes  is 
metabolised  by  mitochondrial  phosphate-activated  glutaminase,  breakdown  of
60glutamine could result  in  release  of high  levels  of ammonia  in mitochondria,  which 
may contribute to an increase in reactive oxygen species.
Increased  levels  of  nitric  oxide  and  reactive  oxygen  species  may  have 
compounded  effects  as  peroxynitrite  is  formed  from  the  combination  of superoxide 
and  nitric  oxide.  Peroxynitrite,  in  the  presence  of carbon  dioxide  can  modify  tissue 
proteins  to  form  nitrotyrosine  which  may  mediate  nitric  oxide-induced  blood  brain 
barrier  damage.  (96)  Furthermore,  an  increase  in  the  permeability  of  the  inner 
mitochondrial  membrane  to  small  solutes  (mitochondrial  permeability  transition) 
results from oxidative and nitrosative stress and ammonia has been recently shown to 
induce similar changes in cultured astrocytes. (97)
1.6.2  EVIDENCE  FOR  THE  ROLE  OF  INFLAMMATION/INFECTION  IN 
ACUTE LIVER FAILURE
Hippocrates  was  the  first  to  write  of the  association  between  infection  and 
impaired brain function in 400 BC and the association between infection and impaired 
brain function  is well recognised.  Septic encephalopathy can arise from the action of 
inflammatory  mediators  on  the  brain  or a  cytotoxic  response  by brain  cells  to  these 
mediators. Septic encephalopathy is usually the sequelae of severe sepsis complicated 
by multiple organ failure and hypotension. (98) Severe sepsis causes plasma and brain 
amino acids to become deranged with a decrease in branched chain amino acids (e.g. 
isoleucine) and an increase in neutral amino acids in the brain similar to the findings 
in  portosystemic  encephalopathy.  (99; 100)  In  patients  with  sepsis  it  was  shown  that 
aromatic  amino  acids  (e.g.  phenylalanine)  correlated  with  APACHE  II  scores  and 
mortality.  Scores  were  greater in  shock  patients  with  higher  levels  of ammonia  and
61sulphur containing amino acids with a higher mortality rate. (101) Oxidative stress is 
important  in  the  pathogenesis  of  ammonia-induced  neurotoxicity.  In 
hyperammonemia,  free-radical  production  may  be  mediated  by  NMDA-receptor 
activation (102) and ammonia-induced mitochondrial dysfunction (103) could also be 
a  source  of  reactive  oxygen  species  such  as  peroxynitrite.  (96)  Furthermore, 
antioxidants  have  beneficial  effects  in  experimental  animal  models  of  hepatic 
encephalopathy  and  hyperammonemia.  (104; 105)  As  previously  mentioned, 
hypothermia  improves  the  outcome  in  acute  liver  failure.  Hypothermia  reduces  free 
radical production which may account for some of its beneficial effects. (106) Takada 
et al. (107) have shown in a pig model of acute liver failure that animals administered 
lipopolysaccharide  and  amatoxin  intraportally  developed  more  pronounced 
intracranial  hypertension  than  animals  given  amatoxin  alone,  even  though  ammonia 
concentrations were similar in both groups. In another pig model of acute liver failure 
induced  by  hepatic  devascularisation,  improvement  in  the  severity  of  hepatic 
encephalopathy  following  treatment  with  albumin  dialysis  occurs  independently  of 
changes  in  ammonia.  (108)  Albumin  dialysis  probably  achieves  this  effect  through 
reduction  in  oxidative  stress  and  restoring  nitric  oxide  metabolism.  These 
observations support a role  for mechanisms  other than ammonia  in  the  pathogenesis 
of hepatic encephalopathy.
Studies  in  patients  with  acute  liver  failure  have  shown  rapid  progression  to 
severe  hepatic  encephalopathy  in  those  with  evidence  of a  systemic  inflammatory 
response,  suggesting  a  possible  link  between  inflammation  and  hepatic 
encephalopathy.  (109; 110)  In addition,  in patients with acetaminophen-induced acute 
liver  failure,  infection  and/or  the  resulting  systemic  inflammatory  response  was 
shown  to  be  an  important  factor  in  contributing  to  deterioration  in  the  severity  of
62hepatic  encephalopathy.  (Ill)  In  the  advanced  stages  of hepatic  encephalopathy  in 
acute  liver  failure,  when  patients  have  uncontrolled  intracranial  hypertension,  the 
brain produces cytokines such as TNF-a, IL-lp and IL-6 . (112; 113)
In  addition,  it  is  likely  that  one  of  the  mechanisms  through  which 
inflammation exerts its deleterious effect is by inducing alterations in cerebral blood 
flow  through  its  effects  on  the  expression  of  the  NOS  proteins.  Accordingly, 
Aggarwal  et  al.  (114)  showed  that  patients  with  high  intracranial  pressure  have 
elevated cerebral blood flow.  More recently a direct correlation between the severity 
of inflammation and  increased cerebral  blood  flow  has  been  observed  in  acute  liver 
failure.  (73)  Further  evidence  supporting  the  role  of inflammation  is  derived  from 
experimental  interventions that reduce brain swelling by altering cerebral blood flow 
and  inflammatory  responses.  In patients  with  uncontrolled  intracranial  hypertension 
and acute liver failure, moderate hypothermia reduces brain flux of TNF-a, IL-lp and 
IL- 6  and  cerebral  blood  flow  contributing  to  reduction  in  intracranial  pressure. 
(105; 115)  Removal  of the  necrotic  liver  in  acute  liver  failure  reduces  circulating 
levels of proinflammatory cytokines such as TNF-a,  IL-lp and  IL-6 ,  lowers cerebral 
blood flow resulting in a reduction in the severity of intracranial hypertension. (116)
631.6.3  EVIDENCE  FOR  THE  ROLE  OF  INFLAMMATION/INFECTION  IN 
CIRRHOSIS
A  distinctive  postmortem  finding  in  human  brains  with  hepatic 
encephalopathy  is  the  presence  of  Alzheimer  Type  II  astrocytosis  (32)  which 
characteristically  contain  increased  amounts  of lipofuscin  pigment  that  consists  of 
peroxidized lipids compatible with oxidative damage. (117) Nitric oxide has also been 
implicated  in  the  pathogenesis  of  hepatic  encephalopathy.  Nitric  oxide  synthase 
activity  has  been  shown  to  be  elevated  in  experimental  models  of  hepatic 
encephalopathy  (118)  and  increased  brain  nitric  oxide  production  was  shown  in 
portacaval-shunted rats given ammonia infusions (76) with evidence of nitrotyrosine 
accumulation  in  astrocytes.  (119)  (Figure  1.8)  Studies  in  portacaval  shunted  rats 
administered an  ammonia  load have demonstrated a rise  in  cerebral  blood  flow that 
paralleled the increase in intracranial pressure and correlated directly with brain water 
content.  (76; 120)  In  cirrhosis,  it  has  been  shown  that  changes  in  regional  cerebral 
blood flow lead to differences in cerebral ammonia uptake. (78)  Cerebral blood flow 
is  higher  in  the  basal  ganglia  and  cerebellum  which  correlates  with  increased 
ammonia extraction. (79)
Further  support  for  interaction  between  ammonia  and  inflammation  is 
provided in a recent paper by Liu et al (121), who showed that alteration of gut flora 
in  patients  with  cirrhosis  with  the  administration  of  fibre  and  probiotics  was 
associated  with  improvement  in  the  severity  of  minimal  hepatic  encephalopathy 
compared  with  a  control  group.  They  showed  that  this  improvement  in  minimal 
hepatic  encephalopathy  was  associated  with  a  reduction  in  venous  endotoxin  and 
ammonia levels at day 30.
64Patients with chronic liver disease are particularly prone to infection which is 
frequently a precipitant of hepatic encephalopathy. (122; 123) Bacterial  infections are 
of particular concern in patients with cirrhosis because they are poorly tolerated. (124) 
Sepsis  and  associated  endotoxaemia  occur  in  approximately  40%  of  hospitalized 
patients with cirrhosis and is a major cause of death. (125; 126) The increased risk of 
infection  is  secondary  to  impairment  of several  host  defence  mechanisms  including 
impaired neutrophil  function.  (127; 128) The hemodynamic derangement  of cirrhosis 
resembles  that produced by endotoxin,  (129)  and bacteremia  can  greatly  exacerbate 
this  state,  producing  hypotension,  hepatorenal  syndrome,  deterioration  in  mental 
status  and  increased portal  hypertension  with  risk  of variceal  bleeding.  Factors  that 
predispose  to  bacterial  infection  include  malnutrition  with  impaired  cell-mediated 
immunity, decreased integrity of the bowel wall leading to bacterial translocation, and 
impaired  phagocytic  activity  of the  hepatic  and  splenic  reticuloendothelial  system 
resulting from portal hypertension.  Tuftsin, a natural tetrapeptide known to stimulate 
phagocytosis by neutrophils, has also been shown to be reduced in cirrhosis.  It is part 
of  a  specific  carrier,  leucokinin,  which  is  cleaved  by  an  enzyme,  tuftsin 
endocarboxypeptidase,  while  circulating  through  the  spleen.  (130)  Neutrophils  from 
patients  with  superimposed  acute  alcoholic  hepatitis  have  depressed  phagocytosis, 
intracellular killing and metabolic activity,  although they have a greater capacity for 
ingestion  and  killing  of bacteria  than  neutrophils  of patients  with  cirrhosis  alone. 
(128)  Our  group  has  recently  shown  that  neutrophil  dysfunction  with  high  resting 
oxidative burst and  reduced phagocytic  capacity  is present  in  patients  with  cirrhosis 
and  alcoholic  hepatitis  which  was  associated  with  a  significantly  greater  risk  of 
infection, organ failure and mortality (131).
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Figure 1.8
Slides showing staining for nitrotyrosine in the cerebral cortex of a portacaval shunted 
rat receiving an ammonia infusion (courtesy of Professor Andrei Blei, Northwestern 
University Feinberg School of Medicine, Chicago and published in Seminars in Liver 
Disease 2003; 23:259-69).  (a)  Shows glial  fibrillary  acidic protein (GFAP) positive 
astrocytes in the cerebral cortex, (b) shows nitrotyrosine staining in astrocytes and (c) 
reveals the overlap of GFAP and nitrotyrosine staining in cortical astrocytes.1.7  NEUTROPHILS
Neutrophils  account  for  70%  of all  white blood  cells  [Figure  1.9]  and  along 
with  macrophages  comprise  the  professional  phagocytes,  being  endowed  with  a 
unique capacity to engulf and thereby eliminate pathogens and cell debris. Phagocytes 
are  equipped  with  specialised  receptors  to  recognise  their  targets;  this  complex 
machinery  initiates  internalisation  and  mediates  an  assortment  of  degradative 
mechanisms that culminate in the killing and disposal of the engulfed particles. (132) 
During  phagocytosis  of microbial  intruders,  professional  phagocytes  of the  innate 
immune system increase their consumption of molecular oxygen through the activity 
of an NADPH-oxidase that generates  superoxide  anion (O2 )  and hydrogen peroxide 
(H2O2).  (133; 134)  The  primary  products  (superoxide  anion  and  H2O2)  generated  by 
the  NADPH-oxidase  are  not  sufficiently  reactive  to  account  for  the  bactericidal 
effects,  however,  these  oxygen  metabolites  give  rise  to  yet  other  reactive  oxygen 
species  that are  strongly  anti-microbial.  (135)  The respiratory burst products are not 
only able to eradicate invading micro organisms, but unfortunately may also damage 
‘innocent  bystanders;’  leading  to  tissue  destruction  and  associated  inflammatory 
reactions. The reactive oxygen species generated by phagocytes function as regulators 
of other immune responsive cells (136) and for apoptotic processes. (137)
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68Glutamine  is  an  important  fuel  for neutrophils  and  enhances  the  function  of 
these immune cells.  (138) Glutamine is converted to glutamate, lactate and aspartate 
by a phosphate-dependent glutaminase  [Figure  1.10] which  is known to be  inhibited 
by 2  mM  ammonium chloride.  (139)  Furthermore,  in rat neutrophils  glutamine may 
give rise to substantial quantities of NADPH for superoxide production. (140) Ogle et 
al. (141) observed that the enhancement of human neutrophil action by glutamine was 
not  due  to  increased  phagocytosis  and  Moinard  et  al.  demonstrated  in  stressed  rats 
with a diet supplemented by glutamine, that respiratory burst is enhanced.  (142)  In a 
further  study,  they  demonstrated  that  ornithine  2-oxoglutarate  (OKG)  was  able  to 
increase  the  chemotaxis  of  neutrophils  5  fold,  but  that  arginine  and  glutamine 
administration  failed  to  show  the  same  effect.  They  also  observed  an  increase  in 
reactive oxygen species production. This is not dependent on glutamine production as 
it  is  unaffected  by  adding  an  inhibitor  of  glutamine  synthetase  (methionine 
sulphoxamine).  Reactive  oxygen  species  production  due  to  OKG  is  mediated  by 
nitric oxide, since the effect of OKG is abolished by S-methylthiourea, an inhibitor of 
inducible nitric oxide synthase.  Furthermore, they observed that the respiratory burst 
was  partially  abolished  by  treatment  with  difluoromethylomithine  (DFMO),  an 
inhibitor  of  ornithine  decarboxylase.  They  suggested  that  OKG  may  generate 
polyamines,  which  could  mediate  an  increase  in  protein  kinase  C  activity  and  thus 
stimulate reactive oxygen species production via activation of NADPH-oxidase. (143) 
The production of NADPH may be substantially increased by the polyamine pathway 
through an increase in glucose-6 -phophate dehydrogenase (G6 PD) activity, providing 
ample substrate for NADPH-oxidase. This is illustrated in Figure  1.11.
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Figure 1.10
Diagrammatic illustration showing glutamine is an important fuel for neutrophils and 
enhances the  function of these  immune  cells.  Glutamine  is  converted  to  glutamate, 
lactate  and  aspartate  by  a  phosphate-dependent  glutaminase  which  is  known  to  be 
inhibited by 2 mM NH4CI.
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Figure  1.11
The  metabolism  of pharmaconutrients,  the  metabolic  pathways  and  their  inhibitors 
involved  in  neutrophil  phagocytosis.  (DFMO:  difluoromethyl  ornithine;  MSO: 
methionine  sulphoxamine;  SMT:  S  -   methylthiourea)  taken  from  Moinard  et  al. 
Clinical Science 2002 ;  102 :288.
711.8  NEUTROPHIL MITOGEN-ACTIVATED KINASES
Mitogen-activated  kinases  (MAP  kinases)  are  proline-directed  serine  and 
threonine  protein  kinases  that  are  activated  by  dual  specificity  kinases  by 
phosphorylation of threonine and tyrosine in a Thr-Xaa-Tyr motif in  a loop near the 
active site. (144; 145) The three types are defined by the intervening Xaa amino acid. 
In the extracellular signal-regulated kinases (ERK), the amino acid is glutamate; in the 
jun-kinases (JNK) it is proline and in the p38-MAP kinases (p38'M APK), it is glycine.
The p38"M A P K  signaling pathway plays an  important role in  inflammation and 
other physiological processes.  Specific inhibitors of p38’M A PK  block production of the 
major  inflammatory  cytokines  tumour  necrosis  factor  a  (TNF-a)  and  interleukin  1  
(IL-1),  and other inflammatory enzymes such as cyclooxygenase-2  (COX-2).  These 
inhibitors are pyridinyl  imidazole compounds e.g.  SB203580 or SB202190.  A  major 
function of the p38'M A P K  pathway is post-transcriptional control of inflammatory gene 
expression.  Many  of the  messenger  RNA’s  (mRNA)  are  unstable  or  untranslatable 
and signaling in the p38'M A P K  pathway counteracts these and stabilizes the mRNA by 
preventing otherwise rapid de-adenylation. (146) There are 4 subtypes of p38‘M A PK :  a, 
P, y and 6.  All  are activated by upstream kinases -  MAP kinase kinase (MKK)  3  or 
MMK6,  in  response to  inflammatory and  stressful  stimuli. The a,  p and  5  forms are 
widely expressed, whereas y is limited to muscle. p38’M A P K  a was first isolated as a 38 
kDa  protein  rapidly  tyrosine  phosphorylated  in  response  to  lipopolysaccharide 
stimulation.  (147; 148)  It  is  strongly  expressed  in  monocytes,  macrophages,  CD4  T 
cells,  neutrophils  and  endothelial  cells,  strongly  suggestive  of a  pivotal  role  in  the 
immune  system.  Macrophages,  CD4  T  cells  and  neutrophils  all  express  comparable
72levels of a and 5, but the inhibitors of p38'M A P K  only inhibit a and P forms. The role of 
y and 5 in inflammation is unknown. (149)
Inflammatory  stimuli  activate  four  major  signaling  intracellular  signaling 
pathways: the nuclear factor-KB (NFkB) and the 3 MAPK kinase pathways (p38'M A PK , 
ERK  and  JNK).  All  4  pathways  drive  transcription  of inflammatory  genes.  It  has 
been  shown  that the protein  p38‘M A PK   is an  important kinase regulating  apoptosis  in 
neutrophils exposed to stress, hypoxia and lipopolysaccharide.(l 50) Furthermore, toll­
like  receptors play  an  important role  in  promoting clearance  of bacteria through  the 
up-regulation  of  macrophage  phagocytic  activity  through  p38"M A PK .  (151) 
Phagocytosis  of  apoptotic  cells  results  in  the  production  of  transforming  growth 
factor-P  (TGF-  p),  which  plays  an  important role  in  the  resolution  of inflammation. 
TGF-  p  prevents  proinflammatory  cytokine  production  through  inhibition  of  p38‘ 
M A PK . Crosstalk between  ERK and p38"M A PK   is essential  for this process.  (152) Other 
inflammatory response proteins depend upon p38~M A P K  signaling for their production 
besides  TNF-a,  IL-1  and  COX-2.  Interleukin-6  (IL-6)  and  interleukin-8  (IL-8) 
stability is regulated by p38'M A PK  and monocytes chemoattractant protein-1, IL-12p40, 
granulocyte macrophage colony-stimulating factor, vascular endothelial growth factor 
and inducible nitric oxide synthase are all p38"M A P K  dependent. (146)
The pathway is also activated by cell stress, growth factors, G-protein coupled 
receptors  and  other  stimuli,  which  might  include  ammonia.  Inhibition  of p38"M A P K  
decreases survival of neutrophils, possibly by phosphorylating caspases 3 and 8. (153) 
This  could  thus  modulate  apoptosis.  Glutamine  exerts  many  of its biological  effects 
through a swelling-induced activation of ERK and p38"M A P K   signaling.  p38‘M A PK  and 
ERK are osmosensors which  are  activated  in response  to  increased cell  hydration or 
swelling.  (154-157)  [Figure  1.12]  A  diagram  of  how  these  receptors  and  signals
73interact, and how the neutrophil lyses the bacteria with reactive oxygen species within 
a phagosome is illustrated in Figure 1.13.
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Figure 1.12
Diagrammatic representation of the mechanism by which the cell  senses an increase 
in  hydration  by  the  p38'M A P K   and  ERK-dependent  pathways.  p38'M A P K   can  be 
inhibited by SB203680 and ERK can be inhibited by U0126.
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Figure 1.13
A diagram to summarise how the neutrophil receptors and signaling pathways interact 
in response to stress or a bacterial  challenge, and of neutrophil  lysis of an engulfed 
bacteria within a phagosome.
761.9  THE ROLE OF MUSCLE IN AMMONIA METABOLISM IN 
ACUTE AND CHRONIC LIVER FAILURE
Glutamine synthetase activity in skeletal muscle is low (158), and it is mainly 
by  virtue  of its  mass  relative  to  other  glutamine  synthetase  containing  organs,  that 
muscle is one of the principle glutamine synthesizing organs. (159) Ammonia can be 
taken up by or released from the muscle, probably related to purine nucleotide cycle 
activation (160) Unidirectional uptake of ammonia in healthy humans was shown in a 
tracer study using positron-emitting isotope enriched ammonia (l3N-ammonia).  It was 
estimated that 50% of the arterial ammonia was extracted by skeletal muscle. (18; 161) 
The considerable difference between the large unidirectional uptake of ammonia and 
the small arterio-venous differences for ammonia across muscle have been interpreted 
to signify that muscle must continuously use and produce ammonia. (18)
Unidirectional  ammonia  uptake  by  skeletal  muscle  has  also  been  shown  in 
patients  with  various  degrees  of  liver  failure.  (18)  Arterio-venous  catheterization 
studies suggest that net ammonia uptake by muscle is probably related to changes in 
arterial ammonia. Net ammonia uptake was shown in hyperammonemic patients with 
decompensated  cirrhosis  in  arterio-venous  difference  measurements  across  the 
forearm  (17; 159; 162; 163)  and  leg.  (164)  A  good  correlation  between  arterial 
ammonia  concentrations  and  muscle  ammonia  uptake  was  observed  in  patients  in 
hepatic coma with (17) or without  (162) active upper gastrointestinal bleeding. This 
is also seen in patients with decompensated cirrhosis (165) and gross muscle wasting 
(159)  but  not  in  compensated  patients  with  normal  muscle  mass.  (17; 159) 
Furthermore,  the  fractional  extraction  of  ammonia  was  reduced  in  patients  with 
muscle wasting, (159) suggesting an important role for cirrhotic patients maintaining
77adequate  muscle  mass.  Leg  ammonia  consumption  correlates  with  glutamine 
production  in  acute  liver  failure  suggesting  that  skeletal  muscle  participates  in 
ammonia detoxification. The total muscle amino acid production was  10 times higher 
than the uptake of ammonia, indicating that the production of glutamine was not only 
the  result  of ammonia  consumption,  but  also  the  result  of net  muscle  catabolism. 
(166)  Furthermore,  it has been  demonstrated  that  in  acute  liver failure  the gene  for 
glutamine  synthetase  is  significantly  up  regulated  (measuring  messenger  RNA) 
compared to the level of gene transcription for p-actin (p < 0.05) [Figure  1.14].  (167)
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Figure 1.14
A  diagram  to  show  upregulation  of muscle  glutamine  synthetase  gene  and  protein 
induction in acute liver failure taken from Desjardins et al. 1999 (167).
79Enhanced  ammonia consumption by  skeletal  muscle has been  shown  in  vivo 
after  ammonia  infusion  in  healthy  rats  (168),  monkeys  (169),  dogs  (169; 170)  and 
pigs.  (171) The ammonia consumption enhanced glutamine production  in only some 
of  these  studies  (169; 171),  whilst  glutamine  production  remained  unchanged  in 
others.  (168; 170)  Muscle  glutamine  release  was  two  to  four-fold  higher  in  chronic 
portacaval  shunted  rats  compared  with  healthy  controls,  whereas  the  corresponding 
net  ammonia  uptake  was  not  observed.  (172)  This  is  most  likely  due  to  enhanced 
muscle  catabolism.  Furthermore,  part  or  all  of  the  ammonia  may  be  trapped  in 
augmented  tissue  ammonia  and  amino  acid  pools  (glutamine).  This  may  not 
necessarily  induce  release  of amino  acids.  There  is  however  an  important  role  for 
muscle  in  ammonia  removal  in  metabolically  stable  patients  with  cirrhosis  and  a 
transjugular  intrahepatic  portosystemic  shunt  in  situ.  Ammonia  uptake  was 
accompanied  by  net  production  of  glutamine,  which  increased  during 
hyperammonemia  in  quantities  exceeding  the  ammonia  taken  up.  (21)  Ammonia 
uptake by muscle, leading to glutamine synthesis and glutamine release from muscle 
does  not  necessarily  indicate  net  ammonia  detoxification.  Glutamine  released  from 
skeletal muscle can be taken up in the splanchnic tissues or in the kidneys and can be 
metabolised  to  ammonia,  abolishing  the  effect  on  whole  body  ammonia  removal. 
Glutamine  acts  thereby  as  a  non-toxic  nitrogen  carrier,  without  contributing  to  net 
nitrogen removal from the systemic circulation.  Skeletal muscle metabolism probably 
plays  an  important  role  in  ammonia  metabolism  in  acute  and  chronic  liver  failure. 
This  is  mainly  because  total  body  skeletal  muscle  mass  probably  constitutes 
quantitatively,  in  toto,  the  most  important  localisation  of  the  enzyme  glutamine 
synthetase.
801.10  AMMONIA LOWERING STRATEGIEG TARGETING THE
MUSCLE
Ammonia  lowering  interventions  are  limited,  however,  L-omithine-L- 
aspartate (LOLA), the  stable  salt of the amino  acids  ornithine  and aspartic  acid,  has 
been  shown  to  reduce  blood  ammonia  concentration  and  improve  psychometric 
performance  in  patients  with  hyperammonemia  and  hepatic  encephalopathy  when 
administered  intravenously.  (173-176)  LOLA  is  believed  to  act  by  stimulating  the 
urea  cycle  and  glutamine  synthesis  to  effect  ammonia  detoxification,  (176; 177) 
though direct evidence for the mechanism of action is lacking.
It has been proposed that ornithine improves the rate of the urea cycle [Figure 
1.15],  especially  through  the  enzyme  carbamyl  phosphate  synthetase.  Carbamyl 
phosphate synthetase catalyses the conversion of bicarbonate, ATP, and ammonia into 
carbamyl  phosphate,  this  reaction  is  the  first  step  in  the  urea  cycle.  The  putative 
action  of aspartate  is  unclear,  though  it  is  known  to  be  a  substrate  for  the  enzyme 
asparagine  synthetase  which  catalyses  the  reaction  between  ammonia  and  aspartate 
forming asparagine [Figure  1.16].
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83It  should  however  be  noted  that  ammonia  uptake  by  muscle,  leading  to 
glutamine synthesis does not necessarily indicate ammonia detoxification.  Glutamine 
released from muscle may be subsequently taken up by the splanchnic tissues or the 
kidneys and re-metabolised to ammonia.
The  increased  muscle  levels  of  glutamine  synthetase  require  sufficient 
substrate  to  effectively  reduce  circulating  ammonia.  In  this  regard  LOLA  offers  a 
significant resource in that for each LOLA administered three molecules of glutamate 
are potentially generated [Figure 1.17]
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Figure 1.17
A diagram to show the metabolic conversion of LOLA to glutamate
84By increasing the amount of glutamate as substrate  for glutamine  synthetase, 
in  the  presence  of  a  ready  supply  of  ammonia,  the  reaction  would  be  driven  to 
produce glutamine, thereby effectively  lowering  the  systemic  ammonia  levels.  This 
effect  has  been  shown  in  a  rat  model  of  acute  liver  failure.  When  rats  were 
administered  LOLA,  glutamate  production  was  significantly  increased  (p<0.001) 
approximately four fold compared to rats given saline.  (176)
851.11  SUMMARY
The  current  perspectives  on  the  molecular  pathogenesis  of  hepatic 
encephalopathy have been described. The importance of the role of ammonia has been 
highlighted with respect to both its direct neurotoxicity and on brain swelling through 
its detoxification  to glutamine  in the  astrocyte,  the cell  most  often  implicated  in  the 
pathogenesis  of  hepatic  encephalopathy.  In  fact,  one  might  say  that  the  key  to 
understanding  the pathogenesis  of hepatic  encephalopathy  is  to  explore  the  story  of 
the  ‘sick  astrocyte’.  The  factors  that  are  believed  to  be  critical  in  modulating  the 
manifest  symptoms  of  hepatic  encephalopathy  have  been  reviewed;  the  most 
important of which is the potential synergistic role of inflammation in modulating the 
cerebral effects of ammonia.  Furthermore, the production of reactive oxygen species 
and increased protein tyrosine nitration may alter astrocyte function and contribute or 
precipitate episodes of hepatic encephalopathy.
We  have  also  described  the  inter-organ  trafficking  of ammonia.  In  healthy 
individuals  the  liver  removes  ammonia  by  detoxification  into  urea.  However,  in 
patients with cirrhosis, the metabolic capacity of the liver is reduced. The muscle then 
becomes an important organ of ammonia detoxification.  Furthermore, we have given 
evidence  for  the  role  of inflammation  in  acute  and  chronic  liver  failure  and  how 
potentially such inflammation could alter the inter-organ metabolism of ammonia.
Finally,  we  have  discussed  the  role  of  neutrophils  in  inflammation  and 
infection. These are the cells which are endowed with a unique capacity to engulf and 
eliminate pathogens and to produce reactive oxygen species, which eradicate invading 
microorganisms  but  also  lead  to  tissue  destruction  and  associated  inflammatory 
reactions.
86In  patients  with  cirrhosis,  hyperammonemia  is  commonly  associated  with  hepatic 
encephalopathy  and  accompanies  gastrointestinal  bleeding,  both  conditions  being 
associated with a high incidence of sepsis and mortality.
Despite  this  extensive  literature  base,  only  the  tip  of the  iceberg  has  so  far 
been uncovered in terms of understanding the  operative mechanisms  involved in the 
pathogenesis  of  hepatic  encephalopathy  in  relation  to  ammonia,  infection  and 
inflammation.
87Chapter 2 
Hypothesis JlncCJiims2.1  HYPOTHESIS
Ammonia  has  a  central  role  in  the  pathogenesis  of hepatic  encephalopathy, 
albeit not as a simple, single-factor relationship. There is a growing evidence base to 
support the role of inflammation as being important in increasing the susceptibility of 
the  brain  to  the  effects  of  ammonia  in  liver  disease.  Therefore  in  an  attempt  to 
understand the complexity of the relationship to hepatic encephalopathy the following 
hypotheses were formulated:
1.  Inflammation  and  infection  are  pivotal  in  the  pathogenesis  of  hepatic 
encephalopathy (Figure 2; Ql).
2.  Ammonia  and  inflammation/infection  act  synergistically  in  the  pathogenesis 
of hepatic encephalopathy (Figure 2; Q2).
If inflammation  modulates  the  cerebral  effect  of ammonia,  then  another key 
question to ask  is whether the relationship is a two way one  i.e, can the presence of 
ammonia  itself influence  the  presence  of infection  or  inflammation?  If one  takes  a 
step back from this supposition, then it might be logical to question whether ammonia 
itself  may  impair  immunity  and  predispose  an  individual  to  the  development  of 
infection or sepsis. This led onto the development of a third hypothesis:
3.  Ammonia impairs neutrophil function (Figure 2; Q3).
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Hypothesis
If inflammation modulates the cerebral effects of ammonia, then the last key 
question to answer is how is the metabolism of ammonia affected by the presence of 
inflammation or infection? The muscle is an important organ in total body ammonia 
metabolism.  As described earlier, the muscle may be an important site for ammonia 
detoxification  and  a  potential  therapeutic  target  for  ammonia  reduction  in  liver 
disease.  By  exploring  how  the  muscle  metabolism  of  ammonia  is  modulated  by 
inflammation, potential mechanisms might be further elucidated.
Thus  these  hypotheses  encompass  the  role  of inflammation/infection  on  the 
metabolism  of ammonia  in  the  brain  and  muscle  and  explore  how  ammonia  may 
impact on  neutrophils  whose  function  is  critical  in  fighting  microbial  invasion  and 
inducing inflammation.
902.2  AIMS
1.  To  investigate  whether  inflammation  and  infection  are  important  in  the 
pathogenesis  of hepatic  encephalopathy  in  patients  with  cirrhosis  (Question  1),  2 
clinical  studies  were  performed  [Chapter  4],  Minimal  hepatic  encephalopathy  is 
common  in  cirrhosis  (178)  but  its  full  pathophysiologic  basis  remains  to  be 
completely defined.  In  the first of these studies,  an  evaluation  was made of whether 
the  presence  of minimal  hepatic  encephalopathy  is  associated  with  the  severity  of 
liver  disease,  ammonia  levels  or  the  presence  of  inflammation  and  the  factors 
determining  neuropsychological  deterioration  accompanying  induction  of 
hyperammonemia  were  assessed.  Studies  in  acute  liver  failure  show  a  correlation 
between  evidence  of a  systemic  inflammatory  response  and  progression  of hepatic 
encephalopathy  (73; 109; 110) but this has not previously been described in cirrhosis. 
Therefore,  in  the  second  study,  the  hypothesis  that  inflammatory mediators,  such  as 
nitric  oxide  and  proinflammatory  cytokines,  may  exacerbate  the  neuropsychological 
effects  of  hyperammonemia  in  cirrhosis  was  tested.  Patients  with  cirrhosis  were 
studied 24-36 hours after admission with clinical evidence of infection, and following 
its resolution.
2.  To  investigate  whether  ammonia  and  inflammation/infection  act 
synergistically  in  the  pathogenesis  of  hepatic  encephalopathy  (Question  2),  the 
pathological  changes  that  occur  in  the  brain  of mildly  hyperammonaemic  animals 
with an induced liver disease leading to rapid hepatic liver fibrosis were studied. This 
was done using the bile duct  ligated  rat  model,  with  and without  an  added bacterial 
endotoxin insult, through the administration of lipopolysaccharide.
913.  Pilot  studies  performed  by  our  group  suggested  that  phagocytosis  and 
oxidative burst in normal neutrophils may be impaired by micromolar concentrations 
of ammonia.  The  exact  mechanism  of action  underlying  this  is  unclear  but  could 
conceivably involve the inhibition of glutaminase.  However, published data suggests 
that  glutaminase  is  usually  inhibited  by  millimolar  rather  than  micromolar 
concentrations  of  ammonium  chloride  (139)  which  might  suggest  alternative 
mechanisms.  It is also known that in astrocyte cultures, exposure to ammonia results 
in cytosolic  alkalinization  leading to calcium-dependent release of glutamate.  (55)  It 
is therefore reasonable to postulate that ammonia may  cause cytosolic  alkalinization 
in  neutrophils  as  well.  Ammonia  freely  passes  into  the  neutrophil  cytosol  and  one 
possibility is that it may alter the activity of intracellular signalers  such  as mitogen- 
activated protein (MAP) kinases, p38-MAP kinase (p38‘M A PK ), Jun-kinase (JNK) and 
extracellular  signal-regulated  kinase  (ERK)  (179).  The  aim  of this  third  study  was 
therefore to characterize  some aspects of neutrophil  morphology and  function  in  the 
presence  of  ammonia,  such  as  phagocytosis  and  oxidative  burst  in  a  series  of 
observational studies. This led onto a mechanistic study in which the hypothesis was 
developed  that  p38’M A PK   signaling  may  be  involved  in  the  ammonia-induced 
impairment  of neutrophil  function.  The  impact  of modulators  of p38‘M A P K   activity 
influence  on  ammonia-induced  phagocytosis  were  investigated  and  comparable 
experiments on resting respiratory burst in unstimulated neutrophils were performed.
4.  To  explore  how  the  muscle  metabolism  of  ammonia  is  modulated  by 
inflammation, a series of studies were performed using chick embryo primary muscle 
cell cultures and later with cultures of the immortilized murine myofibroblast cell line 
C2C12  exploring  whether ammonia  metabolism,  as  measured  by  stable  amino  acid
92isotopes,  could  be  altered  by  the  addition  of  an  inflammatory  stimulus  such  as 
lipopolysaccharide.
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943.1  CLINICAL STUDY METHODS
3.1.1  SIMULATION OF AN UPPER GASTROINTESTINAL BLEED
3.1.1.1 ORAL AMINO ACID SOLUTION
In  1963  Bessman and Hawkins published their findings to show that ingestion 
of  packed  red  blood  cells  causes  a  statistically  significant  greater  rise  in  blood 
ammonia than plasma protein. (165) They concluded that in view of the fact that 95% 
of the  protein  in  an  erythrocyte  is  haemoglobin,  then  this  is  likely  to  be  a  specific 
effect  of this  protein.  The  amino  acid  composition  of the  haemoglobin  molecule  is 
shown below in Table 3.1  (180).
The Amino Acid Composition of Haemoglobin Molecule (180)
Leucine 99.8 Glutamate 33.3 Aspartate 41.6
Isoleucine 0 Asparagine 27.7 Alanine 99.8
Valine 85.9 Glutamine 11.1 Cysteine 8.3
Glycine 55.4 Methionine 8.3 Serine 44.4
Tryptophan 8.3 Arginine 16.6 Phenylalanine 41.6
Threonine 44.4 Tyrosine 16.6 Histidine 52.7
Lysine 61.0 Proline 38.8
NOTE.  Expressed  as  mmol  per  100  gram  amino acid  solution. 
Table 3.1
953.1.1.2 INDUCED HYPERAMMONEMIA
Hyperammonemia  was  induced  by  simulation  of  an  upper  gastrointestinal 
bleed was by  administration of an  oral  bolus of 75  grams of a  specifically prepared 
solution (Nutricia Cuijk, The Netherlands,  Product Number:  24143) that mimics the 
amino  acid  composition  of  the  hemoglobin  molecule  (79; 180).  The  solution  was 
freshly  made  in  200  mis  of  water  and  xanthum  gum  was  added  to  prevent 
sedimentation. The placebo solution looked identical and was comprised of xanthum 
gum only.
3.1.1.3 ETHICAL CONSIDERATIONS
Studies  were  undertaken  with  the  approval  of the  Hospital  Research  Ethics 
Committee and the written  informed consent was  obtained  from each patient before 
enrollment in the study in accordance with the Declaration of Helsinki  (1989) of the 
World  Medical  Association.  Administration  of 75  grams  of an  amino  acid  solution 
mimicking the composition of the hemoglobin molecule to patients with cirrhosis has 
been  shown  to  be  safe  and  no  significant  complications  were  observed  in  previous 
studies  (22;51;79).  Others  have  used  different  formulations  to  produce 
hyperammonemia  in  patients  (173; 181-183);  these  approaches  were  also  shown  to 
produce ammoniagenesis without any significant adverse effects.
3.1.2  MEASUREMENT OF NEUROPSYCHOLOGICAL FUNCTION
A  construct-driven  neuropsychological  test  battery  was  designed.  A  critical 
factor in developing this evaluation was the total  time period needed to complete the 
battery, so it could be used as a tool to assess changes in neuropsychological function 
in response to the administration of the amino acid solution. The following cognitive
96domains  were  tested:  concentration,  memory,  visuospatial-construction  skills  and 
motor function. The neuropsychological test battery consisted of: Trails B Test; (184) 
the  Digit  symbol  substitution  test;  (185)  the  immediate  story  recall  subtest  of the 
Randt  test  battery;  (186)  and  choice  reaction  time.  (187)  The  total  time  required  to 
perform  this  battery  of tests  was  less  than  20  minutes.  The  tests  were  performed 
immediately before the administration of the amino acid solution, and at 2 and 4 hours 
afterwards  (except  Trails  B  test  which  was  only  performed  at  0  and  4  hours).  The 
neuropsychological  tests  were  performed  by  the  same  investigator  (Dr  Rajiv  Jalan) 
and  the  patients  had  one  practice  session  of each  test.  All  the  tests  have  been  well 
validated and parallel forms were used.
3.1.2.1 TRAILS B TEST
This  test  is  a  derivative  of  the  Trail  Making  Test  (184)  and  measures  visual 
conceptual  and  visuomotor  tracking.  Patients  were  asked  to  connect  subsequent 
numbers with letters. The test has to be completed within 420 seconds.
3.1.2.2 THE DIGIT SYMBOL SUBSTITUTION TEST
The test is part of the Wechsler Adult Intelligence Schedule. (185) This test is 
used  to  assess  visuomotor  co-ordination  and  vigilance.  The  subject  substituted  a 
symbol  for a digit from a code that was visible throughout the test. A different code 
was  used  for  each  test  to  control  for  the  effect  of learning.  The  test  score  was  the 
number of symbols correctly substituted in 90 seconds.
973.1.2.3 REACTION TIME
This  test  is  part  of the  Continuous  Performance  Task  (186)  and  measures 
motor  function,  sustained  concentration  and  the  ability  to  suppress  inappropriate 
responses. The patients saw a sequence of letters (X, M, T, E) on a computer display 
at  a rate of one  letter every  1.5  seconds.  The  task was  to press the  space  bar of the 
computer as quickly as possible every time the letter E appeared, except when it was 
immediately preceded by the letter X.  Patients were presented with  10 Es requiring a 
response  and  10  Es preceded  by  Xs  not  requiring  a  response.  The  average  reaction 
time was recorded.
3.1.2.4  IMMEDIATE  STORY  RECALL  SUBTEST  OF  THE  RANDT 
MEMORY TEST
This  measures  immediate  memory  function  and  is  a  subtest  of the  Randt 
memory  test,  which  measures various  aspects  of memory  function  and  include  rote, 
associative,  discourse  and  incidental  memory  as  well  as  recall.  (187)  This  test 
measures  recall  of  20  words  from  a  paragraph  that  has  an  emotionally  charged 
substance  and  includes  fire  and  disaster.  This  single  presentation  takes  about  15 
seconds. The patient was then asked to recall the short story immediately after it had 
been read to them. After this the gist of the story was requested both immediately and 
also  after  20  minutes.  One  point  was  awarded  for  each  word  that  was  recalled 
immediately  after presentation  (acquisition).  For the gist  score,  credit was  given  for 
any block in which the precise word had been retrieved.
983.1.3 ANALYSIS OF PERIPHERAL VENOUS BLOOD
In the clinical studies, a peripheral venous blood sample was taken for analysis 
of white  cell  count  (WCC),  neutrophil  count,  C-reactive  protein  (CRP),  ammonia, 
nitric  oxide  (NOx),  and  interleukin-  6  (IL-6)  at  the  beginning  of  each  study 
immediately  prior to  the  administration  of the  amino  acid  solution.  Blood  sampling 
was repeated at 4 hours after administration of the amino acid solution for analysis of 
ammonia.
3.1.3.1  WHITE  CELL  COUNT,  NEUTROPHIL  COUNT  AND  C-REACTIVE 
PROTEIN
These  were  measured  by  standard  automated  laboratory  techniques  in  the 
haematology and chemical  pathology  laboratories, as part of a standard clinical  care 
protocol.
3.1.3.2 METHOD OF AMMONIA DETERMINATION IN PLASMA USING A 
MODIFIED BETHELOT ASSAY (INDOPHENOL) (188)
Venous  blood  was  taken  and  immediately  placed  in  ice.  Plasma  was  then 
obtained  by  centrifugation.  All  chemicals  were  supplied  from  Sigma-Aldrich  and 
were of the highest laboratory grade.
1.  Fifty pL of plasma was deproteinised by mixing immediately with  150 pL of 
5% trichloroacetic acid.
2.  This was then spun in a microcentrifuge at 11,200 g at 4 °C for 10 minutes.
3.  Fifty pL of the supernatant was pipetted out onto a 96 well plate at 30 °C for 3 
hours  in  200  pL  of  a  solution  containing  phenol  (lOmM),  nitroprusside
99(lOmM),  sodium  hypochlorite  (lOmM)  solution  and  sodium  hydroxide 
(0.5mM).
4.  The blue colour formed by reaction of ammonia with phenol and hypochlorite 
was then measured colorimetrically at 630nm. This was read in a 96 well plate 
reader (Tecan Sunrise, Salzburg, Austria).
5.  Each  sample  was  analysed  in  duplicate  and  compared  to  an  ammonium 
chloride standard curve (Figure 3.1).
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Figure 3.1
A typical ammonium chloride standard curve
1003.1.3.3  METHOD FOR SIMULTANEOUS DETECTION OF NITRATE AND 
NITRITE (NOx) IN PLASMA
Combined  NO2/NO3  levels  were  determined  from  heparinised  plasma 
samples,  by a modified Greiss test (189) which had been  obtained by centrifugation 
and stored at -80 °C. This determination predominantly represents the nitrate content 
in the sample, because the nitrite fraction alone is difficult to measure in this manner 
as  its  level  is  usually  near  the  detection  threshold  of  the  assay  (ca.  I  pM).  All 
chemicals  were  supplied  from  Sigma-Aldrich  (Poole,  Dorset,  UK)  and  were  of the 
highest laboratory grade.
1.  100 p/L of plasma was diluted  1   in 4 with phosphate buffered saline.
2.  This  was  placed  in  a  Whatman  12  kD  molecular  weight  cut  off  filter 
(Vectaspoin,  Whatman, Maidstone, UK) and spun at  18,900 g for 30 minutes 
at 4 °C to centrifugally remove proteins as described by Giovanni et al. (190)
3.  A  saturated solution of vanadium (III) chloride (400mg) was prepared  in  1M 
hydrochloric acid (50 mis) which was stored in the dark.
4.  Greiss  Reagent  A  was  prepared  from  N-(l-Naphthyl)  ethylenediamine 
dihydrochloride (0.1% w/v) in double distilled water which was stored in the 
dark.
5.  Greiss  Reagent  B  was  prepared  from  sulfanilamide  (2%  w/v)  in  5% 
hydrochloric acid which was stored in the dark.
6.  Fifty  p/L  of the  filtrate  was  pipetted  out  into  a  96  well  plate.  To  this  were 
added 50 p/L of vanadium (III) chloride solution, 50 p/L of Greiss Reagent A, 
and 50 p/L of Greiss Reagent B.
1017.  The plate was then left for 2 hours and read colorimetrically at 550nm on a 96 
well  plate  reader  (Tecan  Sunrise,  Salzburg,  Austria)  with  accompanying 
Magellan 3 software. The nitrite/nitrate in the filtrate were determined against 
a  sodium  nitrite  standard  curve  measured  utilizing  methods  described  by 
Miranda et al. (189)
8.  Each sample was analysed in duplicate.  Linear regression of the mean values 
of the absorbance at 550 nm for each standard set minus the blank values was 
utilized to determine the nitrite or total NOx  concentrations in samples. These 
values were then subtracted to give the nitrate concentration.
9.  Nitrite alone was measured in a similar manner except that samples were only 
exposed  to  Greiss  reagents  A  and  B.  Intra-  and  interassay  coefficients  of 
variation were 3.1% and 4.3% respectively.
3.1.3.4  MEASUREMENT  OF  INTERLEUKIN-6,  INTERLEUKIN-l-p  AND
TUMOUR NECROSIS FACTOR-a.
Plasma was obtained by centrifugation and stored at -80 °C.
1.  Capture  antibodies  for tumour necrosis  factor (TNF-a),. interleukin-6  (IL-6), 
interleukin-1-(3  (IL-l-P)  (BioSource  International,  Nivelles,  Belgium)  were 
coated at  1   pg/ml onto 96 well Maxisorb (NUNC, Denmark) ELISA plates.
2.  The  plates  were  blocked  with  bovine  serum  albumin  (Fraction  V,  Sigma, 
Poole,  Dorset, UK) before the addition of 100 pi standard or sample together 
with biotin-conjugated detection antibody (50 pi; 0.4 pg/ml).
1023.  After  incubation  at  room  temperature  for  2  hours  and  washing,  streptavidin 
was  added  before  incubation  with  substrate  (o-phenylenediamine 
hydrochloride) in a borate-citrate buffer.
4.  The  reaction  was  stopped  with  1.8M  sulphuric  acid  and  the  optical  density 
measured  at  450nm  referenced  against  630nm.  Individual  standard  curves 
were established and a lower limit for TNF-a detection set at 5 pg/ml. After a 
single batch analysis, the intra-assay coefficient of variation was 5.4%.
3.1.3.5  MEASUREMENT OF AMINO ACIDS
Plasma was obtained by centrifugation and deproteinised with sulphosalicylic 
acid  for  determination  of  amino  acid  concentration  by  high-performance  liquid 
chromatography (Pharmacia, Woerden, The Netherlands). This was performed at The 
Department of Surgery, Maastricht University, Maastricht, The Netherlands by Dr H. 
van Eijk and Dr N.E.P Deutz. (191)
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1043.A.1 ABSTRACT
Background:  Minimal  hepatic  encephalopathy  is  common  in  cirrhosis,  but  its 
pathophysiological basis remains undefined. This study was done to evaluate whether 
the presence of minimal hepatic encephalopathy was associated with severity of liver 
disease,  ammonia  levels  or  the  presence  of  inflammation  and  assessed  factors 
determining  neuropsychological  deterioration  accompanying  induction  of 
hyperammonemia.
Methods:  Eighty four patients with cirrhosis who had been administered a ‘simulated 
bleed’  were  studied.  A  neuropsychological  test  battery  was  performed  and  blood 
taken  for  ammonia,  WCC,  CRP,  NOx  and  IL-6,  before  and  after,  induction  of 
hyperammonemia  by  administration  of  a  solution  mimicking  the  amino  acid 
composition of haemoglobin or placebo.
Results:  The  presence  and  severity  of  minimal  hepatic  encephalopathy  were 
independent  of severity  of liver disease  and  ammonia  concentration  but  markers  of 
inflammation were significantly higher in those with minimal hepatic encephalopathy 
compared with those without.  Induction  of hyperammonemia produced deterioration 
in one or more neuropsychological tests by >1  SD in 73.3%. This was independent of 
the  magnitude  of change  in  plasma  ammonia  and  severity  of liver disease  but  was 
significantly greater in those with more marked inflammation.
Conclusion:  These data suggest that inflammation is an important determinant of the 
presence  and  severity  of  minimal  hepatic  encephalopathy.  The  change  in 
neuropsychological  function  following  induced hyperammonemia  is  greater in  those 
with more severe inflammation.
1053.A.2 BACKGROUND
The occurrence of hepatic encephalopathy in cirrhosis seriously impairs daily 
functioning  in  both  physical  and  psychological  domains.  This  neuropsychiatric 
syndrome  incorporates  a  spectrum  of  manifestations  which  include  psychomotor 
dysfunction,  impaired  memory,  increased  reaction  time,  sensory  abnormalities  and 
poor concentration. When hepatic encephalopathy is severe in cirrhosis, patients may 
develop  varying  degrees  of confusion  and  coma.  (27)  The  term  minimal  hepatic 
encephalopathy is used to define individuals with cirrhosis who have no overt clinical 
features  of  hepatic  encephalopathy,  but  who,  nevertheless,  have  significant 
abnormalities on psychometric testing and in neuropsychological performance which 
may impact on their quality of life.  Depending on the definition used the prevalence 
of minimal  hepatic  encephalopathy  has  been  shown  to  vary  between  30  -  84%  in 
cirrhotic patients. (178)
Ammonia  is  thought  to  be  central  in  the  pathogenesis  of  hepatic 
encephalopathy. In patients with impaired capacity for detoxification of ammonia into 
urea,  peripheral  glutamine  synthetase  serves  as  a  major  alternative  ammonia 
detoxification pathway. Glutamine synthesis also occurs within astrocytes and causes 
brain swelling. (45; 119)
In  a  recently  published  study,  we  showed  that  simulating  an  upper 
gastrointestinal bleed by the oral administration of a specifically prepared amino acid 
solution identical  to the amino acid profile of haemoglobin to patients with cirrhosis 
results in an increase in brain glutamine and brain water. (51) This pathophysiological 
change  was  associated  with  functional  consequences  manifested  by  worse 
neuropsychological  performances  compared  with  a  placebo-treated  group.  This
106provides a reproducible model to study the pathopysiological and functional effects of 
induced hyperammonemia.
Recent observations in patients with liver disease suggested that inflammatory 
response  may  be  important  in  the  pathophysiology  of hepatic  encephalopathy.  In  a 
preliminary  study  we  have  shown  that  induced  hyperammonemia  resulted  in 
significantly greater deterioration  in the psychotmetric tests in cirrhotic patients with 
ongoing  infection  compared  with  its  effects  after  the  infection  had  resolved.  (192) 
These  observations  served  as  the  basis  of  our  hypothesis  that  inflammation  may 
enhance the deleterious neuropsychiatric effects of ammonia.
The  aims  of this retrospective  study  in patients  with  cirrhosis  who had been 
given an amino acid  load in other study protocols,  (51 ;52;79) were  to determine the 
role  of  inflammation  (in  the  absence  of  proven  infection)  in  modulating  the 
neuropsychiatric  effects  in  cirrhotic  patients  with  no  evidence  of  overt  hepatic 
encephalopathy.  Furthermore,  the  study  was  designed  in  order  to  determine  if 
induction of hyperammonemia causes neuropsychological deterioration  in those who 
were are more inflamed at baseline.
1073.A.3 STUDY PROTOCOL
3.A.3.1  ETHICAL CONSIDERATIONS
Studies  were  undertaken  with  the  approval  of the  Hospital  Research  Ethics 
Committee and the written informed consent from each patient in accordance with the 
Declaration  of  Helsinki  (1989)  of  the  World  Medical  Association  as  detailed 
previously (3.1.1.3).
3.A.3.2 INCLUSION CRITERIA
Patients who had been previously enrolled in studies using an amino acid load, 
some  of  whom  had  been  published  (51;52;79)  were  retrospectively  studied.  All 
patients were recruited from the Edinburgh Royal Infirmary outpatient clinic and were 
included into the study if they had clinical, biochemical and histological evidence of 
cirrhosis.  At  the  time  of the  study  all  patients  were  stable  and  did  not  have  any 
evidence of overt infection on clinical assessment or overt hepatic encephalopathy as 
measured by the West Haven criteria (193). There had been no change in their clinical 
condition for the preceding 6 weeks and were not on any specific therapy for hepatic 
encephalopathy or on antibiotics. Patients who had previous or ongoing hyponatremia 
or renal impairment were not included.
3.A.3.3 EXCLUSION CRITERIA
Patients  were  excluded  if  they  had  clinical  evidence  of  overt  hepatic 
encephalopathy, diabetes, cardiovascular disease, renal dysfunction (serum creatinine 
>150  pmol/1),  serum  sodium  <130  mmol/L,  serum  potassium  <3.2  mmol/L  or  >5 
mmol/L,  concomitant  neurological  disease,  recent  gastrointestinal  bleeding  (within
108the  previous  4  weeks),  antibiotic  use,  malignancy  or  pregnancy.  Patients  had  to  be 
abstinent  from  alcohol  and  benzodiazepines  for  at  least  1   month  prior  to  the  study 
(ensured by random blood and urine testing x 2 prior to inclusion into the study).
3.A.3.4 STUDY PROTOCOL
All  patients  were  studied  after  an  overnight  fast.  The  study  involved  the 
assessment  of  the  neuropsychological  function  by  performing  a  psychometric  test 
battery and blood sampling prior to and after administration of an amino acid solution 
mimicking  the  composition  of the  haemoglobin  molecule  or  an  identical  placebo 
solution.
3.A.3.5 ORAL AMINO ACID SOLUTION
Simulation of the upper gastrointestinal bleed was by administration of an oral 
bolus  of  75  grams  of  a  specifically  prepared  solution  (Nutricia  Cuijk,  The 
Netherlands, Product Number: 24143) that mimics the amino acid composition of the 
haemoglobin molecule (79; 180) as detailed in 3.1.1.2.
3.A.3.6 MEASUREMENT OF NEUROPSYCHOLOGICAL FUNCTION
A  construct-driven  neuropsychological  test battery was designed  and used as 
described in section 3.1.2.
1093.A.3.7 BLOOD SAMPLING AND ANALYSIS
A peripheral venous blood sample was taken for analysis of WBC, neutrophil 
count,  CRP,  ammonia,  NOx,  and  IL-6  at  the  beginning  of each  study  immediately 
prior to the administration of the amino acid solution. Blood sampling was repeated at 
4 hours after administration of the amino acid solution  for analysis of ammonia and 
analysed as described in section 3.1.3.
1103.A.4 STATISTICS AND DEFINITIONS
All  the  clinical  and  biochemical  data  were  expressed  as  mean  and  standard 
error.  The  baseline  neuropsychological  function  test  scores  were  compared  to  a 
normal  population  and  were  corrected  for  age  (184-187; 194).  Patients  were 
considered to have mild minimal hepatic encephalopathy if their score was outside 2 
standard  deviations  (2SD)  of  the  population  mean  and  severe  if  their  score  was 
outside  3  standard  deviations  (3SD).  Following  the  amino  acid  solution  or  placebo 
solution,  a  deterioration  or  improvement  in  the  score  was  noted.  If  the  score 
deteriorated by more than  1   standard deviation (1SD) of the cirrhotic population mean 
in  any  of the neuropsychological  function  tests,  the  patient  was  considered  to  have 
had deterioration  in their neuropsychological  function.  A  deterioration of 2  standard 
deviations or more of the cirrhotic population mean was not used because of previous 
studies showing a relatively large value of the standard deviation from the mean. (52) 
The clinical and biochemical data of the neuropsychological deteriorators and 
non-deteriorators  were  compared  for  normal  distribution  and  equal  variance  before 
using  parametric  or  non-parmetric  statistical  analyses  using  Student’s  t-test  or  the 
Mann  Whitney  test  (Prism  software  version  3.0,  GraphPad,  San  Diego  USA).  A  p- 
value  of <0.05  was  considered  significant.  Unfortunately,  the  number  of  patients 
enrolled was insufficient to perform multivariate analysis to compare the  severity of 
the  underlying  liver  disease,  ammonia,  amino  acid  profile,  neuropsychological 
function tests and multiple inflammatory markers.
Ill3.A.5 RESULTS
3.A.5.1  PATIENTS
All  84  patients  were  clinically  stable  and  had  no  evidence  of  overt  hepatic 
encephalopathy  or  infection  on  clinical,  biochemical  or  microbiological  assessment 
(negative urine, sputum and blood cultures). All patients had biopsy proven cirrhosis 
of  varying  aetiologies.  There  were  no  significant  differences  in  the  clinical  and 
laboratory  parameters  between  the  patients  who  had  cirrhosis  as  a result  of alcohol 
and other aetiologies. Table 4.1  shows  the patient characteristics.  Thirteen of the 84 
had  moderate  ascites  and  4  had  tense  ascites,  but  in  all  cases  this  had  been 
longstanding  and  recent  diagnostic  ascitic  taps  had  excluded  spontaneous  bacterial 
peritonitis on the basis of white cell count and culture.
Table 3.2
Patient Characteristics
Mean age (Range)
n=84 (60 
male, 24 
female)
51.7 (26-79)
Aetiology ALD 50
PSC 5
PBC 7
HCV 9
NASH 2
Cryptogenic 8
Autoimmune 3
Child Pugh A 5
B 51
C 26
Ascites None 23
Mild 43
Moderate 13
Tense 4
1123.A.5.2 BASELINE DATA
3.A.5.2.1 NEUROPSYCHOLOGICAL FUNCTION 
3.A.5.2.1.1 TRAILS B TEST (TRB)
Thirty one of the 80 patients who completed the Trails B test had an abnormal 
score. A Trails B result was not obtained in 4 (2 receiving placebo and 2 receiving the 
amino  acid  solution).  Seventeen  had  a  score  that  was  2SD  above  the  normal  age- 
matched population mean but less than 3SD (mildly abnormal) and  14 had a score that 
was  3SD  or greater above  the  normal  age-matched  population  (severely  abnormal). 
Patients with the  abnormal  tests  had more  markedly  elevated  inflammatory  markers 
(WCC etc.), but the severity of liver disease and ammonia concentrations were similar 
in the 2 groups (Table 3.3).
3.A.5.2.1.2 THE DIGIT SYMBOL SUBSTITUTION TEST (DSST)
Seventy eight of the 83 patients who completed the test had a score which was 
within  normal  limits  when  compared  to  a  normal  age-matched  population.  A  result 
was  not  obtained  in  1   patient  receiving  the  amino  acid  solution.  The  5  abnormal 
scores  were  below  2SD  but  less  than  3SD  of the  normal  age-matched  population 
mean. Two of these patients also had an abnormal TRB test result
3.A.5.2.1.3 REACTION TIME
Eighty  three  of the  84  patients  who  completed  the  reaction  time  test  had  a 
score  which  was  within  normal  limits  when  compared  to  a  normal  age-matched 
population. The one abnormal  score was above 2SD but less than 3SD of the normal 
age-matched population mean.
1133.A.5.2.1.4  IMMEDIATE  STORY  RECALL  SUBTEST  OF  THE  RANDT 
MEMORY TEST
Eighty  three  of the  84  patients  who  completed  the  test  had  a  score  which  was 
within  normal  limits  when compared  to  a  normal  age-matched  population.  The  one 
abnormal  score  was  below  2SD  but  <3SD  of the  normal  age-matched  population 
mean.
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The Child Pugh score, plasma ammonia concentration and inflammatory mediators at 
baseline  in  the patients with  cirrhosis  who  had  a normal  test result  for the  Trails  B 
Test  (TRB),  a  result  which  was  >2SD  outside  the  normal  age-matched  population 
mean and a result which was >3SD outside the normal age-matched population mean.
Normal TRB time 
(secs)
Mildly abnormal 
TRB time (secs)
Severely 
abnormal TRB 
time (secs)
Child Pugh Score
A
8.9 +/- 0.27 8.8 +/- 0.39 9.0 +/- 0.5
Ammonia
(pmol/L)
75.95 +/-3.16 70.71 +/- 4.18 75.57 +/-4.64
WCC (x lO’/L) 7.29 +/- 0.42 6.63 +/-0.72 11.36+/-1.37 ***
Neutrophils (%) 70.05 +/-  1.37 70.00 +/- 3.54 77.57 +/- 2.42 *
CRP (mmol/L) 16.94 +/-  1.62 12.12+/-1.88 35.69 +/-7.45 **
NOx  (pmol/L) 19.15 +/-2.04 14.8+/-  1.5 34.46 +/-7.16 *
IL-6 (pg/ml) 20.1  +/-  1.67 18.5 +/-  1.49 36.83 +/- 7.57 *
A The Child  Pugh  Score is derived  from a  score of 1-3  given  for severity of ascites,  hepatic 
encephalopathy, INR, albumin and bilirubin. The higher the score is, the more severe the liver 
disease.
Normal TRB score = a time (secs) which falls between the mean +/- 2 standard deviations of 
a  normal  age-matched  population.  Mildly  abnormal  TRB  =  a  time  which  is  >2  standard 
deviations of a normal age-matched population and severely abnormal TRB = a time which is 
>3 standard deviations of a normal age-matched population.
All  values  are  in  table  are  expressed  as  mean  +/-  standard  error.  *  p<0.05,  **  p<0.001,
***p<0.0001
1153.A.5.3 RE-TESTING FOLLOWING ADMINISTRATION OF AMINO ACID 
SOLUTION
3.A.5.3.1 NEUROPSYCHOLOGICAL FUNCTION
None  of the  patients  entered  into  the  study  showed  any  evidence  of ‘overt’ 
hepatic  encephalopathy  either prior to  or following  the  administration  of the  amino 
acid solution. Furthermore, none of the patients who received the placebo solution had 
deterioration in their neuropsychological test scores.
3.A.5.3.1.1 TRAILS B TEST
Trails  B  test  scores  were  significantly  better  with  patients  in  the  placebo 
group.  Overall,  induced  hyperammonemia resulted  in a deterioration  in  the Trails B 
test  in  2/58  (3.5%)  patients  tested.  The  deteriorators  had  significantly  greater 
inflammatory  markers  compared  with  the  non-deteriorators;  WCC  p=0.005; 
neutrophils  p=0.03;  IL-6  p=0.001,  [Table  3.4  and  Figure  3.2].  Neither  baseline 
ammonia, nor severity of liver disease predicted neuropsychiatric response to induced 
hyperammonemia.  However,  the  baseline  neuropsychiatric  test  was  predictive  of 
patients that were more likely to deteriorate following induced hyperammonemia.  In 
those  that  had  a  normal  Trails  B  test,  only  10/35  (28.6%)  deteriorated;  whereas  in 
those  induced  with  hyperammonemia  17/23  (74%)  showed  evidence  of  further 
deterioration  in  neuropsychiatric  tests.  Importantly,  the  patients  with  abnormal 
psychometric  tests  at  baseline  had  significantly  greater  inflammatory  markers  at 
baseline; CRP p=0.04; WCC p=0.04; IL-6 p=0.04 and NOx  p=0.04.
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Child Pugh score, ammonia concentration (at 4 hours) and inflammatory mediators in 
the groups which had a deterioration in their neuropsychological function compared to 
those who did not 4 hours following the administration of the amino acid solution.
Neuropsychological Function Test Deteriorators Non-deteriorators
Mean Standard 
Error (+/-)
Mean Standard 
Error (+/-
Child Pugh Score 9.04 0.33 8.74 0.26
Ammonia (pmol/L) 92.27 4.3 88.44 4.38
WCC ( x  109/L)** 22.98 5.23 7.3 0.42
Trails B Test (secs) Neutrophils (%) * 67.87 2.2 54.92 5.08
CRP (mmol/L) 27.08 4.72 17.68 2.58
IL-6 (pg/ml) ** 33.36 4.62 17.9 1.13
NOx (pmol/L) 28.54 4.94 17.32 1.38
Child Pugh Score 9.46 0.41 8.76 0.22
Ammonia (pmol/L) 89.91 7.14 89.42 3.42
WCC ( x  109/L) ** 10.89 1.34 7.44 0.42
DSST Test Score Neutrophils (%) 75.7 2.3 71.2 1.29
CRP (mmol/L) *** 44.1 9.81 16.81 1.76
IL-6 (pg/ml) *** 43.5 8.28 19.61 1.42
NOx (pmol/L) 38.2 9.29 17.93 1.41
Child Pugh Score 8.67 0.55 8.89 0.22
Ammonia (pmol/L) 84.44 5.2 90.35 3.47
WCC ( x  109/L)** 12.33 1.64 7.37 0.39
Choice Reaction Neutrophils (%) 75.38 5.22 71.11 1.14
Time (secs) CRP (mmol/L) * 49.56 12.85 17.17 1.58
IL-6 (pg/ml) *** 49.71 8.74 19.32 1.29
NOx (pmol/L) ** 47.13 10.32 17.57 1.32
Child Pugh Score 9.09 0.29 8.87 0.29
Ammonia (pmol/L) 79.1 3.8 74.32 2.82
Immediate Story WCC ( x  109/L)* 9.11 0.79 6.62 0.31
recall subtest of Neutrophils (%) ** 75.47 1.67 68.43 1.21
the Randt memory CRP (mmol/L) ** 28.09 4.34 13.09 1.0
test IL-6 (pg/ml) *** 30.34 3.43 16.26 0.99
NOx (pmol/L) ** 27.91 3.63 14.2 0.77
*p<0.05, **p<0.001, ***p<0.0001
117Baseline TRB 4 hours post amino
acid/placebo solution
Within normal range 
n=49
2-3 Standard 
deviations outside the 
normal range 
n=17
>3 Standard 
deviations outside the 
normal range 
n=14
placebo n=14
aa solution n=35
placebo n=6
aa solution n=11
placebo n=2
aa solution n=12
All improve
10 deteriorate
25 do not 
deteriorate
All improve 
5 deteriorate
6 do not 
deteriorate
All improve
11  deteriorate
1  does not 
deteriorate
Figure 3.2
A diagram to show the outcome of the Trails B test (TRB) [secs] at baseline and 4 
hours following administration of the amino acid (aa) or placebo solution.
1183.A.5.3.1.2 THE DIGIT SYMBOL SUBSTITUTION TEST (DSST)
Digit Symbol Substitution test scores were significantly better with patients in 
the  placebo  group.  The  deteriorators  (11/71)  had  significantly  greater  inflammatory 
markers  compared  with  the  non-deteriorators  (WCC  p=0.008;  CRP  p=0.0005;  IL-6 
p=0.0006).  Neither  baseline  ammonia,  nor  severity  of  liver  disease  predicted 
neuropsychiatric response to induced hyperammonemia [Table 3.4].  In those patients 
with  an  abnormal  baseline  digit  symbol  substitution  test  score  who  received  amino 
acid solution,  1/3 (33%) where shown to have an improved Digit Symbol Substitution 
test  score;  compared  to  the  11/55  (20%)  patients  who  had  a  normal  baseline  Digit 
Symbol Substitution test score and later received amino acid solution (Figure 3.3).
119Baseline DSST 4 hours post amino
acid/placebo solution
Within normal range 
n=78
2-3 Standard 
deviations outside the 
normal range 
n=5
placebo n=23
aa solution  n=55
placebo n=1
aa solution n=4
All improve 
11  deteriorate
44 do not 
deteriorate
Improved
3 remained the 
same
1  improves
Figure 3.3
A  diagram  to  show  the  outcome  of the  Digit  symbol  substitution  test  (DSST)  at 
baseline  and  4  hours  following  administration  of the  amino  acid  (aa)  or  placebo 
solution.
1203.A.5.3.1.3 REACTION TIME
Reaction  times  were  significantly  better with  patients  in  the  placebo  group. 
The  deteriorators  (9/84)  had  significantly  greater  inflammatory  markers  compared 
with  the  non-deteriorators  (WCC  p=0.004;  CRP  p=0.03;  IL-6  p=0.0005  and  NOx 
p=0.006)  [Table  3.4].  Neither  baseline  ammonia,  nor  severity  of  liver  disease 
predicted neuropsychiatric response to induced hyperammonemia [Table 3.4], In the  1  
patient  with  an  abnormal  baseline  reaction  time  who  received  amino  acid  solution, 
there was no deterioration in reaction time; compared to the 9/59 (15%) patients who 
had  a  normal  baseline  reaction  time  and  later received  amino  acid  solution  [Figure 
3.4]
121Baseline reaction time 4 hours post amino
acid/placebo solution
Within normal range 
n=83
placebo n=24
aa solution n=59
^   All improve
-►  9 deteriorate
2-3 Standard 
deviations outside the 
normal range 
n=1
placebo n=0
aa solution  n=1 Did not 
deteriorate
Figure 3.4
A diagram to show the outcome of the Choice reaction time test at baseline and 4 
hours following administration of the amino acid (aa) or placebo solution.
1223.A.5.3.1.4  IMMEDIATE  STORY  RECALL  SUBTEST  OF  THE  RANDT 
MEMORY TEST
Immediate  story  recall  scores  were  significantly  better  with  patients  in  the 
placebo  group.  The  deteriorators  (33/84)  had  significantly  greater  inflammatory 
markers compared with the non-deteriorators (CRP p=0.005; WCC p=0.02; neutrophil 
count  p=0.0003;  IL-6  p=0.0002;  NOx   p=0.001).  Neither  baseline  ammonia,  nor 
severity  of  liver  disease  predicted  neuropsychiatric  response  to  induced 
hyperammonemia  [Table 3.4].  In the  1   patient with  an  abnormal baseline immediate 
story recall score there was no change in the test score, but the patient only received 
placebo.  In the patients who had a normal baseline immediate  story recall  score and 
later  received  amino  acid  solution,  33/60  (55%)  showed  a  deterioration  in  their 
immediate story recall score [Figure 3.5].
123Baseline immediate story 
recall
4 hours post amino
acid/placebo solution
All improve placebo n=23
Within normal range 
n=83 33 deteriorate
aa solution n=60
27 do not 
deteriorate
2-3 Standard
deviations outside the
normal range
n=1
■►placebo n=1 ►   Improved
Figure 3.5
A   diagram  to  show  the  outcome  of  the  immediate  story  recall  subtest  of  the 
Randt  memory  test  at  baseline  and  4  hours  following  administration  of  the 
amino acid (aa) or placebo solution.
1243.A.6 DISCUSSION
This  study  supports  the  conjecture  for  the  importance  of  ammonia  in  the 
pathogenesis of hepatic encephalopathy, but suggests that the inflammatory response 
may be important in the determining the  neuropsychiatric  effects  of ammonia rather 
than  the  severity  of underlying  liver disease  or hyperammonemia.  Also,  it  has  been 
shown for the first time that those patients that have abnormal neuropsychiatric tests 
have more likelihood of further deterioration with induced hyperammonemia.  As the 
patients  with  abnormal  neuropsychiatric  tests  at  baseline  also  had  more  marked 
inflammation, it is not possible to clarify whether the baseline mental or inflammatory 
states determines adverse neuropsychological effects of induced hyperammonemia.
An important observation of this study is that it demonstrates that some of the 
neuropsychological tests in the battery used are more useful  in differentiating mental 
state  at baseline, while  other tests  are  more  discriminating  in  patients  with  cirrhosis 
and  ammonia-induced  neuropsychological  deterioration.  The  Trails  B  test  was  the 
only test in the battery which differentiated neuropsychological  impairment  between 
patients with cirrhosis in the basal state.  The Trails B test reflects attention shift, but 
its  execution  is  also  influenced  by  visual  search,  psychometric  speed,  fine  motor 
execution,  and by  a  knowledge  of,  and  familiarity  with  the  alphabet sequence.  (29) 
Why  this  test  should  be  more  sensitive  than  the  Digit  Symbol  Substitution  test  is 
unclear,  as  this  assesses  visuomotor  coordination  and  vigilance  and  is  part  of the 
recently  recommended  Psychometric  Hepatic  Encephalopathy  Score  (PHES)  along 
with  Number  Connection  Tests  A  and  B,  line  tracing  and  serial  dotting.  However 
even the PHES score only correctly classified 63% of patients with cirrhosis initially 
which  shows  that  no one  neuropsychological  test  is  entirely  specific  for diagnosing
125minimal  hepatic  encephalopathy.  (195)  In  a  previous  study  it  was  noted  that  the 
immediate story recall subtest of the Randt memory test was not sensitive at detecting 
ammonia-induced deterioration of the mental state. (52) The explanation why this test 
should  be  normal  in  the  basal  state  but  deteriorate  following  induced- 
hyperammonemia is unclear but supports the idea that hyperammonemia may have a 
selective  effect  on  the  neuronal  pathways  controlling  processes  associated  with 
memory and learning. (196)
The  patients  in  this  study  did  not  show  overt  signs  of infection  and  were 
clinically stable at the  time of enrolment in this study.  Despite  this,  several  patients 
had  raised  inflammatory  markers.  The  mechanism  causing  elevated  inflammatory 
markers  in  the  absence  of  overt  infection  is  unclear,  but  may  reflect  chronic 
endotoxemia that is a well known feature of these patients. The relationship of raised 
inflammatory mediators  in  those  who  had  abnormal  neuropsychological  function  at 
baseline,  and  deteriorated  following  induced-hyperammonemia,  suggests  that 
inflammation may be synergistic and modulate the effects of hyperammonemia.
Further  support  for  interaction  between  ammonia  and  inflammation  is 
provided in a recent paper by Liu et al (121), who showed that alteration of gut flora 
with either administration of fibre and probiotics was associated with improvement in 
the severity of minimal hepatic encephalopathy compared with a control group. They 
showed that this improvement in minimal hepatic encephalopathy was associated with 
a reduction in endotoxaemia and ammonia concentration.
The  specific  mechanism  by  which  inflammation  and  oxidative  stress 
modulates neuropsychological  function remains to be elucidated but recent work has 
highlighted  several  possible  mechanisms.  Firstly  in  the  periphery,  inflammatory 
mediators  acting  on  vagal  afferents  will  activate  the  nucleus  tractus  solitarius,  the
126primary  projection  of the  vagus  nerve  (197)  and  subdiaphragmatic  vagotomy  will 
abrogate  the  induction  of IL-1(3  messenger  RNA  in  rat  brain  by  peripheral  IL-lp. 
(198)  Secondly, brain endothelial  cells  have receptors  for IL-ip  and TNF-a.  These 
can transduct signals which can culminate in the intracerebral synthesis of nitric oxide 
and  prostanoids.  (80)  Perivascular  cells  of macrophage  origin  may  be  a  target  for 
these  cytokine  effects.  (86)  Thirdly,  cytokines  may  enter  the  brain  through  the 
circumventricular organs (sites lacking a blood brain barrier) and diffuse directly into 
brain  parenchyma.  (80)  This  may  alter  glutaminergic  neurotransmission  (83)  and 
increase the number of peripheral-type benzodiazepine binding sites which may alter 
cellular osmotic homeostasis.  (84)  Cytokines  may  also modulate  ammonia diffusion 
and  it  has  been  shown  that  TNF-a  and  1L-6  increase  fluid  phase  permeability  and 
ammonia  diffusion  in CNS-derived endothelial  cells.  (85)  High circulating  levels  of 
TNF-a following an intravenous bolus of endotoxin resulted in reduced cerebral blood 
flow  and  this  might  suggest  why  inflammation  causes  neuropsychological 
deterioration  and  changes  in  cerebral  blood  flow.  (199)  Fourthly,  production  of 
reactive  oxygen  species  and  increased protein  tyrosine  nitration by  benzodiazepines 
may  alter  astrocyte  function  and  contribute  or  precipitate  episodes  of  hepatic 
encephalopathy. (200)
In  summary,  these  data  suggest  that  the  presence  and  severity  of minimal 
hepatic encephalopathy is independent of the degree of hyperammonemia and severity 
of liver  disease  but  that  there  is  an  important  synergistic  role  of inflammation  in 
modulating the neuropsychological effects of ammonia.
127STUDY B
AN INVESTIGATION INTO THE EXACERBATION OF THE 
NEUROPSYCHOLOGICAL EFFECTS INDUCED BY 
HYPERAMMONEMIA IN CIRRHOSIS DUE TO AN INCREASED 
SYSTEMIC INFLAMMATORY RESPONSE
This study has been published:
Systemic  inflammatory  response  exacerbates  the  neuropsychological  effects  of 
induced hyperammonemia in  cirrhosis.  Shawcross  DL,  Davies NA, Williams  R.  and 
Jalan R. Journal of Hepatology 2004; 40:247-254. (192)
1283.B.1 ABSTRACT
Background:  Studies  in  acute  liver  failure  show  correlation  between  evidence  of a 
systemic  inflammatory  response  syndrome  (SIRS)  and  progression  of  hepatic 
encephalopathy. In this study, the hypothesis that SIRS mediators, such as nitric oxide 
and  proinflammatory  cytokines,  may  exacerbate  the  neuropsychological  effects  of 
hyperammonemia in cirrhosis was tested.
M ethods:  Ten patients with cirrhosis were studied, 24-36 hours after admission with 
clinical  evidence  of infection,  and  following  its  resolution.  Hyperammonemia  was 
induced  by  oral  administration  of an  amino  acid  solution  mimicking  haemoglobin 
composition.  Inflammatory  mediators,  nitrate/nitrite,  ammonia,  amino  acid  profiles, 
and a battery of neuropsychological tests were measured.
Results:  The hyperammonemia generated in response to administration of an amino 
acid solution was similar prior to and after resolution  of the  inflammation  (p=0.82). 
With  treatment  of  the  infection  there  were  significant  reduction  in  WBC,  CRP, 
nitrate/nitrite,  IL-6,  IL-1B  and  TNF-a.  Induced  hyperammonemia  resulted  in 
significant  worsening  of  the  neuropsychological  scores  when  patients  showed 
evidence of SIRS but not after its resolution.
Conclusion: The significant deterioration of neuropsychological test scores following 
induced hyperammonemia during the inflammatory state, but not after its resolution, 
suggests that the inflammation and its mediators may be important in modulating the 
cerebral effect of ammonia in liver disease.
1293.B.2 BACKGROUND
Hepatic encephalopathy is a neuropsychiatric syndrome, which incorporates a 
spectrum  of  manifestations,  which  include  psychomotor  dysfunction,  impaired 
memory, increased reaction time, sensory abnormalities and poor concentration. This 
occurs  on  the  background  of severe  liver dysfunction  and  has  the  potential  for  full 
reversibility. (27) Ammonia is detoxified in the brain by the synthesis of glutamine in 
astrocytes  from  amidation  of glutamate  by  glutamine  synthetase  and  this  metabolic 
event  is  thought  to  be  central  in  the  pathogenesis  of hepatic  encephalopathy.  (201) 
The  prevailing  hypothesis  suggests  that  the  accumulation  of  glutamine  in  the 
astrocytes  induced  by  hyperammonemia  produces  osmotic  stress  and  causes  the 
astrocytes  to  swell.  (49)  However,  a  direct  correlation  between  plasma  ammonia 
concentrations  and  severity  of hepatic  encephalopathy  is  not  found  and  additional 
factors  may  be  important.  In  patients  with  acute  liver  failure,  the  presence  of  a 
systemic  inflammatory  response  syndrome  (SIRS)  was  recently  shown  to  confer  a 
poorer neurological outcome. (109)  In cirrhosis, infection is a common precipitant of 
hepatic  encephalopathy  suggesting  that  inflammation  may  be  important  in  its 
pathogenesis.  Astrocytes  belong  to  the  macrophage  lineage  and  therefore  have  an 
associated  range  of cytokine  responses.  Increased  signalling  factors  such  as  nitric 
oxide  and  proinflammatory  cytokines  may  be  important  in  modulating  the 
neuropsychological response to hyperammonemia. (80)
One  of the  most  common  precipitating  events  of hepatic  encephalopathy  in 
cirrhosis  is  upper gastrointestinal  bleeding  which  produces  hyperammonemia. (165) 
Simulating  the  metabolic  effects  of  an  upper  gastrointestinal  bleed  by  the  oral 
administration  of  erythrocytes  has  been  shown  to  induce  hyperammonemia  and
130behavioural  disturbance  in  portacaval  shunted  rats.  (202)  In  a  recently  published 
placebo-controlled study, it was shown that simulating an upper gastrointestinal bleed 
by the oral  administration of a specifically prepared amino acid solution  identical to 
the  amino  acid  profile  of haemoglobin  to  patients  with  well-compensated  cirrhosis, 
resulted  in hyperammonemia but was not associated with  significant deterioration in 
neuropsychological  tests.  However,  the  neuropsychological  function  in  the  group 
administered  the  placebo  improved  significantly  suggesting  that  induced 
hyperammonemia produced a learning difficulty in the population studied. (79)
This  study  was  designed  to  test  the  hypothesis  that  inflammatory  mediators, 
such as nitric oxide and proinflammatory cytokines exacerbate the neuropsychological 
effects  of hyperammonemia  in  patients  with  cirrhosis.  We  therefore  evaluated  the 
changes  in neuropsychological  function  following  induction of hyperammonemia by 
oral  administration  of  a  specifically  prepared  solution  mimicking  the  amino  acid 
composition  of haemoglobin  in  patients  with  cirrhosis  with  evidence  of  systemic 
inflammatory response, (203) and after its resolution.
1313.B.3 STUDY PROTOCOL
3.B.3.1  ETHICAL CONSIDERATIONS
These are described in section 3.1.1.3.
3.B.3.2 INCLUSION CRITERIA
Patients  were  included  if  they  had  clinical  and  histological  evidence  of 
cirrhosis  and  had  a  SIRS  score  of 2  or more.  The  components  of SIRS  include  the 
following: temperature >38 °C or <36 °C; heart rate >90 beats per minute; tachypnoea 
>20  breaths  per minute  or  PaC02  <4.3  kPa;  white  blood  cell  count  (WBC)  >12  x 
109/L or the presence of >10% immature neutrophils.
3.B.3.3 EXCLUSION CRITERIA
Patients  were  excluded  if  they  had  clinical  evidence  of  overt  hepatic 
encephalopathy,  (193)  diabetes,  cardiovascular  disease,  renal  dysfunction  (serum 
creatinine >150 pmol/1), serum sodium <130 mmol/L, serum potassium <3.2 mmol/L 
or  >5  mmol/L,  concomitant  neurological  disease,  recent  gastrointestinal  bleeding 
(within the previous 4 weeks), malignancy or pregnancy. Patients had to be abstinent 
from alcohol and benzodiazepines for at least  1   month prior to the study.
3.B.3.4 STUDY PROTOCOL
Patients  were  studied  within  24  -   36  hours  after  correction  of volume  and 
electrolyte  disturbances  and  again  after  resolution  of  the  inflammatory  response 
(defined  as  normalisation  of clinical  indices  of  infection,  WBC  and  C  -  reactive 
protein).  All  patients  were  studied  following  an  overnight  fast.  Antibiotics  were
132commenced  on  the  day  of  admission  and  the  first  study  was  performed  on  the 
following day. No patient received more than 3  doses of antibiotics prior to the first 
study  being  completed  and  all  patients  were  given  a  7-day  course  of  a  suitable 
antibiotic. The second study was performed on the day the patient was thought to be 
well  enough  for  discharge  [mean  9;  range  7-12  days].  Each  study  involved 
assessment of the neuropsychological function and blood sampling prior to and after 
administration of the amino acid solution [Figure 3.6].
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Figure 3.6
Summary of Study Design.
1343.B.3.5 ORAL AMINO ACID SOLUTION
Simulation of the upper gastrointestinal bleed was by administration of an oral 
bolus of 75 grams of a specifically prepared solution as described in section 3.1.1.2.
3.B.3.6 MEASUREMENT OF NEUROPSYCHOLOGICAL FUNCTION
A construct-driven neuropsychological  test battery was designed and  used as 
described  in  section  3.1.2.  The  following  cognitive  domains  were  tested: 
concentration,  memory,  visuospatial-construction  skills  and  motor  function.  The 
neuropsychological  test  battery  consisted  of:  Trails  B  Test;  (184)  the  Digit  symbol 
substitution  test;  (185)  the  immediate  story  recall  subtest  of the  Randt  test battery; 
(187)  and choice reaction  time. (186) A  full  description of the test battery used  has 
been previously described.  (51) The  total  time required to perform this battery was 
less  than  20  minutes.  The  test  battery  was  performed  immediately  before  the 
administration  of the  amino  acid  solution,  and  at  2  and  4  hours  afterwards  (except 
Trails B test which was only performed at 0 and 4 hours). The same investigator (Dr 
Rajiv Jalan) performed the neuropsychological tests and the patients had one practice 
session  of each  test.  All  the  tests  have  been  well  validated  and parallel  forms  were 
used.
3.B.3.7 BLOOD SAMPLING AND ANALYSIS
A peripheral venous blood sample was taken for analysis of WBC, neutrophil 
count, CRP, ammonia, amino acids, NOx, IL-6, IL-1B and TNF-a at the beginning of 
each  study  immediately  prior to  the  administration  of the  amino  acid  solution.  This 
was  repeated  after  2  and  4  hours  for  analysis  of  ammonia  and  amino  acids  as 
described in section 3.1.3.
1353.B.4 STATISTICS
All the data are expressed as median and range. Results were compared using the 
Wilcoxon Sign Rank test. (Prism software version 3.0, GraphPad, San Diego USA). A 
p-value of <0.05 was considered significant.
1363.B.5 RESULTS
3.B.5.1 PATIENTS
Twelve  patients  with  cirrhosis  were  recruited  from  Edinburgh  Royal 
Infirmary;  of these  ten  completed  the  study  and  are  the  subject  of this  report.  Two 
patients were excluded because of worsening in clinical condition with progression to 
renal  dysfunction  in  one  and  development  of ‘overt’  hepatic  encephalopathy  in  the 
other. Each patient had end-stage biopsy-proven cirrhosis, was on the waiting list for 
an  orthotopic  liver  transplant  and  had  been  admitted  to  the  hospital  with  clinical 
evidence  of mild  SIRS.  (203-205)  The  SIRS  was  due  to  confirmed  infections.  All 
patients were clinically stable and had no overt evidence of hepatic  encephalopathy. 
Six  of the  patients  were  male  (mean  age  52;  range  43  to  61).  Patient  details  are 
summarised in Table 3.5.
137iadividual  p a u e il characlesrLstijCS
Patient Sex Age .Aetiology Source of sirs Antibiotic BK1I Pugh
score
Severity 
{Child 1
HE gride Ascites
1 M 56 NASH Urirnrjr tract i iifeciicin Ciprofloxacin 26 9 b 0 Ye*
M 45 PBC Urinar> tract infection Cipro  tk-xacin 27 10 C 0 Ye*
3 M 51 Autoimmune
hepatitis
Spontaneous bacterial 
perikxii tL s
Ciprotk-xacin 23 10 C 0 Ye*
1 F 58 PBC Che si infection Cef uroxime 31 o B 0 No
5 F 61 PSC Spontaneous hoc ter i ll 
peri kxii tit
Ciprofloxacin 28 10 C 0 Ye*
6 M 43 Cryptogenic Urinary tract infection Gprofoxacin 23 9 b 0 Ye*
« F 49 Alcohol Methidllin re-si slant 
Ssaphy Icvwncr aureus 
bacteremia
Vancomyc in 20 12 c c* Ye*
8 M >1 Alcohol SjK.-nuin-c-.Kj-i bacterial 
peritonitis
Ciprotk-xacin 27 10 c 0 Ye*
9 F 53 HCV Source of infection unclear Oeturoxinne
and
Me tronida^nle
26 11 c 0 Yes
10 M 45 HCV Oiest infection Ofuroxime 28 9 b 0 Ye*
Table 3.5
A table to summarise the characteristics of the study patients.3.B.5.2 CLINICAL AND BIOCHEMICAL INDICES
The  median  CRP  [on  admission:  55  mg/L  (34  -   112)  and  post-antibiotic 
therapy: 20.5 mg/L (18-31)  {p=0.002}], WBC [admission:  14.2 x  109/L (9 -23) and 
post: 9 x  109 /L (5.6 -  12.2)  {p=0.002}] and neutrophil count [admission:  82 x  109 /L 
(78 -  82) and post: 69.5 x  109 /L (65 -  78)  {p=0.002}] were reduced significantly with 
resolution of the inflammatory state.
No change was observed in Child Pugh  Score (206) and the grade of hepatic 
encephalopathy  remained  unchanged  at  zero  throughout  the  study.  There  was  no 
significant change in liver function tests, albumin or prothrombin time between the 2 
studies. The median bilirubin on admission was 78  pmol/1 (56 -   132) and 81.5  (71  -  
143)  {p=0.106}  in  the  post-inflammatory  state.  Table  3.6  outlines  the  clinical  and 
biochemical indices of each patient.Table 3.6
Temperature, lieart  rate. respiratory. mean  arterial  blood  pressure,  auuiumia, liilirubia.  C’KF,  VVBL" and  neutrophil count  before  nod  follov.iii^ 
antibiotic therapy
Patient {pre/pcKf 
treitmenl)
Teirperai urt*
X )
Heart rite 
ibeals per rein)
Respi ratlin* rate 
(breathe per mint'
Mean arterial 
blood pres>ure 
(rnmHg)
Ammonia
{pmcl'l)
Bilirubin 
ip. rml.’li
CRP
(rcjpl)
WBC 
{ X I 0°.'l)
Neutrtfihil 
count 
i X lOr ,Vl)
I Pre 3S.I 83 67 64 67 67 13.2 11.75
P*:*i (day 91 5? T? J7 76 59 71 18 9 6.57
2 Pre 38.2 92 23 66 76 111 71 16 14 jQS
Pc>M  (day 10) 36.5 81 n 71 69 121 23 12.2 932
3 Pre 38.2 93 19 77 78 56 54 23 2d* .93
P :*M  iday 8 .1 36.5 76 17 79 71 78 21 12 8.52
4 Pre 57.8 82 19* 77 56 132 112 15 10.09
Pc*fl4 (day 12) 63 16 79 68 127 31 9 5.94
5 Pre 38.2 78 15 67 9? 78 54 15 12.3
Po*l (day 8 j 3 * 7 73 17 72 88 82 9 9 5.85
6 Pre 3*5 78 21 71 112 78 78 12 10.44
P.  el  (day 7) ^ 1 81 16 79 132 81 29 9 6.39
2 Pre 38.7 73 21 70 89 89 56 13.3 10.51
P;el  iday  11  > 37 71 17 72 98 78 13 8.9 6.05
8 Pre 38.3 81 23 78 91 78 41 9 7.11
P uM  (  day 71 37.3 72 21 82 89 87 5.6 3.75
9 Pre 38.3 88 26 73 67 132 47 13.1 14.12
P;e4 iDu.; 9) 37.2 78 18 81 71 143 23 11.2 7.28
10 Pre 37.7 72 21 64 88 65 34 13 10.66
Peel  iday  12) 37.1 73 21.17 73 76 78 11 8.7 6.18
*  Pitient 4  hud PuCa  < 4.3  kPu,  fulfilling  I   criterieti foi  SIRS.3.B.5.3 AMMONIA AND AMINO ACIDS
The  median  basal  venous  ammonia  concentration  was  similar  in  the 
inflammatory state and following antibiotic therapy [83 (56 -  112) and 73.5 (59 -  132) 
pmol/L respectively). The ammonia generated in response to the simulated bleed did 
not differ between the 2 studies (p=0.82) [Figure 3.7],
The  concentrations  of leucine  (p<0.01),  valine  and  phenylalanine  (p<0.001) 
increased following administration of the amino acid solution and the concentration of 
isoleucine decreased (p<0.001), but there was no difference between the inflammatory 
and post-inflammatory states [Table 3.7].Pre Treatment Post Treatment
160-j
140- 
I   100-
S  80'
I   60-
E
<  40-
20 - 
0-
0  2  4  0  2  4
Tim* (hours)  Tim* (hours)
Figure 3.7
Change  in  venous  ammonia  concentration  (jimol/L)  in  each  of  the  ten  patients 
administered the amino acid solution at 0, 2 and 4 hours in the study performed in the 
inflammatory state and then in the repeat study following antibiotic therapy (p = ns).
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m \r.3.B.5.4  INFLAMMATORY MEDIATORS
Measured  inflammatory  markers,  nitrate/nitrite,  IL-6,  IL-1B  and  TNF-a  were 
significantly  reduced  with  resolution  of the  infection  (nitrate/nitrite  p=0.002,  IL-6 
p=0.002,  IL-1B  p=0.031  and  TNF-a  p=0.031)  [Figure  3.8].  IL-1B  and  TNF-a  levels 
were detectable in only 6 (patients  1,2,4,6,7 and 8). Patients 3 and 5 had undetectable 
levels of IL-1B and TNF-a in both the inflammatory and post-inflammatory states. IL- 
1B and TNF-a assays were not available in patients 9 and  10.100-1
i   60- 
I
< ?   *0-  _l
20 -
Past Traatmant
40
z:
20
10
PastTrwtowsnt
< w -
80-
z H
PastTraatraarn Pna Treatment Post Treatment.
Figure 3.8
Measured concentrations of IL-6 (pg/ml), IL-16 (pg/ml), TNF-a (pg/ml) and nitrate/nitrite (pmols/L) in each of patients in the inflammatory and 
the post-inflammatory state (TNF-a and IL-113 were measured in only 8 patients and values were undetectable in 2 patients).3.B.5.5 NEUROPSYCHOLOGICAL FUNCTION
None of the patients showed any evidence of an altered mental  state or overt 
hepatic encephalopathy following the administration of the amino acid solution.
3.B.5.5.1  TRAILS B TEST
Data analysis could only be completed in 6 of the  10 patients. This is because 
the test has to be completed in 420 seconds and if the patient took any longer, the test 
was  abandoned  and  a  time  of 420  seconds  recorded.  4  of the  patients  took  >420 
seconds to  complete the test at 0  and 4  hours  following  administration  of the  amino 
acid solution in the inflammatory state and  1   patient took >420  seconds to complete 
the test in both the studies. There were no significant differences in the time taken to 
complete  the  test  between  the  inflammatory  and  post-inflammatory  state  both  at 
baseline  (p=T)  and  at  4  hours  (p=0.63).  There  were  however  marked  changes  at 
baseline between the inflammatory and post-inflammatory state in individual patients, 
with  8  patients  improving  their performance  time  and  2  patients  showing  a  marked 
deterioration [Figure 3.9],PRE
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400 '
,300-
i  200- 
100- 
0
2  3
Tine (hour)
DSST {p=0.004 at 4 hrs)
POST
400-
45  300
200-
100
0 2 3 1 4
Time (hour)
10
1  5  5 "
Time (hour)
Continuous Performance Test (p=0.002 at 4 hrs)
1350 
|   1200i
1  1050h  
1   900-
750
H  1 ------5------5  T
Time (hour)
Immediate Recall Memory Test (p-0.002 at 4 hrs)
p<D.01
Time (hour)
0   1 2  3   4
Time (hour)
1 0 6 O J P-0,4
900
750
0 1 2 3 4
Tens (hour)
T
1  2   3
Time ihour)
Figure  3.9  Change  in  neuropsychological  function  (Trails  B  test,  Digit  Symbol 
Substitution  test,  Choice  reaction  time  (secs)  and  Immediate  story  recall)  in  patients 
administered the amino acid solution at 0, 2 and 4 hours performed in inflammatory state (pre) 
and  in  the  post-inflammatory  state.  [Trails  B  test:  data  from  4  of the  patients  tested  on 
admission are not shown as they took more than 420 seconds to complete the test at 0 and 4 
hours following administration of the amino acid solution in the inflammatory state and  1   of 
them took more than 420 seconds to complete the test  in  both  the  studies].  The difference 
between groups was tested using the Wilcoxon Signed Rank test.
1473.B.5.5.2 THE DIGIT SYMBOL SUBSTITUTION TEST
There was a significant overall improvement in the baseline scores between the 
inflammatory  and  post-inflammatory  states  (p=0.002).  Induced  hyperammonemia 
resulted in significant worsening (p=0.004) of the test scores at 4 hours when patients 
showed evidence of inflammation (Figure 3.9). After resolution of inflammation, there 
was  no  significant  change  in  the  score  from  baseline  following  induced 
hyperammonemia (p=0.8).
3.B.5.5.3 REACTION TIME
There was a significant overall improvement in the baseline scores between the 
inflammatory and post-inflammatory  states  (p=0.01).  The  induced hyperammonemia 
resulted in a significant deterioration (p=0.002) in the reaction time at 4 hours when 
patients  showed  evidence  of  inflammation  (Figure  3.9).  After  resolution  of 
inflammation,  there  was  no  significant  change  in  the  score  from  baseline  following 
induced hyperammonemia (p=0.4).
3.B.5.5.4  IMMEDIATE  STORY  RECALL  SUBTEST  OF  THE  RANDT 
MEMORY TEST
There was no significant overall  improvement in the baseline scores between 
the  inflammatory  and  post-inflammatory  states  (p=0.58).  The  induced 
hyperammonemia  resulted  in  a  significant  deterioration  (p=0.002)  in  the  number 
scored at 4 hours when patients showed evidence of inflammation (Figure 3.9). After 
resolution of inflammation, there was no significant change in the score from baseline 
following induced hyperammonemia (p=0.6).
1483.B.6 DISCUSSION
The results of this study show that hyperammonemia induced by administration of 
an amino acid solution to cirrhotic patients, results in deterioration in neuropsychological 
function  in the  presence  of a  systemic  inflammatory  response.  Following  resolution  of 
SIRS,  there  was  no  deterioration  in  neuropsychological  function  despite  equivalent 
severity  of induced  hyperammonemia.  We  believe  that  these  data  provide  supportive 
evidence  suggesting  that  inflammation  plays  a  crucial  role  in  the  neuropsychological 
effects of hyperammonemia in patients with cirrhosis.
The  most  important  observation  of this  study  is  that  the  induction  of a  similar 
degree  of  hyperammonemia  produced  significant  deterioration  in  all  the 
neuropsychological  function  tests  only  in  the  inflammatory  state.  This  suggests  that 
inflammatory  mediators  may  modulate  the  effects  of hyperammonemia.  SIRS  is  the 
clinical manifestation of inflammation and therefore the end product of the activation of a 
normally  quiescent  system  comprising  many  components,  including  leucocytes, 
endothelial  cells  and  cytokine  networks.  Patients  performed  significantly  better  at 
baseline in the post-inflammatory state in 2 of the 4 neuropsychological tests (DSST and 
Choice  Reaction  time).  In  the  Trials  B  tests  there  were  marked  changes  at  baseline 
between  the  inflammatory  and  post-inflammatory  state  in  individual  patients,  with  8 
patients improving their performance time. The difference in the direction of the changes 
and the exclusion  in the analysis of anyone taking longer than 420 seconds to complete 
the test (4 of the 8 patients who had an improvement in their performance time) is likely 
to  explain  the  lack  of statistically  significant differences  in  the  group  when  tested  as  a 
whole. The lack of significant improvement in overall baseline scores for the ImmediateRecall  Memory test  is also  likely to be  for similar reasons, where 4  patients  showed a 
dramatic improvement, 3 remained the same and 3 marginally deteriorated.
The  association  between  infection  and  impaired  brain  function  is  well 
recognised.(207)  Septic  encephalopathy  can  arise  from  the  action  of  inflammatory 
mediators on the brain or a cytotoxic response by brain cells to these mediators.  Septic 
encephalopathy  is  usually  a  sequelae  of severe  sepsis  complicated  by  multiple  organ 
failure  and  hypotension.(98)  The  patients  in  this  study  however,  although  fulfilling 
criteria  for  SIRS,  had  relatively  mild  infections  and  no  evidence  of  ‘overt’  hepatic 
encephalopathy.  We  showed  that  resolution  of  inflammation  was  associated  with 
improvement in the mental state despite similar liver function and ammonia concentration 
further  highlighting  the  importance  of  inflammation  in  modulating  derangement  in 
neuropsychological  dysfunction.  It  is  not possible  from  the present  study  to  define  the 
neuropsychological  effects  of mild  sepsis,  which  need  to  be  further  explored.  Severe 
sepsis  causes  plasma  and  brain  amino  acids  to  become  deranged  with  a  decrease  in 
branched chain amino acid’s (e.g.  isoleucine) and an  increase in neutral  amino acids in 
the  brain  similar  to  the  findings  in  portosystemic  encephalopathy.(99;100)  In  patients 
with sepsis it was shown that aromatic amino acids (e.g. phenylalanine) correlated with 
APACHE  II  scores  and  mortality.  Scores  were  greater  in  shock  patients  with  higher 
levels of ammonia and sulphur containing amino acids associated with a higher mortality 
rate.(lOl) However, amino acid derangements such as these could not be demonstrated in 
the  present  study,  making  it  less  likely  that  septic  encephalopathy  could  explain  our 
findings.
150Studies in patients with acute liver failure have shown rapid progression to severe 
hepatic  encephalopathy  in  those  patients  that  have  overt  evidence  of  SIRS  further 
suggesting a link between inflammation and hepatic encephalopathy. (109) The effect of 
inflammation  on  neuropsychological  function  in  patients  with  cirrhosis  has  not  been 
systematically  studied.  The  patient  population  that  we  chose  to  study  had  evidence  of 
SIRS  fulfilling  2  or  more  criteria.  Furthermore,  all  the  patients  had  raised  CRP, 
nitrate/nitrite  and  IL-6  values  on  admission,  which  significantly  decreased  following 
antibiotic therapy. It is unclear why 2 of the patients had undetectable levels (<5 pg/ml) 
of IL-113  and  TNF-a  in  the  inflammatory  state  despite  other  markers  of inflammation 
being raised. This however, is not an unusual finding in our experience of other, ongoing 
studies, and may reflect the fact that the cytokines are measured in peripheral blood rather 
than  at  sites  of inflammation.  In  this  context  it  is  interesting  that  circulating  soluble 
receptor levels  (TNF-R1  and  TNF-R2)  are profoundly  elevated  in decompensated  liver 
disease  and  the  binding  between  TNF-a  and  its  soluble  receptors  may  mask  TNF-a 
epitopes,  thus  making  the  antibody  ‘blind’  to  protein  levels  (Hodges  S.J,  personal 
communication).
Inflammation  is  associated  with  increased  nitric  oxide  possibly by  induction  of 
nitric  oxide  synthase  in  response  to  proinflammatory  cytokines.  (208;209)  We  have 
shown in this study a significant reduction in the levels of nitrate/nitrite with resolution of 
inflammation.
The  specific  mechanism  by  which  an  inflammatory  response  modulates  the 
neuropsychological  response  to  hyperammonemia  remains  to  be  elucidated.  There  are 
several possibilities. First, recent work on cytokine effects on glutamate uptake by human
151astrocytes has shown that proinflammatory cytokines inhibit astrocyte glutamate uptake 
by  a  mechanism  involving  nitric  oxide  resulting  in  altered  glutaminergic 
neurotransmission.(83) Second,  it  has  been  shown  that  IL-16  and  TNF-a  increase  the 
expression of peripheral-type benzodiazepine binding  sites in cultured  astrocytes which 
may  alter  cellular  osmotic  homeostasis.(84) Third,  it  is  possible  that  the  difference  in 
neuropsychological deterioration following the amino acid solution is related to changes 
in cerebral blood flow. Recent work by Moller et al. (199) has shown that high circulating 
levels of TNF-a following an intravenous bolus of endotoxin resulted in reduced cerebral 
blood flow. Fourth, it is possible that cytokines may modulate ammonia diffusion within 
the central nervous system. It has been shown that TNF-a and IL-6 increase fluid phase 
permeability  and  ammonia  diffusion  in  central  nervous  system-derived  endothelial 
cells.(85)
There has previously been doubt that the peripheral immune system could signal 
the brain.  Cytokines (15-20 kD) cannot directly cross the blood brain barrier and, while 
it remains intact, these signalling proteins would be unable to have a direct affect. (2 1 0) 
Recent studies, however, suggested that peripheral cytokines can affect the brain by three 
routes  (80):  Firstly,  peripheral  tissues,  innervated  by  the  peripheral  and  autonomic 
nervous systems, can send direct signals to the brain via the vagus nerve. (211) Secondly, 
the brain  vasculature  can  convey  signals  through  secondary  messengers,  such  as  nitric 
oxide and prostaglandins by activation and induction of their synthesising enzymes (2 1 2) 
produced in response to cytokines binding to their receptors expressed in cerebral blood 
vessels. For example, in the brain, TNF-a and IL-113 are potent stimuli for inducible nitric 
oxide  synthase production.  (213)  Thirdly,  cytokines can  directly  act  at  the  level  of the
152brain  parenchyma  after  crossing  the  blood  brain  barrier  by  active  transport  or  after 
entering brain areas that lack a blood brain barrier.
In summary, the results of this study provide the first evidence that mediators of 
the  systemic  inflammatory  response  may  modulate  the  neuropsychological  effects  of 
hyperammonemia in patients with cirrhosis.
153Chapter 4
The effect of inflammation on the 
6rain in a rat modeC of chronic
Civer disease
1544.1 PREFACE
The  results  of both  studies  described  in  Chapter  3  provide  good  evidence  that 
inflammation and infection are important in the pathogenesis of hepatic encephalopathy, 
thus  supporting my  first hypothesis (Ql;  section 2.1).  Moreover,  as ammonia has been 
shown  to  be  central  in  the  pathogenesis  of  hepatic  encephalopathy,  the  question  of 
whether  ammonia  and  inflammation  act  synergistically  in  the  pathogenesis  of hepatic 
encephalopathy is raised. This second hypothesis (Q2; section 2.1) will now be explored 
in this chapter using a rat model of chronic  liver disease:  the common bile duct ligated 
rat.
1554.2 ABSTRACT
Background:  There  is  growing  evidence  to  support  the role  of inflammation  as  being 
important in increasing the susceptibility of the brain to the effects of hyperammonemia. 
This  study  tests  the  hypothesis  that  endotoxaemia  induces  brain  oedema  through 
inflammatory  mediators,  such  as nitric  oxide,  in  an  animal  model  of cirrhosis,  the bile 
duct ligated (BDL) rat.
Methods:  Four  weeks  after bile  duct  ligation  (BDL;  n=12)  or  sham  operation  (n=14) 
adult  Sprague  Dawley  rats  were  treated  with  endotoxin  [lipopolysaccharide  (LPS),  0.5 
mg/kg,  IP)]  or saline,  and  sacrificed  3  hours  later.  Plasma  ammonia  and  nitrite/nitrate 
concentrations as well as samples of the frontal cortex and cerebellum were obtained for 
the measurement of brain water, nitrotyrosine and histopathology.
Results:  Plasma  ammonia  levels  were  significantly  higher  in  BDL  rats  than  sham- 
operated  controls  and  did  not  change  significantly  with  the  administration  of LPS  in 
either group.  LPS administration  increased brain water in both BDL and sham-operated 
groups  (p=0.004  and p=0.03  respectively);  this was  associated with  coma  in  BDL  rats, 
but had no such effect on sham-operated controls. Injection of LPS led to collapsed brain 
microvessels and astrocyte swelling predominantly in cirrhotic rats. Plasma nitrite/nitrate 
levels  increased  significantly  in  both  LPS  treated  groups  compared  to  the  non-LPS 
treated  controls  (p<0 .0 1),  but  frontal  cortex  nitrotyrosine  levels  only  increased  in  the 
cirrhotic rats injected with LPS compared to non-LPS treated cirrhotic rats (p<0.005). 
Conclusions:  Injection  of  LPS  into  cirrhotic  rats  causes  worsening  cytotoxic  brain 
oedema  and  coma,  potentially  related  to  the  formation  of  reactive  nitrogen  species 
leading to nitration of brain proteins.
1564.3 BACKGROUND
The susceptibility of the brain to the effects of hyperammonemia is variable and 
the ammonia concentration alone cannot account for the degree of brain swelling in acute 
liver failure. Recently, attention has been focused on inflammation as being critical in the 
manifestation  of  intracranial  hypertension  and  hepatic  encephalopathy  in  acute  liver 
failure.  (214)  Sepsis  is  a  well  described  and  frequent  precipitant  of  hepatic 
encephalopathy and recent studies have suggested a rapid progression  in the severity of 
hepatic encephalopathy in those patients with acute liver failure that have a more marked 
inflammatory response.  (109) Takada et al.  (215)  showed  in a pig model  of acute  liver 
failure  that  animals  administered  LPS  and  amatoxin  intraportally  developed  greater 
intracranial  hypertension  than  animals  given  amatoxin  alone,  even  though  ammonia 
concentrations were similar in both groups.
Astrocytes  have  a  repertoire  of  cytokine  responses  and  have  the  ability  to 
synthesise  interleukin-1(3  in  response  to  peripheral  inflammation,  (216)  which  may 
induce soluble mediators such as nitric oxide, superoxide and prostaglandins, which may 
make  the  brain  more  susceptible  to  the  effects  of hyperammonemia.  Cytokines  may 
modulate  the  expression  of glutamate  receptors  on  the  astrocyte  and  recent  work  on 
human astrocytes has shown that proinflammatory cytokines inhibit astrocyte glutamate 
uptake by a mechanism  involving nitric  oxide.(83)  Furthermore,  cerebral  blood  flow  is 
likely  to  be  critical,  and  Moller et  al.  (199)  have  shown  that  high  circulating  levels  of 
TNF-a, following an intravenous bolus of endotoxin, resulted in decreased cerebral blood 
flow, whilst cerebral oxidative metabolism remained unchanged. Sharshar et al. have also
157recently published a study in which they demonstrated neuronal and glial apoptosis in the 
brain  autonomic  centres  in  patients  who  died  of  septic  shock.  Immunohistochemical 
analysis showed expression of TNF-a in glial cells and of inducible nitric oxide synthase 
within  the vascular endothelium.  The  intensity  of apoptosis  correlated  with  endothelial 
expression of inducible nitric oxide synthase and not with TNF-a. (82)
Recently,  Jalan  et  al.  reported  a  correlation  between  the  severity  of increased 
intracranial  hypertension  and  the  circulating  levels  of  proinflammatory  cytokines  in 
patients  with  acute  liver  failure.  (73)  Furthermore,  an  increased  production  of brain 
cytokines  in  a  group  of  acute  liver  failure  patients  with  uncontrolled  intracranial 
hypertension was observed. Moreover, in patients with cirrhosis, I have demonstrated in 
chapter  4  that  induced  hyperammonemia  resulted  in  significant  worsening  of 
neuropsychological function in those patients with evidence of an inflammatory response 
due  to  bacterial  infection  but  not  after  resolution  of the  infection  following  antibiotic 
therapy. (192) However, the importance of the inflammatory response in the pathogenesis 
of hepatic  encephalopathy,  though  indicated  by  such  observations,  lacks  experimental 
evidence  and  the  mechanism  remains  undefined.  More  specifically,  although  we  know 
that  ammonia  is  central  to  the  pathogenesis  of  hepatic  encephalopathy  and  that 
inflammation  modulates  the  cerebral  effects  of ammonia  in  cirrhosis,  direct  evidence 
supporting the synergistic effects of ammonia and inflammation/infection are lacking.
The  aim  of  this  collaborative  study  was  to  explore  the  hypothesis  that  the 
inflammatory  response  induced  by  administration  of  bacterial  cell  wall 
lipopolysaccharide  (LPS)  exacerbates  brain  oedema  in  cirrhosis.  This  study  was 
performed  using  the bile  duct  ligated  rat  (BDL)  model  of cirrhosis  as  it  has  been  well
158characterized by our group (217) and the cirrhosis is known to progress to jaundice and 
ascites.
Chronic  bile  duct ligation  (BDL)  in  the  rat  is  a  very  frequently  used  technique 
which  produces  an  experimental  model  of  liver  cirrhosis  with  cholestasis.  (218)  It 
reproduces some of the human features of cirrhosis and is known to progress to jaundice 
and  ascites.  Chronic  BDL  induces  a  circulatory  hyperdynamic  state,  with  arterial 
hypotension  and  increased  cardiac  output,  similar  to  that  found  in  other  experimental 
models of cirrhosis and in cirrhotic patients. There is also concomitant sodium retention 
and  activation  of  the  intrarenal  hormones,  plasma  renin  activity,  aldosterone  and 
angiotensin  II.  (219)  This  is  associated  with  portal  hypertension  and  an  excessive 
production of vasodilator substances, such as nitric oxide and bile acids,  and a reduced 
pressor  response  to  circulating  endogenous  vasoconstrictors.  (220)  Creatinine,  urea, 
bilirubin and  liver function tests  are higher in  BDL  rats  than weight  matched controls. 
Plasma glucose and haematocrit are always lower in BDL rats. (219)
Complete  diversion  of bile  from  the  gut  lumen  changes  the  bacterial  flora  and 
causes loss of mucosal integrity which decreases endotoxin inactivation leading to portal 
bacteremia  and  endotoxemia.  This occurs  in the BDL  cirrhotic  rat,  in  which  endotoxin 
concentration in the portal blood is increased approximately 7-fold at 3 weeks after BDL. 
Increased  systemic  endotoxin  levels  have  also been  reported  in  patients  with  cirrhosis. 
(221)  Furthermore,  sepsis  and  associated  endotoxemia  occur  in  approximately  40%  of 
hospitalised  patients  with  cirrhosis  and  is  a  major  cause  of death.  (126)  BDL  rats  are 
markedly  sensitive  to  lipopolysaccharide  (LPS).  This  is  associated  with  an  enhanced 
TNF-a response and increased lipid peroxidation. (217) LPS is a component of the outer
159membrane  of gram-negative  bacteria.  Macrophage  and  endothelial  cells  of the  hepatic 
sinusoids  are  the  major  sites  of clearance  of LPS  from  the  circulation,  most  of which 
appears to originate from the digestive tract. Interaction of macrophages with LPS results 
in  increased  production  of  reactive  oxygen  intermediates  and  of  proinflammatory 
cytokines. (2 2 2)
Nitric oxide reacts in biological  systems with  oxygen,  superoxide and  transition 
metals  to  form  reactive  nitrogen  species  that  can  support  nitrosylation  reactions  with 
nucleophiles such as thiol groups to form S-nitrosothiols,  or can lead to the nitration of 
amino  acids  such  as  tyrosine.  The  S-nitrosylation  of  extracellular  proteins,  such  as 
albumin,  gives rise to a circulating pool of nitric oxide, which may release nitric oxide 
directly,  or  transfer  nitric  oxide  into  the  intracellular  milieu  via  transnitrosylation 
reactions with cell surface thiols, thus affecting vascular and platelet function. (223-226) 
In BDL rats, Ottesen et al.  have  shown that hepatic nitrotyrosine levels were  increased 
compared to controls and that this was further increased after the administration of LPS. 
Therefore, there is likely to be increased formation of S-nitrosothiols and nitrotyrosine in 
these rats which is markedly upregulated during endotoxaemia.
It has been shown that bile duct ligation induces hepatic encephalopathy in rats as 
evidenced by  a decrease  in  motor activities.  (227)  Furthermore,  it has been  shown  that 
motor  activities  correlate  with  the  neurobehaviour  score.  (228)  However,  the  chronic 
administration of a non-selective nitric oxide synthase inhibitor, Nw  -  nitro -  L-arginine 
methyl  ester  (L-NAME),  does  not  have  any  significantly  detrimental  or  therapeutic 
effects on the severity of encephalopathy in BDL rats. (227)
160Modulation of soluble guanylate cyclase by nitric  oxide is altered in brain  from 
cirrhotic patients. Rodrigo et al. using rat bile duct ligation, alone or combined with diet- 
induced hyperammonemia for 7-10 days tried to reproduce the alterations in nitric oxide 
modulation of soluble guanylate cyclase found in brains from cirrhotic patients.  Soluble 
guanylate cyclase activity  was  measured  under basal  conditions  and  in  the  presence  of 
nitric oxide in the cerebellum and cerebral cortex of controls, bile duct ligated without or 
with  hyperammonemia  and  hyperammonemia  without  bile  duct  ligation.  In  the 
cerebellum,  activation  of  soluble  guanylate  cyclase  by  nitric  oxide  was  significantly 
lower in bile duct ligated rats with or without hyperammonemia than in control rats.  In 
the cerebral cortex activation of soluble guanylate cyclase by nitric oxide was higher in 
rats with bile duct ligation with hyperammonemia but not without hyperammonemia than 
in control rats.  The combination  of bile duct ligation and hyperammonemia reproduced 
the alterations  in  the  modulation  of soluble  guanylate  cyclase  by nitric  oxide  found  in 
cerebral  cortex  and  cerebellum  of  cirrhotic  patients  while  bile  duct  ligation  or 
hyperammonemia alone reproduced the effects in cerebellum but not in cerebral cortex. 
(229)
1614.4 METHODS
4.4.1  EXPERIMENTAL CONDITIONS
All  animal  experiments  were  conducted  according  to  Home  Office  guidelines 
under  the  UK  Animals  in  Scientific  Procedures  Act  1986.  Male  Sprague-Dawley  rats 
(body  weight  230  -  280  g)  were  obtained  from  the  comparative  biological  unit  at  the 
Royal Free and University College Medical  School (Royal Free Campus, London, UK). 
All  animals  were  housed  in  the  comparative  biological  unit  and  given  free  access  to 
normal rodent chow and water, with  a light:dark cycle of  12  hours, at a temperature of 
19-23 °C, and humidity of approximately 50%.
4.4.2 COMMON BILE DUCT LIGATION
All  rats  underwent  bile  duct  ligation  to  induce  biliary  cirrhosis  or  a  sham 
operation. A midline abdominal incision was made under anaesthesia. The common bile 
duct was isolated, triply ligated with 3-0 silk, and sectioned between ligatures. After bile 
duct ligation all animals continued to gain weight. Overall mortality was  less than  10% 
and the infrequent deaths occurred within 36 hours of surgery. Control rats underwent a 
sham procedure in which the common bile duct was located but not ligated.
4.4.3 ANIMAL STUDY PROTOCOL
The  rats  were  anaesthetised  (pentobarbital)  and  sacrificed  28  days  following 
common  bile  duct  ligation  or  sham  surgery.  Subgroups  of  rats  received
162lipopolysaccharide  {Salmonella  typhimurium  0.5  mg/kg)  which  was  administered  by 
intraperitoneal  injection  3  hours  before  sacrifice.  After  this  time  point,  animals  were 
sacrificed  by  full  exsanguinations  under  anaesthesia  (60mg/kg  Inactin;  5-ethyl  5-[l- 
methylpropyl]  -2-  thiobarbituric  acid).  Blood  was  then withdrawn  from  the  descending 
aorta  until  full  exsanguination  into  tubes  containing  6 8  iu  lithium  heparin  and  then 
immediately  centrifuged.  The  plasma  was  then  stored  at  -80°C  until  assay.  The  whole 
brain was collected immediately for estimation of the brain water content in the forebrain 
and cerebellum.
Six  rats  were  perfused  with  100  -150  ml  sodium  cacodylate  buffer  (Agar 
Scientific) [2M pH 7.2-7.4] followed by 200 ml of half strength Kamovskys fixative mix 
(1%  formaldehyde  and  2.5%  glutaraldehyde)  (230;231)  to  fix  brain  tissue  for  light 
microscopy. A midline incision from the base of the abdomen to the rib cage was made 
exposing  the  xiphoid  sternum.  Then  using  Spencer  Wells  forceps  to  lift  the  xiphoid 
sternum, the diaphragm and rib cage were incised to expose the heart. The perfusion was 
performed via a cannula inserted  into the left cardiac ventricle at a constant pressure of 
100-110  mmHg as  illustrated  in  Figure 4.1.  The brain was then  removed  and  stored  in 
half-strength Kamovskys fixative until examination of brain histology at a later date.
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Figure 4.1
A diagram to illustrate the perfusion & fixation of the rat brain for light microscopy
1644.4.4 MONITORING OF LEVEL OF CONSCIOUSNESS
The conscious levels of rats used in this study were rated using an established
neurological scale. (232)
4.4.5 MEASUREMENT OF BRAIN WATER
This was performed by a gravimetric technique and is illustrated in Figure 4.2.
This allows the percent gram water per gram tissue of samples less than 2 mm3 to be
determined within minutes to an accuracy of greater than 1%. (233)
1.  Two mixtures of kerosene and bromobenzene were used in the preparation of the 
gradient.  One  litre  of mixture  A  was prepared  from  735.6  mis  of kerosene  and 
264.4 mis bromobenzene to give a specific gravity of 0.9750. One litre of mixture 
B was prepared from 608.8 mis kerosene and 391.2 mis of bromobenzene to give 
a specific gravity of 1.0650.
2.  A flask containing lOOmls of mixture B was placed 40 cm above an empty  100ml 
graduated cylinder.  lOOmls of mixture A was then placed 43cm above mixture B.
3.  The fluid kinetics of this system is such that a linear gradient column is produced 
if the  outflow  from  the  constantly  mixed  Mixture  B  to  a  100  ml  graduated 
cylinder  is  exactly  twice  the  outflow  from  A  to  B.  This  was  accomplished  by 
using equal lengths of polyethylene outflow tubing of length 90 cm and internal 
diameter 0.76mm  from  flask  B  to the  graduated  cylinder and  a  single  length  of 
tubing from Flask A to Flask B. By this technique, the specific gravity at the very 
bottom of the graduated cylinder is equal to that of Mixture B (1.065), while the
165specific  gravity  at  the  top  is  equal  to  the  arithmetic  mean  of the  two  solutions 
(1.020).
4.  A  steady  flow  to  the  surface  of  the  graduated  cylinder  was  maintained  by 
gradually lowering the cylinder in  2  mm increments as the fluid level  increased. 
When  a  cylinder  volume  of  100ml  was  reached  the  tubes  were  clamped.  The 
gradient  was  then  permitted  to  stabilize  for  15  minutes  and  calibrated  with 
standards made up of potassium sulphate (K 2SO4) of known specific gravity.
5.  The concentrations of the  K 2SO4 solutions were  5.99,  5.34, 4.7 and 3.4 g/lOOml, 
corresponding to specific gravities of 1.045,  1.040,  1.030 and  1.025. One drop of 
each standard was gently placed in the column by means of a small  syringe. The 
depth of equilibration was recorded at the end of 2 minutes.
6 .  The specific gravity of forebrain and cerebellum was measured in 2 mm3 pieces of 
tissue and placed gently in the column by needle tip.  The depth of equilibration 
was  recorded  at  the  end  of  2  minutes.  Six  pieces  for  each  brain  area  were 
recorded.
7.  The specific gravity of the samples was calculated using the gradient of the  line 
(y= mx + c) generated from a graph of the specific gravity of the K 2SO4 standards 
(x axis) and the column position (y axis).
8.  Using  a  constant  (c)  to  represent  the  specific  gravity  of the  solid  component 
(1.298 in rat frontal cortex and  1.269 in rat cerebellum) the percentage brain water 
can be calculated using the following formula:
[c/(c-l)] / SpG] -  [l/(c-l)] x  100%
166Gravimetric technique: brain water measurement
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Figure 4.2
Diagrammatic  representation  of  the  experimental  setup  for  the  gravimetric 
technique which allows the measurement of brain specific gravity from which brain 
water content can be calculated.
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1674.4.6  METHOD FOR SENSITIVE AND SPECIFIC MEASUREMENT OF 
NITRITE IN PLASMA USING A CHEMILUMINESCENCE ASSAY  (234)
As mentioned the combined NO2/NO3  levels were determined using  a modified 
Greiss test (190) but this determination predominantly represents the nitrate content in the 
sample, because the nitrite fraction alone is difficult to measure in this manner as its level 
is  usually  near  the  detection  threshold  of the  assay.  Therefore,  nitrite  levels  were  also 
determined separately by a method with much greater sensitivity (ca. 5nM), using a Nitric 
Oxide analyzer:
I 3" , synthesised by the addition of potassium iodide and iodide to acetic acid and 
water, will reduce nitrite (but not nitrate) to nitric oxide gas. The released nitric oxide gas 
is carried from the solution in a stream of nitrogen gas into the chemiluminescent nitric 
oxide analyser which can detect from 0.3  to  1   pmole nitric oxide gas. The instrumental 
setup is illustrated in Figure 3.4 as detailed by Samouilov et al. (235)
All chemicals were supplied from Sigma-Aldrich (Poole, Dorset, UK) and were of 
the highest laboratory grade.
1   A stock solution of 180 ml of I3' reagent was prepared from 2g potassium iodide
and  1.3g of iodine dissolved in 40 ml double distilled water.  140 ml of acetic acid 
was then added and mixed thoroughly for 30 minutes.
2.  Nitrogen gas was bubbled through the 9 ml I3'reagent in a glass purge vessel. The
vessel  is  linked to a trap containing  15  ml  of 1M  sodium hydroxide and is then 
connected  to  the  chemiluminescent  nitric  oxide  analyser  (Sievers,  Model  280, 
Boulder, Colorado, USA) as illustrated in Figure 4.3.
1683.  The system was then allowed to reach steady baseline.
4.  One hundred  iL of plasma was diluted 1   in 4 with phosphate buffered  saline.
5.  This was placed in a Whatman  12 kD molecular weight cut off filter  and spun at
18,900 g for 30 minutes at 4 °C.
6.  Ten  pL  of the  filtered  plasma  was  then  injected  via  a  syringe  into  the  purge 
vessel.  The  nitric  oxide  released  then  passes  into  the  nitric  oxide  analyser  to 
produce an optical signal which is detected by a photomultiplier tube.
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Figure 4.3
A schematic diagram of the chemiluminescence instrumental setup (235)
1694.4.7 MEASUREMENT OF BRAIN TISSUE NITROTYROSINE LEVELS
Nitrotyrosine  levels  were  measured  by  a  stable  isotope  dilution  gas 
chromatography  mass spectrometry  method  following the extraction of tissue or plasma 
proteins and  alkaline hydrolysis.  (236)This was  only  performed  on  tissue  samples  from 
the frontal cortex in the sham-operated and BDL animals.
All chemicals were supplied from Sigma-Aldrich (Poole, Dorset, UK) and were of the 
highest laboratory grade.
1.  Brain proteins were precipitated  from brain tissue that was initially homogenised 
in  13 ml of chloroforrmmethanol (2:1) with a blade homogeniser on ice,  followed 
by the addition of 2 ml of saline and further homogenisation.
2.  Following centrifugation at 3000 g for 30 minutes, the aqueous and organic layers 
were removed, and the protein precipitate lyophilised under vacuum overnight.
3.  A  known  amount  of the  lyophilised  protein  (2  mg)  was  then  hydrolysed  in  1ml 
4M sodium hydroxide at  120 °C overnight, following the addition of 10 ng [C13 9]- 
nitrotyrosine and  10 pg [D4]-tyrosine as internal standards. Alkaline hydrolysis of 
the  protein  is  preferable  to  acid  hydrolysis,  because  this  avoids  artifactual 
formation of nitrotyrosine by acid and nitrate/nitrite.
4.  Samples  were  then  extracted  and  analysed  by  gas  chromatography  mass 
spectrometry as described by Frost et al. (236), following reverse-phase columnic 
chromatograph  purification  using  LC18  and  ENV+  cartridge  extraction  and 
derivatization  to  the  hcptafluorobutyric  amide  and  tertbutyldimcthylsilyl 
derivatives. This method has an intra-assay and inter-assay variation of < 4% and
1705% respectively.  All  results are expressed  in relation to dry weight of protein  as 
measured by direct weighing prior to hydrolysis.
4.4.8 TISSUE PREPARATION  FOR LIGHT MICROSCOPY AND 
HISTOPATHOLOGICAL ASSESSMENT
This was performed at St George’s University Hospital in the Department of 
Anatomy, Basic Medical Sciences Division by Gavin Wright, Ceri Davies and Heather 
Brooks.4.5 EXPERIMENTAL PROTOCOL
In brief, all rats underwent bile duct ligation to induce biliary cirrhosis or a sham 
operation.  Twenty  eight  days  after  surgery,  the  rats  were  randomized  into  4  groups  as 
summarised in table 4.1  below.
Animal and Study Condition No of animals studied
Sham operated 7
Sham  + Lipolysaccharide 7
Bile duct ligated 6
Bile Duct Ligated + Lipopolysaccharide 6
Table 4.1
BDL or sham operated rats were injected with LPS (Salmonella typhimurium, 0.5 
mg/kg intra-peritoncally made up to 0.5 mis in saline) or given 0.5 mis saline alone. The 
rats were allowed free access to food and water for a period of 3 hours post-intervention 
in  a  temperature  controlled  environment  and  were  then  sacrificed  by  exsanguinations 
under  terminal  anaesthesia  (Hyponorm  400  pL/kg  intraperitoneally,  Janssen 
Pharmaccutica,  Belgium).  Blood  was withdrawn  from the descending aorta  into heparin 
containing  tubes  until  full  exsanguination,  centrifuged,  and  the  plasma  collected  and 
stored at -80 °C until assayed.
172The  conscious  levels  of rats  used  in  this  study  was  rated  using  an  established 
neurological  scale.  (232)  Immediately after death, the whole brain  was rapidly removed 
and  2  mnr  samples  were  dissected  from  the  frontal  cortex  (grey  matter)  and  the 
cerebellar  cortex.  Brain  tissue  water  content  (as  a  measure  of cerebral  oedema)  was 
determined using a gravimetric technique. (233)  Ammonia  was  measured  in  the 
heparinised  plasma  using  a  modified  indophenol  detection  method  (237)  as  detailed  in 
section  3.1.3.2.  Combined nitrite/nitrate levels were determined using a modified Greiss 
test  (189)  as  detailed  in  section  3.1.3.3.  Nitrite  concentrations  were  measured  in  the 
filtrate  by  chemiluminescence.  (234)  Measurement  of brain  tissue  nitrotyrosine  levels 
were performed on brain homogenates. (236)
Histopathological  assessment  of  brain  tissue  for  high  power  scanning  light 
microscopy  was  performed  on  a  further  16  rats  as  the  necessary  perfusion  and  fixation 
process,  makes  it  impossible  to  use  serum  or  brain  tissue  for  the  other  measurements 
described above.
1734.6 STATISTICS
The data are expressed as the mean and standard error of the mean for each group 
of animals.  The  significance of any  differences  seen  was tested  with  the  unpaired  t-test 
and  Mann  Whitney  test,  indicated  in  figure  legends;  <0.05  was  taken  to  be  statistically 
significant.  Software  used  included  Microsoft  Excel  2003  (Microsoft  Corp.,  Redmond, 
WA) and GraphPad Prism 4.0 (GraphPad Software, Inc., San Diego, CA).
1744.7 RESULTS
4.7.1  RATS
All  rats  continued  to  gain  weight  following  surgery.  Rats  were  weighed 
immediately before sacrifice. BDL rats were found to be marginally heavier compared to 
sham -operated controls (BDL mean 320 g; n^ 12; sham mean 296 g; n= 14); p-^0.01. The 
difference was attributed to the presence of ascites.  At day 28, all  BDL rats were deeply 
jaundiced. All rats remained alive at 3 hours post injection of saline or LPS.
4.7.2 CONSCIOUS LEVEL
BDL  rats had a marked deterioration  in their conscious  level  following  injection 
of LPS, with all reaching pre-coma stages at the 3 hour sacrifice time point. The BDL and 
sham-operated  rats  administered  saline  and  the  sham-operated  rats  administered  LPS 
remained fully alert.
4.7.3  BRAIN WATER
There was a significant increase in the water content of the frontal cortex of BDL 
rats  administered  LPS  compared  to  BDL  rats  given  saline  (p=-0.004)  as  measured  by 
gravitometry. There was also a significant increase in the water content within the frontal 
cortex of sham-operated rats administered  LPS compared to sham-operated administered 
saline  (p-0.03)  using  this  technique.  There  was  no  significant  difference  in  the  brain 
water  content  between  non-LPS  treated  groups  (BDL/sham-opcrated  and  saline)  or 
between  the  LPS  administered  groups  (BDL/sham-operated  and  LPS);  p^0.07
175respectively [Figure 4.4], There was no effect of LPS on cerebellar water content [Figure 
4.5],
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Sham  BDL  Sham + LPS  BDL + LPS
* P<0.03: Sham versus sham + LPS animals
# P<0.004: BDL versus BDL + LPS animals
Figure 4.4
Frontal cortex brain water content
There was a significant increase in percentage water content with  LPS administration  in 
both BDL and sham-operated rats (BDL + LPS compared to BDL + saline rats, p<0.004# 
and  sham-operated  +  LPS  compared  to  sham-operated  +  saline  rats,  p<0.03  * 
respectively, as determined using Mann-Whitney test to compare groups.1
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Figure 4.5
Cerebellar brain water content
In the cerebellum of both BDL and sham-operated rats, there was no significant increase 
in percentage water content following administration of LPS or saline.
1784.7.4 PLASMA AMMONIA
The  plasma  ammonia  concentration  in  BDL  rats  with  saline  or  LPS  was 
significantly higher than  in  sham-operated and  saline treated  rats (mean +/-  SEM:  BDL 
173  +/-  12.4  pmol/L  versus  sham-operated  134  +/-  12  pmol/L);  p=0.035  [Figure  4.6]. 
Following  injection  of  LPS  there  was  no  change  in  plasma  ammonia  concentrations 
compared to BDL rats (p=0.7) or sham-operated rats (p=0.08) administered saline.
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Figure 4.6
Plasma ammonia levels
The  plasma  ammonia  levels  were  significantly  higher  in  saline-treated  BDL:  rats
compared  to  saline-treated  sham-operated  rats  (p<0.035*,  as  determined  using  Mann
Whitney  test  to  compare  groups).  LPS  treatment  did  not  significantly  affect  plasma
ammonia levels in either BDL or sham-operated rats.
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1804.7.5 PLASMA NITRITE/NITRATE
The  plasma  concentration  of  nitrite  and  nitrate  [Figure  4.7]  was  significantly 
higher in rats treated with  LPS compared to the non-LPS administered groups (BDL and 
LPS versus BDL; p<0.008 and saline and sham-operated and  LPS versus sham-operated 
and  saline;  p<0.018).  BDL  rats,  with  or  without  LPS,  also  had  higher  levels  of 
nitrite/nitrate  compared  to  sham-operated  and  saline  rats;  p<0.06.  Similarly,  the 
BDL/sham-operated rats treated with LPS also had higher plasma nitrite values compared 
to the BDL/sham-operated and saline treated rats; p<0.05, respectively [Figure 4.8].
181Sham  Sham + LPS  BDL  BDL + LPS
*  p<0.018: Sham  versus  sham  +  LPS 
U  p<0.008: BDL versus  BDL +  LPS
Figure 4.7
Plasma nitrite/nitrate levels
There  was  a  significant  increase  in  plasma  nitrite/nitrate  levels  with  administration  of 
LPS  in  BDL/sham-operated  rats  compared  to  BDL/sham-operated  rats  (in  BDL  +  LPS 
compared to BDL + saline rats; p<0.008 # and sham-operated +  LPS compared to sham- 
operated  +  saline  rats;  p<0.018  *  respectively)  as  determined  using  the  Mann-Whitney 
test to compare groups.
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p=0.045: Sham vs Sham + LPS 
*  p=0.04: BDL vs BDL + LPS
Figure 4.8 
Plasma nitrite levels
There was a significant  increase  in plasma nitrite levels  in  LPS  treated  BDL  rats versus 
saline treated BDL rats; p<0.04 # and also,  LPS treated sham-operated rats compared to 
saline treated  sham-operated  rats;  p<0.045  *,  as determined  using the  unpaired  t  test  to 
compare groups.
1834.7.6 BRAIN NITROTYROSINE/TYROSINE RATIO
A  significantly  increased  nitrotyrosine/tyrosine  ratio  (NT/T)  was  present  in  the 
BDL  rats  administered  LPS,  compared  to  saline  administered  to  BDL;  p<0.005  #  and 
sham-operated  rats;  p<0.04  *  respectively  [Figure  4.9],  There  was  no  difference  in  the 
NT/T  ratio  between  saline  administered  to  BDL  and  sham-operated  rats;  p=0.3. 
Administration of LPS to sham-operated rats did not increase the NT/T ratio compared to 
saline administered sham-operated rats; p^O.8.
184Sham  Sham + LPS  BDL  BDL & LPS
*  p<0.005:   BDL versus BDL +  LPS
# p<0.04  sham versus sham + LPS
Figure 4.9
Brain Nitrotyrosine/Tyrosine ratio
There  was  a  significant  increase  in  the  brain  nitrotyrosine/tyrosine  ratio  in  LPS  treated 
BDL rats compared to saline-treated BDL; p<0.05 # and sham-operated rats; p<0.04 * as 
determined using the Mann-Whitney test to compare groups.
1854.7.7 HIGH POWER LIGHT MICROSCOPY OF THE BRAIN
Light  microscopy  of  BDL  rat  forebrain  revealed  partially  collapsed  venules, 
perivascular  oedema  and  neuronal  oedema  [Figure  4.11].  When  given  LPS,  massive 
perivascular  oedema  was  seen  accompanied  by  completely  collapsed  venules  and 
neuronal  death  [Figure  4.13].  Sham-operated  forebrain  did  not  show  any  evidence  of 
venule  collapse  or  oedema  [Figure  4.10],  but  when  given  LPS,  the  forebrain  was 
observed to develop mild perivascular oedema [Figure 4.12],
186Figure 4.10
A scanning light micrograph (magnification x 200) of a sham-operated rat forebrain 
showing 3 normal venules (V).
187Figure 4.11
A  scanning  light  micrograph  (magnification  x  200)  of a  BDL  rat  forebrain  showing  a 
partially collapsed vessel (V), perivascular oedema and neuronal swelling.
188Figure 4.12
A  scanning  light  micrograph  (magnification  x 200) of a  sham-operated  rat  forebrain  3 
hours after the administration of LPS showing venule (V) collapse and mild perivascular 
oedema (O).
189Figure 4.13
A scanning light micrograph (magnification x 200) of a BDL rat forebrain 3 hours after 
the  administration  of  LPS  showing  massive  perivascular  oedema  (O)  surrounding  a 
venule (V) and severe neuronal oedema (N).
1904.8 DISCUSSION
This study has explored whether an inflammatory stimulus in cirrhotic rats would 
produce cerebral oedema. The data arising from this study has shown that although BDL 
and  sham-operated  rats  had  similar brain  water content  3  hours  after  administration  of 
LPS  compared  to  their  saline  counterparts,  the  BDL  and  LPS  rats  reached  pre-coma 
stages,  whereas  the  mental  state  of  the  LPS  treated  sham-operated  rats  remained 
unchanged  in  this time.  High  power light microscopy  suggests that  forebrain  oedema  is 
perivascular in origin and related to astrocyte swelling. An increase in forebrain water is a 
hallmark  of  advanced  cerebral  changes  in  acute  liver  failure.  Recent  studies  have 
indicated  that  patients  with  cirrhosis  have  low-grade  cerebral  oedema  (238;239).  This 
study describes low-grade brain oedema in cirrhotic rats, similar to the low-grade oedema 
observed in cirrhotic patients. This cerebral oedema worsened after the administration of 
LPS.
These data did not show any differences in the basal brain water content between 
BDL rats and sham-operated controls as measured by the gravimetric technique however; 
histopathologically there  is evidence of astrocyte swelling and brain oedema.  Following 
the induction of endotoxemia with LPS, the brain water content rose in the frontal cortex 
but not the cerebellum in all animals and this was accompanied by evidence of worsening 
astrocyte  swelling  and  brain  oedema  histopathologically.  There  were  no  significant 
differences between the plasma ammonia values in each group, which would suggest that 
there is no direct relationship between the plasma ammonia concentration and brain water 
content.  The observation  of a  similar  increase  in  brain  water and  astrocytic  swelling  in 
both  the  sham-operated (normal ammonia) and  the  BDL  rats (high  ammonia)  following
191the  administration  of  LPS,  suggests  that  inflammatory  mechanisms  are  likely  to  be 
important in the pathogenesis of brain swelling.
An  interesting  observation  of  this  study  is  that  there  is  brain  swelling  with 
endotoxaemia in the control animals. This demonstrates the importance of inflammation 
in brain swelling in the absence of liver dysfunction and is likely to be explained by the 
development of a septic encephalopathy. The association between infection and impaired 
brain  function  has  been  recognized  for  a  long  time  since  it  was  first  described  by 
Hippocrates 2000 years ago.  (207)  Septic encephalopathy  can  arise  from  the action  of 
inflammatory  mediators  on  the  brain  or  a  cytotoxic  response  by  brain  cells  to  these 
mediators.  Septic  encephalopathy  is  usually a  sequelae of severe  sepsis complicated by 
multiple organ failure and hypotension. (98)
In the presence of liver dysfunction, urea synthesis is impaired and the brain acts 
as  a  major  alternative  ammonia  detoxification  pathway.  Astrocytes,  which  provide 
physical and nutritional  support for neurons also eliminate ammonia by the synthesis of 
glutamine  through  amidation  of glutamate.  Accumulation  of  glutamine  in  astrocytes, 
induced by hyperammonemia, produces osmotic stress and causes the astrocytes to swell. 
(49)  In  acute  liver  failure,  astrocytes  swell  and  cytotoxic  brain  oedema  develops.  This 
observation has been replicated  in cultured astrocytes exposed to high concentrations of 
ammonia. (32) In chronic liver disease, astrocytes show the characteristic morphological 
features  of Alzheimer Type  II  astrocytosis.  Astrocytes  exhibit  a  large  swollen  nucleus, 
prominent  nucleolus,  margination  of the  chromatin  pattern  and  marked  enlargement  of 
the  cytoplasm  associated  with  a  proliferation  of cytoplasmic  organelles  which  has  also 
been replicated in astrocytes exposed chronically to ammonia. (33) This may not however
192equate to overt cell swelling and it may therefore perhaps not be surprising that the BDL 
animals  did  not  exhibit  increased  brain  water  content  (as  measured  by  the  gravimetric 
technique) 28  days  following surgery.  No significant change was observed  in  the water 
content of tissue collected from the cerebellum, which was utilised as a control tissue as it 
is devoid of astrocytes and therefore may not be expected to display cell swelling in this 
model.
The  BDL  rats  administered  LPS  showed  universal  deteriorating  levels  of 
consciousness (to pre-coma and coma stages) as has previously been observed (217).  In 
the BDL/sham operated rats administered saline and the sham-operated rats administered 
LPS,  no  change  in  conscious  level  occurred.  This  is  despite  the  LPS  treated  sham- 
operated rats and saline BDL rats showing some evidence of brain swelling and astrocyte 
oedema.  It is therefore possible that in the BDL rats hyperammonemia in some way acts 
synergistically  with  the  systemic  inflammatory  response  to  alter  the  level  of 
consciousness.  This  concept  fits  with  the  observation  in  chapter 4  in  cirrhotic  patients, 
where  induction of hyperammonemia  resulted  in  neuropsychological deterioration when 
the  patients  were  infected  and  showed  evidence  of an  inflammatory  response.  (192) 
Following resolution of infection, similarly induced hyperammonemia did not result in an 
alteration  in  neuropsychological  function  supporting  the  hypothesis  that  ammonia  and 
inflammation  may  be  synergistic.  Furthermore,  the  suggestion  of  synergy  between 
hyperammonemia and inflammation is supported by the recent observation that BDL rats 
that  were  fed  a  high  ammonia  diet  (and  which  showed  evidence  of  a  low  level  of 
inflammation), developed increases in brain water (240).
193Harry  et  al.  have previously  shown  that  the administration  of LPS  resulted  in  a 
sustained  increase  in  TNF-a  and  F2  isoprostanes  in  the  BDL  rats  3  hours  after  the 
administration  of LPS  (217).  In  sham-operated  rats  administered  LPS,  the  increase  in 
both TNF- a and isoprostanes was transient.  In support of this observation, we observed 
that both the BDL and sham-operated rats administered LPS had higher nitrite/nitrate and 
nitrite.  These observations  indicate that  in  this model  of cirrhosis an altered response to 
injury  may  contribute  to  the  differences  in  the  observed  conscious  level  and  cerebral 
oedema  in  the  BDL  rats  administered  LPS  compared  to  the  sham-operated  rats 
administered  LPS.  In  order  to  explore  whether  this  altered  peripheral  inflammatory 
response was  reflected  in  the brain,  nitrosylation  of protein  in the brain  was  measured. 
The observation of increased brain nitrotyrosine/tyrosine ratio in the BDL animals given 
LPS  argues  that  the  exacerbated  inflammatory  response  on  a  background  of 
hyperammonemia  may  play  an  important  role  in  the  clinical  presentation  in  these  rats. 
Stimulation of astrocytes  in  culture with  LPS  results  in  upregulation  of inducible  nitric 
oxide that culminates in increased production of nitric oxide. (91) A similar phenomenon 
is  observed  with  ammonia.  Schleiss  et  al.  have  provided  evidence  of protein  tyrosine 
nitration  in ammonia-treated cultured astrocytes and also in vivo in brains of rats treated 
with an ammonia load. (92)  Similarly, LPS itself can lead to nitrosylation of proteins in 
the  brain.  (241)  Furthermore,  the  addition  of ammonia  to  astrocyte  cultures  generates 
reactive  oxygen  species,  a  process  involving  the  synthesis  of glutamine.  Treatment  of 
astrocytes  with  glutamine  also  increases  free  radical  production.  (93)  As  most  of the 
glutamine in astrocytes is metabolised by mitochondrial phosphate-activated glutaminase, 
breakdown  of  glutamine  could  result  in  release  of  high  levels  of  ammonia  in
194mitochondria, which is a likely to increase reactive oxygen species.  It is conceivable that 
hyperammonemia  and  LPS  together  provide  an  environment  for  nitrosylation  of brain 
proteins  and  act  as  an  important  pathway  in  producing  alteration  in  the  mental  state. 
Though an  increase in nitrotyrosine/tyrosine  ratio  in the LPS treated  sham-operated rats 
was  observed,  this  was  not  significantly  different  to  the  nitrotyrosine/tyrosine  ratio  in 
saline treated BDL/sham operated rats.
The mechanisms leading to increased protein nitrosylation are thought to involve 
formation of peroxynitrite. This is formed from the combination of superoxide and nitric 
oxide. Peroxynitrite, in the presence of carbon dioxide can modify tissue proteins to form 
nitrotyrosine  which  may  mediate  nitric  oxide-induced  blood  brain  barrier damage.  (96) 
An  increase  in  the  permeability  of the  inner  mitochondrial  membrane  to  small  solutes 
(mitochondrial  permeability  transition)  results  from  oxidative  and  nitrosative  stress  and 
ammonia has been  recently shown to induce similar changes in cultured astrocytes. (97) 
Increased  cerebral  nitric  oxide,  increased  markers  of oxidative  stress  and  nitrotyrosine 
accumulation  within  brain  microvessels  have  been  associated  with  raised  intracranial 
pressure and brain oedema in models of ammonia-induced brain oedema (76).  However, 
evidence implicating activation of nitric oxide synthase (NOS) in ammonia-induced brain 
oedema  is not universal, with  the role of nitric oxide being refuted  due to  the  failure of 
NOS  inhibitors  to  impact  on  the development  of brain  oedema  and  cerebral  hyperemia 
( 120).
In  conclusion,  this  study  provides  further  evidence  to  indicate  that  on  a 
background  of  cirrhosis  with  hyperammonemia,  inflammation  has  an  important 
synergistic  role  in  the  development  of  hepatic  encephalopathy.  Although  the  exact
195mechanism  of how  ammonia and  LPS  produce cerebral  oedema and  coma  is  not  clear, 
these data support an important role for the nitrosylation of brain proteins.
1964.9 FUTURE AVENUES OF STUDY
In  order to  further  investigate  the  synergistic  nature  of the  relationship  between 
ammonia  and  inflammation,  it  would  have  been  interesting  to  co-administer  ammonia 
and  endotoxin  in  the  BDL  model  and  compare  this  to  sham-operated  controls.  The 
problem with achieving this is that the animals do not tolerate this toxic combination well 
and  many  succumbed  in  pilot  studies.  It  might  be argued  that  this  can  be overcome  by 
sacrificing the animals  after a  shorter time  period  or by  using  lower doses  of ammonia 
and endotoxin. However, this may not allow sufficient time for brain oedema to develop. 
One possible way of overcoming this problem may have been  to  feed the rats on a diet 
rich  in  ammonia  or  ammonia  generating  nitrogenous  compounds,  rendering  them 
hyperammonemic. This should allow ample time for astrocyte swelling to develop as the 
rats will be adjusted to a chronic level of hyperammonemia.
Another aspect of this investigation that deserves further study is the origin of the 
nitric oxide. Western blots of homogenized brain tissue would allow the identification of 
tissue  nitric  oxide  synthase  isoforms;  defining  the  relative  amounts  of  inducible, 
endothelial  and  neuronal  nitric  oxide  synthase.  Furthermore,  immunohistochemistry 
performed on  the  sections obtained  for high  resolution  light  microscopy would  indicate 
the location of these nitric oxide synthases within the brain.
Finally,  although  the  brain  tissue  sections  visualized  under  light  microscopy  are 
highly informative and clearly demonstrate astrocyte swelling,  it would be even better if 
the blood brain barrier could be visualized by electron microscopy in these animal models 
in  the  presence  and  absence of endotoxacmia.  Contact  and  communication  between  the
197neurovascular unit, which is a dynamic structure consisting of vascular endothelial cells, 
pericytes, and closely juxtaposed astrocytes and neurons, modulates cerebral blood flow 
and influences the permeability properties of the blood brain barrier. Electron microscopy 
utilizing  intravascular ionic  tracers  such  as  lanthanum  nitrate,  would  allow detection  of 
blood brain barrier integrity to paracellular movement and would  allow  visualization  of 
the  tight junctions  which  may  allow  the  study  of the  effect  of hyperammonemia  and 
inflammation on the tight junction proteins such as claudin and occludin.
198Chapter 5
The effect of ammonia on 
neutrophilfunction: an 
o6servationaC study
1995.1 PREFACE
Thus  far it has been shown that inflammation is an important determinant of the 
presence  and  severity  of minimal  hepatic  encephalopathy.  Furthermore,  the  change  in 
neuropsychological  function  following  induced  hyperammonemia  was  greater  in  those 
with  more  severe  inflammation.  Following  on  from  this,  patients  with  cirrhosis  were 
studied 24-36 hours after admission with clinical evidence of infection, and following its 
resolution.  Significant deterioration of neuropsychological  test scores  following induced 
hyperammonemia  during  the  inflammatory  state,  but  not  after  its  resolution,  suggested 
that inflammation and its mediators may be important in modulating the cerebral effect of 
ammonia  in  liver  disease.  Moreover,  in  an  animal  model  of cirrhosis,  the  BDL  rat, 
increased  brain  water and  astrocyte  swelling  which  was  exacerbated  by  endotoxin  and 
was  accompanied  by  a  rise  in  nitric  oxide  and  brain  nitrotyrosine,  but  not  in  plasma 
ammonia,  suggested  that  inflammation  may  play  an  important  synergistic  role  with 
ammonia  in  the pathogenesis  of hepatic  encephalopathy.  These  findings  provide  strong 
supportive evidence for my hypothesis as stated in chapter 2 [Figure 2.1].
If inflammation modulates the cerebral effects of ammonia, then a key question to 
then  go  on  to  ask  is  how  is  the  metabolism  of ammonia  affected  by  the  presence  of 
inflammation or infection? If one takes a step back from this supposition, then it might be 
logical  to  question  whether  ammonia  itself may  impair  immunity  and  predispose  an 
individual to the development of infection or sepsis. This led onto the development of the 
third hypothesis [Figure 2.1], that ammonia impairs neutrophil  function. This hypothesis 
will be tested in the following 2 chapters of this thesis [Chapters 5 &  6 ],
2005.2 ABSTRACT
Background:  In patients with cirrhosis, hyperammonemia is commonly associated with 
hepatic encephalopathy and accompanies gastrointestinal bleeding, both conditions being 
associated with a high incidence of sepsis and mortality. We aimed to determine whether 
incubation of normal  neutrophils  with  ammonia  concentrations  similar to  that  found  in 
cirrhosis  impaired  phagocytosis  and  influenced  resting  and  E.coli-induced  oxidative 
burst.  Methods:  Whole blood  from  12  healthy volunteers was  incubated  for 90 minutes 
at  37°C  with  0  -  500  pM  ammonium  chloride (NH4CI).  Quantification  of phagocytosis 
was  performed  using  the  Phagotest®  which  utilises  an  opsonised  FITC-labeled  E.coli. 
Quantification of oxidative burst was determined using the Burstest® which measures the 
percentage of neutrophils which produce reactive oxidants. Isolated neutrophils were then 
labeled with anti-CD 16-R-PE antibodies and analysed using flow cytometry. The pH was 
monitored  and  did  not  change.  Myeloperoxidase  activity  was  also  measured.  Results: 
Phagocytosis  was  significantly  impaired  by  12-20%  following  incubation  with  75  pM 
NH4CI  (p<0.0005).  Spontaneous  respiratory  burst  increased  by  10.7%  (p<0.0005)  and 
myeloperoxidase  activity  likewise  with  75pM  NH4CI  (p<0.001).  Furthermore, 
neutrophils  increased  in  volume  by  2  %  (on  flow  cytometry),  suggesting  cell  swelling. 
Ammonia-induced apoptosis or necrosis was excluded by staining with propidium iodide 
and annexin V-FITC. Conclusions:  Hyperammonemia impaired neutrophil phagocytosis 
and induced spontaneous oxidative burst. The mechanisms have yet to be fully elucidated 
but cell swelling and activation of key oxidative enzymes were important. Consequently, 
in  the presence of hyperammonemia neutrophils  may be unable to respond to  microbial 
challenge, in part accounting for the increased susceptibility to infection.
2015.3 BACKGROUND
Our  group  has  recently  shown  that  neutrophil  dysfunction  with  high  resting 
oxidative burst and reduced phagocytic capacity  is present in patients with cirrhosis and 
alcoholic  hepatitis  which  was  associated  with  a  significantly  greater  risk  of infection, 
organ failure and mortality (131).
Furthermore,  pilot  studies  performed  by  our  group  suggested  that  phagocytosis 
and oxidative burst in normal neutrophils may be impaired by micromolar concentrations 
of  ammonia.  The  exact  mechanism  of  action  underlying  this  is  unclear  but  could 
conceivably involve the inhibition of glutaminase. However, published data suggests that 
glutaminase is usually  inhibited by millimolar rather than  micromolar concentrations of 
ammonium chloride (139) which might suggest alternative mechanisms.  It is also known 
that in astrocyte cultures, exposure to ammonia results in cytosolic alkalinization leading 
to calcium-dependent release of glutamate. (55) It is therefore reasonable to postulate that 
ammonia  may  cause  cytosolic  alkalinization  in  neutrophils  as  well.  Ammonia  freely 
passes into the neutrophil  cytosol  and one possibility  is that  it  may  alter the  activity  of 
intracellular signalers such as mitogen-activated protein (MAP) kinases, p38-MAP kinase 
(p38‘M A PK ), Jun-kinase (JNK) and extracellular signal-regulated kinase (ERK) (179).
As  neutrophil  function  is  impaired  in  cirrhosis,  I  hypothesise  that,  as 
hyperammonemia  is  invariably  present  in  acute  and  chronic  liver  dysfunction,  that 
hyperammonemia impairs the ability of neutrophils to function normally. The aim of this 
study was therefore to characterize some aspects of neutrophil morphology and  function 
in the presence of ammonia, such as phagocytosis and oxidative burst.
202Phagocytosis  was  assessed  using  a  test  kit  (Phagotest  ®)  which  was  devised  to 
test  the phagocytic  activity  in  various  congenital  and  acquired  neutrophil  abnormalities 
(242) and to evaluate the effect of drugs. Abnormal phagocytosis can occur with a variety 
of clinical disorders (242). The defects can be associated with the neutrophil itself or with 
an  immunoglobulin or complement defect.  Known  inborn defects are actin dysfunction, 
tuftsin deficiency and complement receptor C3bi deficiency. These deficiencies can result 
in increased susceptibility to infection due to defective neutrophil phagocytosis. Acquired 
defects associated  with  altered phagocytic  activity  can  be  observed  in  trauma,  diabetes, 
renal failure and infection. The Phagotest ® also allows the study of phagocytic activity 
of HL-60 promyelocytic leukaemia cells or of isolated monocytes or macrophages.
Oxidative  burst  activity  was  assessed  using  a  test  kit  (Burstest®)  which  was 
devised to investigate the altered oxidative burst activity found in various disorders and to 
evaluate  the  effect  of drugs.  Reduced  or  missing  burst  activity  is  observed  in  inborn 
defects  like  chronic  granulomatous  disease  (CGD).  This  is  a  heterogenous  group  of 
inherited disorders that usually manifests itself during the first 2 years of life.  (242) The 
disease  is  characterized  clinically  by  repeated  and  life-threatening  infections  caused  by 
bacterial  and  fungal  organisms.  These  infections  typically  consist  of  pneumonia, 
lymphadenitis  or  abscesses  involving  the  lymph  nodes,  lung  and  liver.  The  NADPH 
oxidase  is  the  enzyme  system  responsible  for  producing  superoxide  anion,  which  is 
quickly  converted  to  hydrogen  peroxide  and  hydroxyl  radicals.  Abnormalities  in  the 
constituent  peptides  of  NADPH  oxidase  enzyme  system  lead  to  the  dysfunctions 
characteristic  of  CGD.  Neutrophils  from  CGD  patients  fail  to  produce  a  significant
203oxidative burst following stimulation. The Burstest® is a rapid and sensitive method for 
the diagnosis of CGD and for the detection of X-linked carriers.
2045.4 METHODS
5.4.1 AMMONIA INCUBATION
1.  Venous  blood  was  collected  from  12  healthy  fully  consented  individuals  in  4  ml 
vacuum tubes containing 6 8 iu lithium heparin (BD Vacutainer®). On average 30mls was 
collected  and placed  immediately  in  ice  for  10  minutes  to  pre-cool  the  neutrophils  to  0 
°C.
2. The stock ammonia solution used was prepared from 50mls of a  1M solution of NH4C1 
(Sigma) [2.67 grams in 50 mis ddFUO]. From this a  10 mM NH4CI solution was prepared 
by adding 0.5 mis of the 1M solution to 49.5 mis double distilled water (ddFUO).
3.  Two  mis  of heparinised  whole  blood  was  then  incubated  at  37  °C  in  a  water  bath 
(Grant Instruments, Cambridge,  UK) with 0, 25, 50,  75,  100,  125,  150, 250, 300 or 500 
pmol NH4CI for 90 minutes after gentle mixing on a blood rotator (SB1, Stuart Scientific) 
for 1   minute. 5ml Falcon polystyrene round bottom tubes  12 x 75mm (Becton Dickinson; 
UK)  were  used.  Each  concentration  was  tested  in  triplicate.  An  incubation  time  of 90 
minutes  was  chosen  on  the  basis  of  pilot  studies  which  showed  that  neutrophils 
incubated,  with  and  without  ammonia,  did  not  die or begin  to  apoptose  until  at  least  5 
hours following venesection. As the neutrophil isolation, preparation and flow cytometry 
steps take a minimum of 2 hours, incubation of the neutrophils for longer than 90 minutes 
would have compromised the health of the neutrophils.
4. The blood was gently re-mixed on the blood rotator for a further  1   minute after 30 and 
60 minutes incubation in the water bath.
2055.4.2 NEUTROPHIL ISOLATION
5.4.2.1 NEUTROPHIL ISOLATION USING PHAGOTEST® AND BURSTESTS®
1. After pre-incubation,  100 pL of blood was pipetted into 5ml Falcon polystyrene round 
bottom tubes 12 x 75mm (Becton Dickinson, UK) tubes.
2. These were then treated with 20 pL of E.coli (concentration 2 x  109 bacteria) or 20 pL 
of neutrophil wash solution and incubated in the water bath  for 20 minutes according to 
the manufacturer’s instructions (Phagotest® and Burstest®).
3.  100 pL of tryptan blue was then added to each tube to quench neutrophil phagocytosis 
in the case of the Phagotest® and re-incubation in the water bath with 20 uL of substrate 
in the case of the Burstest®.
4. The tubes were then filled with 2 mis of neutrophil wash solution [Phosphate Buffered 
Saline  (PBS) -   salts  (0.1M  Sodium  dihydrogen  orthophosphate,  0.1M  sodium  chloride 
and 0.1M  disodium hydrogen  orthophosphate) reconstituted in  lOOOmls double distilled 
water  (ddH:0)]  and  centrifuged  (Biofuge  Primo  R,  Heraeus)  with  20  x  75mm  tube 
carriers at 4 °C at 516 g for 5  minutes. The supernatant was then removed carefully and 
the cells re-washed with a  further 2  mis of washing solution. The supernatant  was once 
again removed after centrifugation.
5. The tubes were then centrifuged at 4 °C at 516 g and the lysing solution was removed. 
The  cells  (leucocytes)  were  then  washed  twice  as  before  with  neutrophil  washing 
solution.
2066. After the final wash, the supernatant was removed and 20 pi of anti- CD16-PE IgGj or 
20 pi of neutrophil wash solution was added in the case of the Phagotest® and Burstest®. 
The tubes were then placed in a dark cupboard at room temperature for 1   hour.
7. The leucocytes were then re-washed twice with neutrophil wash solution.
8. After the second wash the supernatant was removed and the cells were re-suspended in 
60 pi of neutrophil wash solution.
5.4.2.2 NEUTROPHIL ISOLATION USING POLYMORPHOPREP ™
Polymorphoprep ™ (Axis Shield, Norway) is a ready made, sterile and endotoxin 
tested  solution  for the  isolation  of polymorphonuclear  granulocytes  from  whole  blood. 
The solution contains sodium diatrizoate  13.8% (w/v) and dextran 500 8% (w/v). Using a 
mixture of sodium metrizoate and Ficoll (Lymphoprep),  Boyum (243) developed a one- 
step  centrifugal  technique  for  the  isolation  of mononuclear  cells.  In  this  technique  the 
polymorphonuclear  cells  are  centrifuged  to  the  bottom  of the  tube  together  with  the 
erythrocytes.  Polymorphoprep™,  is  a  further  development  of  this  method.  The 
mononuclear and  the polymorphonuclear  leucocytes  are  separated  into  2  distinct  bands 
free from red blood cells.
1.  Venous blood was collected  from  12  healthy  fully consented  individuals in 4 ml 
vacuum  tubes  containing  68  iu  lithium  heparin  (BD  Vacutainer®)  and  used 
immediately. This was not pre-chillcd as in the previous isolation method.
2072.  Five mis of blood was layered with a pipette over 5 mis of the polymorphoprep ™ 
in  a  12ml  Falcon  Tube  taking  particular  care  not  to  mix  the  blood  with  the 
separation fluid.
3.  The  samples were  then centrifuged  (Biofuge  Primo  R,  Heraeus  )  with  4  x  15ml 
tube carriers for 690 g for 35 minutes at  18 °C.
4.  After  centrifugation,  2  leucocyte  bands  were  visible.  The  top  band  at  the 
sample/medium  interface  consists  of mononuclear  cells  and  the  lower  band  of 
polymorphonuclear  cells.  The  erythrocytes  were  pelleted  at  the  bottom  of the 
tube.  The  polymorphonuclear  band  was  harvested  using  a  Pasteur  pipette  and 
diluted by the addition of one volume of neutrophil wash solution at 50% of the 
normal concentration in order to restore osmolality [Figure 5.1].
5.  The  cells were  then  washed  twice  with  neutrophil  wash  solution,  centrifuged  at 
516 g for 5 minutes and resuspended in 60 pL of neutrophil wash solution.
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Figure 5.1
Isolation of polymorphonuclear cells before and after centrifugation, using the 
polymorphprep™ method.
2095.4.3 NEUTROPHIL FUNCTION TESTS
5.4.3.1  PHAGOTEST® (Orpegen Pharma, Heidelberg, Germany): 
QUANTIFICATION OF PHAGOCYTIC ACTIVITY OF NEUTROPHILS IN 
HEPARINISED WHOLE BLOOD
This in vitro test allows the quantitative determination of leukocyte phagocytosis 
in  heparinised  whole  blood.  This  measures  the  overall  percentage  of monocytes  and 
granulocytes  showing  phagocytosis  (ingestion  of  one  or  more  bacteria  per  cell).  By 
incubating these cells with anti CD 16 IgGi antibodies labeled with R Phycoerythrin (PE), 
leucocytes including neutrophils, can be identified using flow cytometry.
Materials and Reagents:
Contained within Phagotest ® kit:
•  Opsonised FITC-labeled E. coli suspension (opsonised with immunoglobulin and 
complement of pooled sera).
•  Tryptan  Blue  quenching  solution  (for  suppressing  fluorescence  of  bacteria 
attached to the outside of the cell).
•  Lysing solution (contains diethylenglycol and formaldehyde).
•  Neutrophil wash solution [Phosphate Buffered Saline (PBS) -  salts (0.1M Sodium 
dihydrogen orthophosphate, 0.1M  sodium chloride and 0.1M  disodium hydrogen 
orthophosphate) reconstituted in  lOOOmls double distilled water (ddFEO)].
Other:
•  Anti- CD16-PE IgG|(IOTest®, Beckman Coulter)
210Method:
The  Phagotest™  was  performed  according  to  the  manufacturer’s  instructions,
briefly:
1.  Venous blood  was  collected  from  12  fully  consented healthy  individuals  in 4ml 
vacuum  tubes  containing  68  iu  lithium  heparin  (BD  Vacutainer®).  On  average 
30mls was collected and placed immediately in ice for  10 minutes to pre-cool the 
neutrophils to 0 °C.
2.  Neutrophil washing salts were re-constituted with  lOOOmls ddFEO.
3.  The opsonised E. coli and tryptan blue were pre-cooled on ice.
4.  Fifty  mis  of lysing  solution  was  prepared  by  adding  45  mis  of ddEEO  to  5mls 
stock solution.
5.  After pre-incubation with ammonia,  100 pL of blood was pipetted into tubes [5ml 
Falcon polystyrene  round bottom tubes  12  x  75mm (Becton  Dickinson)]  A-D  to 
quantify the phagocytosis.  A-D were done  in triplicate. Tubes B-D were used as 
the controls to set flow cytometry parameters.
6.  Twenty pL of E.coli or 20 pL of neutrophil wash solution was then added to the 
100  pL  of  blood  in  tubes  A-D  as  shown  in  Table  3.1  and  incubated  in  the 
waterbath for 20 minutes.
7.  One  hundred  pL  of tryptan  blue  was  then  added  to  each  tube  to  quench  the 
neutrophil phagocytosis.
8.  The tubes were then filled with 2 mis of neutrophil wash solution and centrifuged 
at 4 °C  at  516 g  for 5  minutes. The supernatant was then  removed  carefully andthe cells re-washed with a further 2 mis of washing solution. The supernatant was 
once again removed after centrifugation.
9.  Two mis of lysing solution was then added to lyse the red blood cells. The tubes 
were placed  on  the blood  rotator to  thoroughly  mix  the  lysing  solution  with  the 
blood cells for 5 mins and then left standing for a further 20 minutes.
10. The  tubes  were  then  centrifuged  at  4  °C  at  516  g  and  the  lysing  solution  was 
removed. The cells (leucocytes) were then washed twice as before with neutrophil 
washing solution.
11. After the  final  wash,  the  supernatant was removed and 20 pL of anti-  CD16-PE 
IgGi or 20 pL of neutrophil wash solution was added to tubes A-D as per Table 
5.1.  The  tubes  were  then  placed  in  a  dark  cupboard  at  room  temperature  for  1  
hour.
12. The leucocytes were then re-washed twice with neutrophil wash solution.
13. After  the  second  wash  the  supernatant  was  removed  and  the  cells  were  re­
suspended in 60 pL of neutrophil wash solution.
212Tube No Blood E.coli - FITC Anti- CD16-PE
A (Test sample) 100 pL Yes Yes
B 100 pL No Yes
C 100 pL No No
D 100 pL Yes No
Table 5.1
The experimental protocol for the phagocytosis experiments.
2135.4.3.2 FLOW CYTOMETRY AND THE PHAGOTEST®
The  cells  were  then  analysed  by  flow  cytometry  [Fluorescent  Activated  Cell 
Sorting] (FACScan™, Becton Dickinson, UK) using Cellquest™ software using the blue- 
green excitation light (488 nm argon-ion laser) by forward scatter (FL1) and side scatter 
(FL2), and by FITC (FL1) and CD16-PE (FL2) on the gated population of granulocytes 
[Figure 5.2]. The control samples (B-D) were used to set markers for FL1  and FL2 so that 
less than  1% of the events are positive. The percentage of phagocytosing cells in the test 
sample  could  then  be  determined  by  counting  the  number of events  above  this  marker 
position  i.e.  in the  upper right quadrant  [Figure  5.3].  The  mean  fluorescence  correlated 
with the number of bacteria per individual granulocyte (geometric mean of fluorescence 
intensity).
214CONTROL B.003
o
q.
0  200  400  600  600  1000
Forward Scatter 
CONTROLC 002
CONTROL B 003 o
o  -
o
prrc
200  400  600  800  1000
Forward Scatter
CONTROLC 002 o
°
o -
RTC
CONTROL.0001
o
o
oo
200  400  600  800  1000
Forward Scatter
CONTROL D.001 o
n o
F1TC
Figure 5.2
Plots  generated  from  flow  cytometry  illustrating  the  gated  population  of 
granulocytes  (left  hand  columns)  and  the  plots  obtained  from  the  control  samples 
(tube  B  (anti-CD16-PE  control;  top  right  plot),  tube  C  (double  negative  control; 
middle right plot) and tube D (E.Coli control; bottom right plot)]
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Figure 5.3
A typical plot obtained from a test sample. In this case 83.51% of the neutrophils 
have undergone phagocytosis and have been gated in the right upper quadrant 
(lower panel).
2165.4.3.3 BURSTEST ® (Orpegen Pharma, Heidelberg, Germany):
QUANTIFICATION  OF  THE  OXIDATIVE  BURST  ACTIVITY  OF 
MONOCYTES AND GRANULOCYTES IN HEPARINISED WHOLE BLOOD
This  in  vitro  test  allows  the  quantitative  determination  of leukocyte  oxidative 
burst  in  heparinised  whole  blood.  This  determines  the  percentage  of phagocytic  cells 
which  produce  reactive  oxidants  by  measuring  the  conversion  of  dihydrorhodamine 
(DHR)  123 to rhodamine (R)  123 and their enzymatic activity calculated as the amount of 
R  123 per cell. By incubating these cells with anti-CD 16 IgG i  antibodies labeled with R 
Phycoerythrin  (PE),  leucocytes  including  neutrophils,  can  be  identified  using  flow 
cytometry.
Materials and Reagents:
Contained within Burstest® kit
•  Opsonised  non-labeled  E.  coli  suspension  (opsonised  with  immunoglobulin  and 
complement of pooled sera).
•  100 pL containing the chemotactic synthetic peptide formyl-Met-Leu-Phe (fMLP) 
(200 x stock solution,  ImM). fMLP is a synthetic peptide that mimics the activity 
of bactcrially-derived peptides with formylated N-terminal methionine groups.
•  100 pL containing phorbol  12-myristate  13-acetate (PMA)  [200 x  stock solution,
1.62mM], PMA activates protein kinase C.
•  Substrate disk (DHR  123) reconstituted in  1   ml of neutrophil washing solution.
•  Lysing solution (contains dicthylcnglycol and formaldehyde).
217•  Neutrophil wash solution [Phosphate Buffered Saline (PBS) -  salts (0.1M Sodium 
dihydrogen orthophosphate, 0.1M  sodium chloride and 0.1M disodium hydrogen 
orthophosphate) reconstituted in  lOOOmls double distilled water (ddFLO)].
Other:
•  Anti- CD16-PE IgG|(IOTest®, Beckman Coulter)
Method:
The  Burstest™  was  performed  according  to  the  manufacturer’s  instructions,
briefly:
1.  Venous  blood  was  collected  from  12  fully  consented  healthy  individuals  in  4  ml 
vacuum  tubes  containing  68  iu  lithium  heparin  (BD  Vacutainer®).  On  average  30  mis 
was collected and placed immediately in ice for 10 minutes to pre-cool the neutrophils to 
0°C.
2. Neutrophil washing salts were re-constituted with  1000 mis ddFEO.
3. The opsonised E. coli was pre-cooled on ice.
4. Five pL of the PMA stock solution was added to  1ml of neutrophil wash solution.
5. Five pL of the fMLP stock solution was added to  1ml of neutrophil wash solution.
6.  Fifty  mis  of lysing  solution  was  prepared  by adding 45  mis  of ddHLO  to  5mls  stock 
solution.
7.  After  pre-incubation  with  ammonia,  100  pL  of blood  was  pipetted  into  tubes  5ml 
Falcon polystyrene round bottom  tubes  12  x  75mm (Becton  Dickinson)  1-7  to quantify 
the  oxidative  burst.  1-7  were  done  in  triplicate.  Tubes  3-7  were  used  as  controls.  8.
218Twenty pL of E.coli  or 20 pL of neutrophil wash solution or 5  jiL   PMA (high neutrophil 
control  stimulus) or 5  pL  fMLP (low neutrophil control  stimulus) was then added to the 
100  pL  of blood  in  tubes  1-7  as  per  Table  5.2  and  incubated  in  the  waterbath  for 20 
minutes.
9. Twenty pL of the substrate (DHR  123) was then added to tubes  1, 2, 3, 4 and 6 and 20 
pL  of neutrophil  washing  solution  was  added  to  tubes  5  and  7.  The  tubes  were  then 
incubated for a further 20 minutes in the waterbath.
10. The tubes were then filled with 2 mis of neutrophil wash solution and centrifuged at 4 
°C at 516 g for 5  minutes. The supernatant was then removed carefully and the cells re­
washed  with  a  further  2mls  of  washing  solution.  The  supernatant  was  once  again 
removed after centrifugation.
11. Two mis of lysing solution was then added to lyse the red blood cells. The tubes were 
placed on the blood rotator to thoroughly mix the lysing solution with the blood cells for 
5 mins and then left standing for a further 20 minutes.
12. The tubes were then centrifuged at 4 °C at 516 g and the lysing solution was removed. 
The  cells  (leucocytes)  were  then  washed  twice  as  before  with  neutrophil  washing 
solution.
13. After the final wash, the supernatant was removed and 20 pL of anti- CD16-PE IgGi 
or 20 pL of neutrophil wash solution was added to tubes  1-7 described in Table 5.2. The 
tubes were then placed in a dark cupboard at room temperature for 1   hour.
14. The leucocytes were then re-washed twice with neutrophil wash solution.
21915.  After the second wash the supernatant was removed and the cells were re-suspended 
in 60 pL of neutrophil wash solution.
Tube No Blood E.coli - 
FITC
PMA/fTVlLP Substrate Anti- CD16- 
PE
1   (Test 
Sample)
100 pL YES YES YES
2 (Resting 
oxidative 
burst)
100 pL NO YES YES
3 (High 
neutrophil 
stimulus)
100 pL NO PMA YES YES
4 (low 
neutrophil 
stimulus)
100 pL NO fMLP YES YES
5 100 pL NO NO YES
6 100 pL YES YES NO
7 100 pL NO NO NO
Table 5.2
The experimental protocol for the oxidative burst experiments.
2205.4.3.4 FLOW CYTOMETRY AND THE BURSTEST®
The  cells  were  then  analysed  by  flow  cytometry  [Fluorescent  Activated  Cell 
Sorting]  (FACScan™,  Beckton  Dickinson,  UK)  using  Cellquest™  software  using  the 
blue-green  excitation  light  (488  nm  argon-ion  laser)  by  forward  scatter (FL1)  and  side 
scatter  (FL2),  and  by  R  123  (FL1)  and  CD16-PE  (FL2)  on  the  gated  population  of 
granulocytes. The control samples (tubes 5-7) were used to set markers for FL1  and FL2 
so that less than  1% of the events are positive. The percentage of granulocytes that have 
produced  reactive  oxygen  metabolites  in  the  test  sample  could  then  be  determined  by 
counting the number of events above this marker position i.e. in the upper right quadrant 
(Figure 5.4). The mean fluorescence correlated with the oxidation quantity per individual 
leucocyte.  Figure  5.5  shows  the  resting  oxidative  burst  plots  obtained  and  Figure  5.6 
shows the plot obtained from PMA (high neutrophil stimulus) and fMLP (low neutrophil 
stimulus). Figure 5.7 shows the plots obtained from the control tubes used to set the flow 
cytometry parameters.
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Figure 5.4
A  typical  plot  obtained  from  FITC-labeled,  E.coli  challenged  neutrophils.  In  this  case 
81.78% of neutrophils have undergone oxidative burst and have been gated  in the right 
upper quadrant (top right panel).
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Figure 5.5
A  typical  plot  obtained  from  a  FITC-labeled  tube with  no  bacteria  added  (resting 
burst activity).  In  this case,  26.64%  of neutrophils  have undergone oxidative burst 
in  the  resting  state  and  have  been  gated  in  the  right  upper  quadrant  (top  right 
panel).
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Figure 5.6
A typical plot obtained from a FITC-labeled tube exposed to PMA (high  neutrophil 
stimulus)  and  fMLP  (low  neutrophil  stimulus).  In  this case, 97.52%  of neutrophils 
have undergone oxidative burst with PMA and 75.22% with fMLP.BURST 5 006 BURST 5 006
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Figure 5.7
Plots generated from flow cytometry used to set the flow cytometry parameters. The 
top  panels  show  the  anti-CD 16-PE  control,  the  middle  panels  show  the  E.Coli 
control and the lower panels show the double negative control.
2255.4.3.5 ASSESSMENT OF NEUTROPHIL MORPHOLOGY BY FLOW 
CYTOMETRY
If neutrophils swell or become more rounded, then they will produce less forward 
scatter from the laser during flow cytometry and this can measured during analysis. Light 
is  scattered  in  the  same  plane  as  the  incident  laser  light,  which  is  proportional  to  the 
volume  of the  cell  therefore  can  be  used  to  measure  cell  volume  indirectly.  Therefore 
neutrophils were  incubated  with  ammonia  up  to  75  pM  NH4CI  for 90  minutes  and  the 
forward scatter was measured using flow cytometry.
5.4.3.6 ASSESSMENT OF EFEECT OF AMMONIA ON EXTRACELLULAR pH
Two  mis  of heparinised  whole  blood  was  incubated  at  37  °C  in  a  water  bath 
(Grant Instruments, Cambridge,  UK) with 0, 25,  50, 75,  100, 250 and 500 pmol  NH4CI 
for  90  minutes  after  gentle  mixing  on  a  blood  rotator  (SB1,  Stuart  Scientific)  for  1  
minute.  Five ml  Falcon polystyrene round bottom tubes  12  x 75mm (Becton  Dickinson, 
UK)  were  used.  The  blood  was  gently  re-mixed  on  the  blood  rotator  for  a  further  1  
minute after 30 and 60 minutes incubation in the water bath and then the pH  and partial 
pressure of carbon dioxide  (pCO:) were measured using a  Radiometer ABL  700  Series 
blood gas analyzer.
5.4.3.7 ASSESSMENT OF NEUTROPHIL APOPTOSIS/DEATH
5.4.3.7.1  TRYPAN BLUE EXCLUSION TEST
After diluting trypan blue (Sigma)  1   in  10 with neutrophil wash solution, 400 pL 
of diluent was added to 400 pL of neutrophils re-suspended in wash solution  which had
226been  pre-incubated  with  0  or  500  pM  NH4CI  and  isolated.  Twenty  microlitres  of 
neutrophil mixture was then examined on a haemocytometer slide (Assistent, Thoma) and 
the  number  of blue-stained  cells  counted  under  a  light  microscope.  Blue-stained  cells 
were counted as non-viable.
5.4.3.7.2 ANNEXIN V-FITC AND PROPIDIUM IODIDE
To  ensure  that  neutrophil  function  was  not  impaired  through  the  induction  of 
apoptosis, an experiment was performed using Annexin V-FITC (BD Pharminogen) and 
Propidium  Iodide  [BD  Pharminogen].  Annexin  V-FITC  is  a  sensitive  probe  for 
identifying apoptotic cells (244-246) and binds negatively charged phospholipid surfaces 
(Kd of ~ 5 x  10  ) (247) with a higher specificity  for phosphatidylserine than most other 
phospholipids.  Phosphatidylserine  is  principally  associated  with  the  inner  leaflet  of the 
plasma  membrane  bilayer.  Annexin  V-FITC  is  used  quantitatively  to  determine  the 
percentage of cells undergoing apoptosis.  Therefore,  it  relies on the property  of cells to 
lose  membrane  asymmetry  in  the  early  phases  of  apoptosis.  In  apoptotic  cells,  the 
membrane phospholipid  phosphatidylserine  is  translocated  from  the  inner leaflet  of the 
plasma membrane to the outer leaflet, thereby exposing phosphatidylserine to the external 
environment.  Propidium iodide is used to assess plasma membrane integrity in  Annexin 
V  apoptosis assays (246).  It  is  a  fluorescent dye  that  stains  DNA.  It does not  cross  the 
plasma membrane of cells that arc viable or in the early stages of apoptosis because they 
maintain plasma membrane integrity. In contrast those cells in the late stages of apoptosis 
or  already  dead  have  lost  plasma  membrane  integrity  and  are  permeable  to  propidium 
iodide. Propidium iodide is detected in the orange range of the spectrum using a 562-588
227nm  band  pass  filter.  Cells  that  stain  positive  for  Annexin  V-FITC  and  negative  for 
propidium iodide are undergoing apoptosis. Cells that remain positive for both Annexin- 
V-FITC  and  propidium  iodide  are  either  in  the  end  stage  of  apoptosis,  undergoing 
necrosis, or already dead. Cells that stain negative for both are alive and not undergoing 
measurable apoptosis.
Two experiments were performed. The first assessed apoptosis/cell death and the 
duration of incubation with ammonia, and the second assessing the relationship between 
concentration of ammonia and apoptosis/cell death.
5.4.3.7.2.1  APOPTOSIS/ DEATH AND TIME
1. Four mis of blood was collected in a heparinised tube and immediately 2 mis of blood 
was aliquoted into 2  x  5ml  Falcon polystyrene round bottom tubes  12  x  75mm (Becton 
Dickinson,  UK) and  incubated  in a water bath at 37 °C.  One tube contained  100  pL  of 
lOmM  NH4CI giving  a  final  concentration  of 500  pM  NH4CI  and  the other  100  pL  of 
neutrophil  wash  solution  as  a  control.  A  positive  control  was  also  prepared  which 
consisted of 20 pL of lipopolysaccharide (E. coli 0111:B4, Sigma) 5 mg/mL in 2 mis of 
blood. All the tubes were left to incubate in the waterbath for 30 mins.
2. One hundred pL of blood was then removed immediately and every 30 mins thereafter 
for 5 hours with gentle inversion of the tube every 30 mins at sampling.
3. The red cells in the timed samples were lyscd with 2 mis of lysing solution. The tubes 
were  gently  mixed  for  1   minute  by  inversion  and  then  left  standing  for  a  further  20 
minutes.
2284. The tubes were then centrifuged at 4 °C at 516 g and the lysing solution was removed. 
The  cells  (leucocytes)  were  then  washed  twice  as  before  with  neutrophil  washing 
solution.
4. After the final wash, the supernatant was removed and the cells were re-suspended in 
100 pL of binding buffer (lOmM Hepes/NAOH, pH 7.4,  140mM NaCl, 2.5 mM CaCb).
5. In a FACS tube, 5 pL of Annexin V-FITC and  10 pL of propidium iodide were added 
and gently mixed. The tubes were then incubated for 15 minutes at room temperature (20- 
25  °C)  in  the  dark.  Control  tubes  containing  neither  Annexin  V-FITC  nor  propidium 
iodide  (double  negative),  Annexin  V-FITC  only  and  propidium  iodide  only  were  also 
prepared to set the flow cytometry parameters.
6 . The tubes were then analysed by flow cytometry.
5.4.3.7.2.2. APOPTOSIS AND AMMONIA CONCENTRATION
Following the same protocol above, an experiment was performed in which 2 mis 
of  blood  was  incubated  at  37  °C  in  a  waterbath  for  90  minutes  with  varying 
concentrations of ammonia  ranging from 0 to 500 pM NH4CI.
5.4.3.8  ASSESSMENT OF CD1 lb EXPRESSION
The  Phagotest®  and  Burstest®  were  repeated  using  anti-CDllb  (BD 
Pharminogen)  instead of anti-CD 16 as a neutrophil  marker.  CD1 lb (or C3b receptor)  is 
the  alpha  chain  of the  integrin  Mac-1,  a  ligand  for  the  intercellular adhesion  molecule 
(ICAM).  This was performed to assess whether ammonia  impairs the expression of this 
neutrophil cell surface marker, as this receptor allows the neutrophil  to bind to ICAM-1
229on  the  endothelium  which  is  a  critical  step  in  allowing  the  neutrophil  to  bind  and 
transmigrate the endothelium. (248;249)
5.4.4  ASSESSMENT OF LEUCOCYTE AMMONIA CONTENT
1.  Six mis of blood was collected  in a heparinised tube and immediately 2  mis of blood 
was aliquoted into 3 x 5 ml Falcon polystyrene round bottom tubes  12 x 75 mm (Becton 
Dickinson, UK) in a water bath at 37 °C. One tube contained  100 pL of 10 mM  NH4CI 
giving  a  final  concentration  of 500  pM  NH4CI,  one  tube  contained  15  pL  of  lOmM 
NH4CI  with  85  pL  of neutrophil  wash  solution  giving  a  final  concentration  of 75  pM 
NH4CI and the other 100 pL of neutrophil wash solution as a control.
2. The blood was incubated at 37 °C in a water bath for 90 minutes after gentle mixing on 
a blood rotator for 1   minute. The blood was gently re-mixed on the blood rotator for a 
further 1   minute after 30 and 60 minutes incubation in the water bath.
3. The red cells were lysed with 2 mis of lysing solution. The tubes were gently mixed for 
1   min by inversion and then left standing for a further 20 minutes.
4. The tubes were then centrifuged at 4 °C at 316 g and the lysing solution was removed. 
The  cells  (leucocytes)  were  then  washed  twice  as  before  with  neutrophil  washing 
solution.
4. After the final wash, the supernatant was removed and the cells were re-suspended in 
400 pL neutrophil wash solution.
5. Twenty pL was then added to a haemocytometer (Assistcnt, Thoma) and the numbers 
of cells were counted under a light microscope.
2306. Fifty pL was then removed from each sample and added to  15 pL of 5% trichloroacetic 
acid.
7. This was then freeze thawed three times in a -80 °C freezer to homogenize the cells and 
then spun in a microcentrifuge at  11,200 g at 4 °C for 10 minutes.
8. Fifty pL of the supernatant was pipetted out onto a 96 well plate at 30 °C for 3 hours in 
200  pL  of  a  solution  containing  phenol  (10  mM),  nitroprusside  (10  mM),  sodium 
hypochlorite (10 mM) solution and sodium hydroxide (0.5 mM).
9. The blue colour formed by reaction of ammonia with phenol and hypochlorite was then 
measured  colorimetrically  at  630nm.  This  was  read  in  a  96  well  plate  reader  (Tecan 
Sunrise, Salzburg, Austria).
10.  Each  sample  was  analysed  in  duplicate  and  compared  to  an  ammonium  chloride 
standard curve (Figure 3.1).
11. The ammonia content of each neutrophil was then calculated in nM.
5.4.5  CO-INCUBATION WITH AMMONIA AND DIFLUOROMETHYL 
ORNITHINE (DFMO) AND OXIDATIVE BURST
1. Two mis of heparinised whole blood was incubated at 37 °C in a waterbath with either 
10 mM  DFMO (Sigma) or with  100 pL of neutrophil washing solution as a control, and 
75 pM NH4C1 for 90 minutes after gentle mixing on a blood rotator for 1   minute. Mixing 
was repeated for 1   minute after 30 and 60 minutes incubation.
2. The Burstest® was then performed and the results were analysed by flow cytometry.
2315.4.6 MYELOPEROXIDASE ASSAY
This is a classical guaiacol peroxidation assay.(250;251) It is affected by the 
presence of even a small number of eosinophils since eosinophils have an even higher 
peroxidase activity (EPO) and content than neutrophils, therefore this assay utilizes 3- 
amino-1,2,4-triazole [AMT] (Sigma) which inhibits EPO.
1. Blood was incubated with 0, 75  or 300 pM ammonia for 90 mins and the neutrophils 
were isolated using polymorphoprep™ .
2.  The  neutrophils  were  then  re-suspended  in  400  pL  of neutrophil  wash  solution  and 
then  20  pL  was  placed  on  a  haemocytometer  and  the  cells  counted  under  a  light 
microscope.
3.  The  myeloperoxidase  buffer  was  then  prepared  by  adding  0.02%  w/v 
cetyltrimethylammonium bromide  [CTAB]  (Sigma) and  13  mM guaiacol (sigma) to 200 
mis of phosphate-buffered saline, pH 7.0.
4. Three mis of MPO buffer was then added to a cuvette, along with 50,000 neutrophils 
and 6 pL of 2 mM AMT.
5. The reaction was then started by adding 4  pL of 1   pM of hydrogen peroxide (Sigma) 
whilst the reaction mixture was maintained at 37 °C by a heated mount and the increase 
in optical density was followed kinetically at 470 nm using a spectrophotometer.
2325.5 RESULTS
In  the  presentation  of this  work  on  neutrophils,  there  are  components  of the 
research  that  employ  by  the  very  nature  of the  methodology,  a  mixed  granulocyte  or 
leucocyte population.  When  the  former is the case, the term  neutrophils will  be used  in 
the description as >95% of the cells isolated are  likely to be neutrophils (the remaining 
small  fraction  of granulocytes  will  be basophils  and  eosinophils).  In  the  later case,  the 
cell  population  will  be  identified  as  leucocytes,  70%  of which  will  be  neutrophils,  the 
remainder of which will be mainly lymphocytes.
5.5.1  AMMONIA AND PHAGOCYTOSIS
Phagocytosis was significantly impaired by  12-20% following incubation with 75 
pM  NH4CI  (0  versus  75  pM  NH4C1;  p<0.0005  Mann  Whitney).  The  critical  ammonia 
concentration  which  had  a  significant  effect  on  phagocytosis  was  75  pM  and  the 
additional  effect  of 100  -  500  pM  was  only  marginally  more  detrimental.  Two  distinct 
neutrophil populations were seen, one functioning more optimally than the other.  [Figure 
5.8]  The  sub-optimal  population  increased  with  rising  ammonia  concentration.  That  is, 
the  number  of neutrophils  which  were  CD 16  positive  (functional)  but  did  not  express 
FITC,  increased  with  rising  ammonia  concentration.  This  can  be  seen  clearly  in  Figure 
5.9  which  shows  that  only  59.63%  of  neutrophils  are  ‘optimally’  phagocytosing 
(neutrophils  fall  in  the right upper quadrant)  whilst 35.99%  are  falling  in  the  left  upper 
quadrant (sub-optimal) following incubation with 500 pM NH4C1.
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Figure 5.8
Graphs  showing  the  percentage  of neutrophils  undergoing  ‘optimal’  (above)  and  ‘sub- 
optimal’  (below)  phagocytosis,  following  incubation  with  0  -  150  pM  ammonium 
chloride (NH4Cl).
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Typical flow cytometry plots to demonstrate the ‘optimal’ (top right quadrant of top right 
cytometry  plot  [UR])  and  ‘sub-optimal’  (top  left  quadrant  of top  right  cytometry  plot 
[UL])  neutrophil  populations  following  incubation  for  90  minutes  with  500  pM 
ammonium chloride (NH4CI).5.5.2 AMMONIA AND OXIDATIVE BURST
Oxidative  burst  was  determined  using  the  Burstest®  (Orpegen  Pharma)  which 
measures  the  percentage  of  neutrophils  that  produce  reactive  oxidants  converting 
dihydrorhodamine to rhodamine which fluoresces. Oxidative burst following the addition 
of opsonised E.coli approached 95-98 % in all samples in both the presence and absence 
of ammonia which  was similar to  that produced  by  adding the positive control  phorbol 
12-myristate  13-acetate (PM A). Spontaneous resting burst in the absence of bacteria, was 
increased in all studies by the addition of up to 500 pM NH4CI. Spontaneous respiratory 
burst was increased by a mean  10.7 +/-  1.8 % following incubation with 75pM NH4CI (0 
versus  75  pM  NH4CI;  p<0.0005  Mann  Whitney).  However,  as  with  phagocytosis,  the 
critical  ammonia  concentration  which  had  a  significant  effect  on  inducing  spontaneous 
respiratory  burst  was  75  pM  and  the  additional  effect  of  100  -  500  pM  was  only 
marginally greater.
5.5.3 AMMONIA AND NEUTROPHIL MORPHOLOGY ASSESSED BY FLOW 
CYTOMETRY
Following isolation and incubation with 75pM NH4C1 for 90 minutes the forward 
scatter of the neutrophils was measured using flow cytometry. The mean of the forward 
scatter  and  standard  error  for  100,000  gated  neutrophils  was  509  +/-  4.9  for  controls 
versus  502.7  +/-  3.8  for  neutrophils  incubated  with  75  pM  NH4CI  (p=0.02  Mann 
Whitney).  The  ammonia-incubated  neutrophils  were  2  %  bigger  than  controls  on  How 
cytometry of 1 0 0 , 0 0 0 gated neutrophils, most likely to represent cell swelling.
2365.5.4 THE EFEECT OF AMMONIA ON EXTRACELLULAR pH
The  pH  and  partial  pressure  of carbon  dioxide  (pCCL)  were  measured  using  a 
Radiometer ABL 700 Series blood gas analyzer on whole blood samples with 0 - 500 pM 
NH4CI, to assess for changes in extracellular pH resulting from incubating whole blood, 
and  thus the neutrophils,  with  ammonia.  There were  no detectable differences  in  either 
extracellular pH  or pC02  between  controls  and  whole blood  incubated  with  up  to  500 
pM NH4CI from which the neutrophils were isolated 90 minutes later [Figure 5.10].
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Figure 5.10
Graphs to show the effect on extracellular (a) pH  and  (b) pC02  of adding 0 -  500  pM 
NH4CI to whole blood from which the neutrophils are isolated.
2385.5.5 NEUTROPHIL APOPTOSIS/DEATH
5.5.5.1 TRYPAN BLUE EXCLUSION TEST
There  was  no  difference  in  the  number of non-viable  cells  between  neutrophils 
isolated  from control  whole blood and neutrophils  isolated  from whole blood  incubated 
for 90 minutes with 75 or 500 pM NH4C1 [1.57,  1.78 and  1.77% non-viable for 0, 75 and 
500 pM NH4CI respectively],
5.5.5.2 ANNEXIN V-FITC AND PROPIDIUM IODIDE
Two experiments were performed. The first assessed apoptosis/cell death and the 
duration of incubation with ammonia, and the second assessing the relationship between 
concentration of ammonia and apoptosis/cell death.
Ammonia-induced apoptosis or necrosis was excluded by staining with propidium 
iodide and annexin V-FITC. Up to 5 hours of incubation in a waterbath at 37 °C with 75 
pM  NH4CI  resulted  in  only  1-2%  of neutrophils  showing  evidence  of early  apoptosis 
(annexin  V-FITC  positive,  propidium  iodide  negative)  and  necrosis/cell  death  (annexin 
V-FITC positive and propidium iodide positive) as measured with flow cytometry. After 
5  hours,  the  neutrophils  began  to  die  with  >20%  of them  staining  positive  with  both 
annexin  V-FITC  and  propidium  iodide as  measured  with  flow  cytometry.  Furthermore, 
incubation with ammonia for up to  120 minutes at concentrations of NH4C1 up to 500 pM 
did  not  induce  apoptosis  or  cell  death  and  this  cannot  therefore  account  for  the 
impairment in phagocytosis or increase in spontaneous respiratory burst activity.
2395.5.6 NEUTROPHIL CD1 lb EXPRESSION
The  Phagotest®  and  Burstest®  were  repeated  using  anti-CD lib  (BD 
Pharminogen) instead of anti-CD 16 as a neutrophil marker. This was performed to assess 
whether ammonia impaired the expression of this neutrophil cell  surface marker, as this 
receptor allows the neutrophil to bind to ICAM-1  on the endothelium which  is a critical 
step in allowing the neutrophil to bind and transmigrate the endothelium. Incubation with 
up  to  500  pM  NH4CI  however,  did  not  alter  the  expression  of  CDllb  during 
phagocytosis and oxidative burst tests as analysed by flow cytometry.
5.5.7 INTRACELLULAR NEUTROPHIL AMMONIA CONCENTRATION
The intracellular neutrophil ammonia concentration was calculated from 7.6 x  106 
granulocytes  isolated  with  Polymorphoprep™.  The  mean  intracellular  neutrophil 
ammonia concentration following 90 minute incubation with and without ammonia, were
0.26  nM  in  controls  and  0.32  nM  following  incubation  with  both  75  pM  and  500  pM 
NH4CI.  This  demonstrates  that  ammonia  is  taken  up  by  the  neutrophil  during  the 
incubation period but that this does not rise beyond 0.32 nM with increasing extracellular 
ammonia concentration.
5.5.8 DIFLUOROMETHYLORNITHINE HYDROCHLORIDE (DFMO) AND 
OXIDATIVE BURST
Whole  blood  was  incubated  with  the  ornithine  decarboxylase  inhibitor  DFMO 
with  and  without  75  pM  NH4CI.  DFMO  partially  inhibits  respiratory  burst  which  is 
crucial  in  the  production  of polyamines  and  reactive  oxygen  species.  The  ammonia-
240induced  increase in spontaneous burst activity was prevented by  the addition of DFMO 
and  both  control  and  ammonia-incubated  neutrophils  showed  reduced  respiratory  burst 
[Figure 5.11]. Therefore the inhibition of ornithine decarboxylase negated the increased 
spontaneous  respiratory  burst  activity  induced  by  ammonia.  DFMO  did  not  affect 
phagocytosis.
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Figure 5.11
Graphs  showing  the  effect  of  incubation  of  75  pM  NH4CI  on  (a)  induced  and  (b) 
spontaneous  oxidative  burst  with  and  without  the  ornithine  decarboxylase  inhibitor 
DFMO.
*p< 0.05; **p< 0.001
2425.5.9 AMMONIA AND MYELOPEROXIDASE ACTIVITY
Myeloperoxidase activity, a further measure of oxidative burst, was measured by 
the classical guaiacol peroxidation  assay  and  increased significantly with  incubation of 
75  pM  NH4CI  (p<0.001).  In  the  same  experiment,  the  percentage  of  neutrophils 
undergoing  spontaneous  respiratory  burst  at  rest  increased  from  6.54  to  21.62% 
(p<0.0005), as measured by the Burstest®.
2435.6 DISCUSSION
These  observational  studies  examining  the  effect  of  ammonia  on  neutrophil 
function  have  shown  that  the  presence  of  ammonia  is  detrimental  to  the  ability  of 
neutrophils  to  phagocytose  and  that  ammonia  induces  spontaneous  respiratory  burst  in 
unstimulated  neutrophils.  Myeloperoxidase  activity,  a  measure  of  oxidative  burst, 
increased  significantly  in  the  presence  of  ammonia  but  an  inhibitor  of  ornithine 
decarboxylase,  an  enzyme crucial  in  the production  of polyamines and reactive  oxygen 
species,  prevented  ammonia-induced  increases  in  respiratory  burst  activity.  This 
occurred  in  the  absence  of an  extracellular  pH  change,  and  without  any  evidence  of 
increased apoptosis or early cell death. The intracellular ammonia concentration has been 
shown  to  rise  and  the neutrophil  morphology  changes,  with  cells  appearing  to  become 
more rounded as a result of swelling on flow cytometry.  Furthermore, the expression of 
CD1 lb surface receptors did not change in the presence of ammonia making it unlikely 
that the ability of the neutrophil to bind to ICAM-1  on the endothelium is impaired.
These  studies  provide  the  first  direct  evidence  that  ammonia,  in  concentrations 
which  are  commonly  found  in  both  acute  and  chronic  liver  dysfunction,  impairs  the 
morphology  and  function  of neutrophils  in  the  absence  of the  other physiological  and 
biological  factors  which  may  contribute  to  neutrophil  dysfunction  in  liver  disease. 
Therefore, the presence of hyperammonemia  is  likely to represent yet another insult  on 
these  already  poorly  functioning  neutrophils,  reducing  the  response  to  microbial 
challenge  and  increasing  susceptibility  to  infection.  Hyperammonemia  is  commonly 
associated  with  hepatic  encephalopathy and  accompanies gastrointestinal  bleeding,  both 
conditions being associated with a high incidence of sepsis and mortality (124). Therefore
244one  might  postulate  that  in  addition  to  infection  making  a  cirrhotic  individual  more 
susceptible  to  the  cerebral  effects  of  hyperammonemia,  that  hyperammonemia  itself 
might  also  make  them  more  susceptible  to  the  development of infection.  Moreover,  as 
ammonia  induces  spontaneous  respiratory  burst  in  resting  neutrophils,  then  this  may 
account  in  part  for  the  raised  levels  of proinflammatory  cytokines  and  inflammatory 
markers  measured  in  cirrhotic  individuals  even  in  the  absence  of overt  infection  when 
repeated cultures are negative. This adds another dimension to the synergistic relationship 
between  ammonia  and  infection  in  the  pathogenesis  of  hepatic  encephalopathy  and 
supports my hypothesis.
Clearly these studies are observational ones and the mechanisms which lead to the 
ammonia-induced impairment in neutrophil function have yet to be fully elucidated. The 
changes in neutrophil morphology shown on flow cytometry hint that neutrophil swelling 
could be important in their reduced ability to phagocytose but also the activation of key 
oxidative  enzymes  must  be  important.  We  had  hoped  to  have  examined  the 
morphological  changes  in  the  neutrophils  more  specifically  with  electron  microscopy 
before and after incubation with ammonia, allowing for the cytoskeleton and cell volumes 
to be observed, however, the images obtained showed that the cell membranes had been 
damaged in the processing of the neutrophils for electron microscopy.
Ammonia  freely  passes  into  the  neutrophil  cytosol  and  one possibility  is  that  it 
may  activate  intracellular  signalers  such  as  mitogen-activated  protein  (MAP)  kinases; 
p38-MAP kinase (p38'M A P K ), Jun-kinase (JNK) and extracellular signal-regulated kinase 
(ERK)  (179).  Inflammatory  stimuli  activate  these  four  major  signaling  intracellular 
signaling  pathways:  the  nuclear  factor-KB  (NFkB)  and  the  3  MAPK  kinase  pathways
245(p38‘M A PK ,  ERK  and  JNK).  All  4  pathways  drive  transcription  of inflammatory  genes 
which are central to the inflammatory response. Exploration of the influence of ammonia 
on  these  signaling  pathways  poses  an  interesting  mechanistic  approach,  although  as 
ammonia  freely passes into the neutrophil  cytosol, many  essential  pathways,  key to the 
successful functioning of a neutrophil, are likely to be affected in some way or other.
In  conclusion,  ammonia  impairs  neutrophil  phagocytosis  and  induces  oxidative 
burst in unstimulated neutrophils. The mechanisms have yet to be fully elucidated but cell 
swelling  and  activation  of key  oxidative  enzymes  are  important.  Consequently,  in  the 
presence  of  hyperammonemia  neutrophils  may  be  unable  to  respond  to  microbial 
challenge,  in  part  accounting  for  the  increased  susceptibility  to  infection.  In  the  6 th  
chapter of this  thesis,  I  chose  to  explore  one  specific  area  in  relation  to  elucidating  a 
possible mechanism of action involving the effect of ammonia on the mitogen-activated 
kinases.
246Chapter 6
The effect of ammonia on 
neutrophilfunction: an 
investigation into ap3Sm(FK 
dependent mechanism
2476.1 BACKGROUND
It has already been shown  in chapter 5 that phagocytosis is impaired by  12-20% 
following  incubation  with  75  pM  NH4CI  (p<0.0005;  Mann  Whitney)  and  that 
spontaneous  respiratory  burst  was  increased  by  10.7  +/-  1.8  %  (p<0.0001;  Mann 
Whitney). If the p38'M A P K  signaling pathway plays an important role in inflammation and 
also  acts  as  an  osmoregulator,  activated  in  response  to  increased  cell  hydration,  it  is 
conceivable that it could have an  important role in  the ammonia-induced  impairment of 
neutrophil  function. As neutrophils have also been shown to morphologically change by 
becoming more rounded and thus most likely to have swollen  in response to exogenous 
ammonia.  The  hypothesis  was  developed  that  p38’M A P K   signaling  is  involved  in  the 
ammonia-induced impairment of neutrophil function. In the first study of this chapter the 
impact of modulators of p38'M A P K   activity  influence on  ammonia-induced  phagocytosis 
has  been  investigated  and  comparable  experiments  on  resting  respiratory  burst  in 
unstimulated neutrophils explored.
2486.2 ABSTRACT
Background:  It  has  been  previously  shown  that  phagocytosis  is  impaired  following 
incubation with 75  pM ammonia [p<0.0005] and that spontaneous respiratory burst was 
increased  (p<0.0005).  The  p38~M A P K   signaling  pathway  plays  an  important  role  in 
inflammation  and  acts  as  an  osmoregulator,  activated  in  response  to  increased  cell 
hydration. As neutrophils were also found to swell in response to exogenous ammonia, it 
was  hypothesised  that  p38’M A P K   signalling  is  involved  in  the  ammonia-induced 
impairment of neutrophil  function.  Aims:  To determine whether specific  modulators of 
p38'M A P K  activity influence ammonia-induced phagocytosis or resting oxidative burst. 
Methods: Whole blood from healthy volunteers was incubated for 90 mins at 37°C with 
75pM NH4CI  with or without a  specific p38  agonist (lpM  isoproterenol) or antagonist 
(lOpM  SB203580). Quantification of phagocytosis was performed using the Phagotest® 
utilizing  opsonised  FITC-labeled  E.Coli.  Oxidative  burst  was  determined  using  the 
Burstest® which measures the percentage of neutrophils that produce reactive oxidants. 
Isolated  neutrophils  were  then  labeled  with  anti-CD 16-R-PE  antibodies  and  analyzed 
using  flow  cytometry.  Results:  75  pM  NH4C1  impaired  phagocytosis  by  18.4%  and 
caused cell swelling, this was further exacerbated by the addition of SB203580. The p38 
agonist prevented the ammonia-induced impairment of phagocytosis and resulted in 2.5% 
cell  shrinkage.  Spontaneous  respiratory  burst  was  induced  by  ammonia  but  the  p38 
agonist  was  not  protective.  Conclusions:  The  p38'M A P K   pathway  is  important  in  the 
ammonia-induced  impairment  of  phagocytosis.  p38'M A P K   agonist  prevents  neutrophils 
from swelling in the presence of ammonia and improves phagocytosis.
2496.3 METHODS
6.3.1 AMMONIA AND CELL INTRACELLULAR SIGNALLING
As  part  of the  investigation  to  elucidate  the  mechanisms  by  which  ammonia 
impairs  neutrophil  function  experiments  were  performed  to  explore  the  effects  of 
ammonia  incubation  on  leucocyte  intracellular signal  pathways using  specific  and  non­
specific agonists and antagonists of the intracellular signalers ERK2, JNK, MAPK and in 
particular p38'M A PK .
6.3.1.1 CELL SIGNALLING INHIBITORS USED IN THIS STUDY
6.3.1.1.1 SB 203580
[4-(4-Fluorophenyl)-2-(4-methylsulfmylphenyl)-5(4-pyridyl)lH-imidazole 
(Calbiochem, San Diego, California) is a highly specific, cell-permeable inhibitor of p38‘ 
M A P K  (IC5o=34 nM).  It is also known as reactivating kinase and cytokine synthesis anti­
inflammatory drug binding protein) (252).  It does not significantly inhibit JNK or p42‘ 
M A P K   even  at  100  pM.  It  has  been  shown  to  inhibit  IL-1  and  TNF-a  release  from 
lipopolysaccharide-stimulated  human  monocytes.  It  was  also  shown  to  be  an  effective 
inhibitor of inflammatory cytokine production in vivo in both mice and rats. (253)
6.3.1.1.2 PD 98059
[2’-amino-3’-methoxyflavone]  (Calbiochem)  is  a  selective  and  cell-permeable 
inhibitor of MAP kinase (MEK) that acts by inhibiting the activation of MAP kinase and 
subsequent phosphorylation of MAP kinase substrates. (254)
2506.3.1.1.3 SP 600125
[anthra(l,9-cd)pyrazol-6(2H)-one;  1,9-pyrazoloanthrone]  (Calibiochem)  is  a 
potent,  cell-permeable,  selective  and  reversible  inhibitor  of  c-Jun  N-terminal  kinase 
(JNK)  (IC5o=  40  nM  for  JNK-1  and  JNK-2  and  90  nM  for  JNK-3.  The  inhibition  is 
competitive with respect to ATP.  It exhibits over 300-fold greater selectivity for JNK as 
compared  to  ERK1  and p38-MAPK.  (255)  It  inhibits  the phosphorylation  of c-Jun  and 
blocks  the expression  of IL-2,  IFN-y,  TNF-a  and  COX-2  in  synovial  cells  and blocked 
IL-1-induced accumulation of phosphor-Jun and induction of c-Jun transcription. (256)
6.3.1.1.4 UO 126
[l,4-diamino-2,3-dicyano-l,4-bis(2-aminophenylthio)  butadiene  is  a  potent  and 
specific inhibitor of MEK1  (IC50 = 72 nM) and MEK2 (ICso= 58 nM). The inhibition is 
non-competitive with respect to MEK substrates, ATP and ERK.  It has very little effect 
on the other kinases, such as ERK, JNK, MEK, MKK-3 and MKK-6 . (257;258) It acts as 
an  immunosuppressant  by  effectively  blocking  IL-2  synthesis  and  T-cell  proliferation 
without affecting the long-term outcomes of either T cell activation or tolerance.  (259)
6.3.1.2  CELL SIGNALLING AGONISTS USED IN THIS STUDY
6.3.1.2.1  PHORBOL 12-MYRISTATE 13-ACETATE (PMA)
This  is  a  non-specific  agonist  of all  the  intracellular  signalers  including  ERK2, 
JNK, MAPK and p38"M APK as it activates protein kinase C.
2516.3.1.2.3  ISOPROTERENOL
This  p-adrenergic  agonist  increases  the  activity  of the  stress-activated  p38"M A P K  
over  10-fold in freshly isolated rat epididymal fat cells. Stimulation of p38"M A P K  is rapid, 
sustained for at least 60 mins and sensitive to the specific p38'M A P K  inhibitor, SB 203580. 
Half-maximal stimulation occurs at  13 nM and the effect is achieved via increases in the 
activity of cyclic-AMP dependent protein kinase. It has no effect on JNK. (260)
6.3.2  CO-INCUBATION OF NEUTROPHILS WITH CELL SIGNALING 
AGONISTS AND INHIBITORS AND AMMONIA
1. Two mis of heparinised whole blood was incubated at 37 °C in a waterbath with either 
50  pM  PD98059  (Calbiochem),  10  pM  U0126  (Calbiochem),  10  pM  SB203580 
(Calbiochem)  and  10  pM  SP600125  (Calbiochem)  dissolved  in  dimethyl  sulfoxide 
(DMSO),  and  75  pM  NH4CI  for 90  mins  after  gentle  mixing  on  a  blood  rotator  for  1  
minute.  Control  samples were  incubated  with  an  equivalent volume  of DMSO.  Mixing 
was repeated for 1   minute after 30 and 60 mins incubation.
2.  PMA (a non-specific activator of protein kinase C) and isoproterenol (specific agonist 
of p38'M A P K ) were used as positive controls.
3. The Phagotest® and Burstest® were then performed and the results were analysed by 
flow cytometry.
2526.4 PROTOCOL
Heparinised whole blood from 3 healthy volunteers was incubated for 90 minutes 
at  37°C  with  75  pM  NH4CI  with  or  without  a  specific  p38'M A P K   agonist  (1  pM 
isoproterenol) or p38M A P K  antagonist (10 pM  SB203580; Calbiochem. Quantification of 
phagocytosis was performed using the Phagotest® (Orpegen Pharma) utilizing opsonised 
FITC-labelled  E.coli.  Quantification  of  oxidative  burst  was  determined  using  the 
Burstest® (Orpegen Pharma) which measures the percentage of neutrophils that produce 
reactive oxidants converting dihydrorhodamine to rhodamine which  fluoresces.  Isolated 
neutrophils were then  labeled  with  anti-CD 16-R-Phycoerythrin antibodies and  analysed 
using flow cytometry. The pH was monitored and did not change by adding NH4C1.
2536.5 RESULTS
6.5.1 AMMONIA AND INTRACELLULAR SIGNALLING INHIBITORS
Initial pilot studies were performed to look at the effect of 4 different inhibitors on 
the  intracellular  signaling  pathways.  In  theses  studies,  U0126  an  ERK2  inhibitor, 
PD98059 a MEK inhibitor and SP60025 a JNK inhibitor had no effect on phagocytosis or 
respiratory burst, in both the presence and absence of ammonia. However, co-incubating 
healthy  neutrophils  with  the  specific  p38‘M A P K   inhibitor  SB203580,  resulted  in 
phagocytosis being dramatically impaired. It was therefore decided that all further studies 
would  be  focused  on  the  role  of p38‘M A P K   in  phagocytosis  and  respiratory  burst  in  the 
presence and absence of ammonia.
6.5.2 AMMONIA, PHAGOCYTOSIS AND p38'M A PK  ANTAGONISM
Incubation  of neutrophils with  75  pM  NH4C1   impaired  phagocytosis by  18.4  % 
(p<0.05) with the percentage of neutrophils undergoing phagocytosis being 91.09 % with 
0 pM NH4CI and 71.81  % with 75  pM NH4CI respectively. Co-incubation with the p38’ 
M A P K  antagonist SB203580 (75  pM NH4CI +  10 pM  SB203580) exacerbated this further 
with only 64.43 % (p<0.05) of neutrophils undergoing phagocytosis [Figure 6.1].
6.5.3 AMMONIA, OXIDATIVE BURST AND p38 M A PK  ANTAGONISM
Incubation  of neutrophils  with  75  pM  NH4C1,  with  and  without  the  p38'M A P K  
antagonist SB203580, did not alter the number of neutrophils undergoing oxidative burst 
with  E.coli  which  approached  95%  in  all  groups  [Figure  6.2].  Spontaneous  respiratory
254burst  in  unstimulated  neutrophils  was  however  induced  by  75  pM  NH4C1  (4.74%  in 
controls  versus  9.66%  in  those  incubated  with  ammonia;  p<0.05).  The  p38'M A P K  
antagonist  SB203580  prevented  the  ammonia-induced  increase  in  spontaneous 
respiratory burst reducing the levels back to those in controls (4.98 %) [Figure 6.3].
6.5.4 AMMONIA, PHAGOCYTOSIS AND SPECIFIC p38 M A PK  AGONISM
The  specific  p38'M A P K   agonist  isoproterenol  (1  pM)  prevented  the  ammonia- 
induced impairment of phagocytosis with 75  pM NH4CI (91.09 % of control neutrophils 
undergoing phagocytosis versus 95.69 % incubated with ammonia and p38‘M A P K  agonist) 
[Figure 6.1].
6.5.5 AMMONIA, OXIDATIVE BURST AND SPECIFIC p38 M A PK  AGONISM
Incubation of neutrophils with 75  pM NH4C1, with and without the specific p38‘ 
M A P K  agonist  1  pM  isoproterenol,  did  not  alter  the  number  of neutrophils  undergoing 
oxidative  burst  with  E.  coli  which  approached  95%  in  all  groups  [Figure  6.2].  In  the 
unstimulated  neutrophils,  the  percentage  undergoing  spontaneous  respiratory  burst  was 
not altered by co-incubation with the specific p38‘M A P K  agonist [Figure 6.3].
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Figure 6.1
Bar graph  representing the effect of the specific  p38*M A P K  agonist isoproterenol (1  pM) 
and the specific p38’M A P K  antagonist SB203580 (10 pM) on the percentage of neutrophils 
undergoing phagocytosis with and without 75 pM NH4C1.
* p<0.05
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Figure 6.2
Bar graph  representing the effect of the specific p38 M A P K  agonist isoproterenol  (1  pM) 
and the specific p38'^ ^  antagonist SB203580 (10 pM) on the percentage of neutrophils 
undergoing oxidative burst with and without 75 pM NH4CI.
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Figure 6.3
Bar graph  representing the effect of the specific  pSS*1 ^ ^  agonist isoproterenol  (1  pM) 
and  the  specific  pSS'1 ^ ^   antagonist  SB203580  (10  pM)  on  the  percentage  of 
unstimulated neutrophils undergoing spontaneous respiratory burst with and without 75 
pM NH4C1.
* p<0.05
2586.5.6 NEUTROPHIL SWELLING AND p38 M A PK
Neutrophils  exposed  to  75  pM  NH4CI  increased  in  volume  (as  measured  by  a 
reduction in forward scatter on flow cytometry of an average of 100,000 neutrophils) by
2.01  +/-  0.36  %.  The  specific  p38'M A P K   agonist  isoproterenol  led  to  cell  shrinkage 
compared to controls of 2.48 +/- 2.55 % and when the neutrophils were co-incubated with 
ammonia and p38'M A P K  agonist, the neutrophil  size was no different to controls showing 
that the p38"M A P K  agonist prevented ammonia-induced neutrophil swelling.
The  specific  p38’M A P K   antagonist  SB203580  however,  increased  neutrophil 
volume by 2.74 +/- 0.43 % compared to controls, which was exacerbated by the addition 
of 75 pM NH4CI to 5.16 +/- 0.92 % preventing normal neutrophil osmoregulation.
2596.6 DISCUSSION
In  conclusion,  this study  demonstrates  that the  ammonia-induced  impairment  in 
phagocytosis is exacerbated by the addition of the specific p38’M A P K  antagonist SB203580 
and  prevented  by  the  addition  of a  p38’M A P K  agonist  suggesting  that  p38'M A P K  plays  a 
pivotal role in the ammonia-induced alterations in neutrophil function, which may have a 
significant  relationship  to  neutrophil  function  in  the  hyperammonaemic  liver  disease 
patient.  As  p38'M A P K   is  an  important  cell  osmoregulator,  then  its  inhibition  may  be 
preventing  the  neutrophil  from  regulating  its  water  uptake  and  excretion  and  thus 
explains why the neutrophil increases in volume on flow cytometry.
As the addition of a p38 M A P K  agonist abrogates the ammonia-induced impairment 
in  phagocytosis,  this  would  imply  that  ammonia  either  inhibits  p38’M A P K  directly  or its 
metabolism within the cell leads to the production of a substance which exerts an osmotic 
effect within the neutrophil; a potential candidate is glutamine. This has been shown to be 
the case  in the astrocyte which  contains glutamine synthetase,  which in the presence of 
ammonia,  amidates  glutamate  to  form  glutamine.  Glutamine  exerts  an  osmotic  effect 
within the astrocyte, causing it to take in water and thus swell (49).  Glutamine has been 
shown  to  exert  many  of its  biological  effects  through  a  swelling-induced  activation  of 
ERK  and  p38~M A P K   signaling  in  rat  hepatocytes  (154-157)  and  vom  Dahl  et  al.  have 
shown in the perfused rat liver with hypoosmotic exposure,  that p38'M A P K  (but not Erks 
or PI-3-kinase) is critical in cell volume regulation (157) and that cell hydration controls 
autophagosome formation in rat liver in a microtubule-dependent way downstream  from 
p38M A P K   activation  (261).  Hepatocytes  express  both  glutamine  synthetase  and 
glutaminasc, but in  neutrophils however,  the dominant enzyme is glutaminase,  which  is
260necessary  to  break  glutamine  down  to  glutamate,  lactate  and  aspartate  which  are 
important  fuels  for the neutrophil  (138; 139).  Therefore,  the production  of glutamine by 
neutrophils in response to exogenous ammonia is unlikely.  Furthermore, the addition of 
the glutamine synthetase  inhibitor (methionine  sulphoxamine)  in pilot  studies,  made no 
difference  to  neutrophil  function  in  both  the  presence  and  absence  of ammonia.  This 
therefore leads us to the conclusion that ammonia inhibits p38"M A P K  activation directly or 
through  another metabolic derivative other than  glutamine,  which  consequently  impairs 
neutrophil osmoregulation.
Conversely,  in  regard  to  the  ammonia-induced  increase  in  resting  respiratory 
burst, the p38’M A P K  agonist made no difference at all.  However,  the p38‘M A P K  antagonist 
SB203580  prevented  the  ammonia-induced  increase  in  spontaneous  respiratory  burst 
reducing the levels back to those seen in controls. This implies that p38'M A P K  is important 
in the activation of background spontaneous respiratory burst and that its inhibition can 
abrogate  the  increased  spontaneous  respiratory  burst  induced  by  ammonia.  However, 
inhibition  of p38‘M A P K   did  not  alter  the  number  of neutrophils  undergoing  respiratory 
burst with  E.coli. This would imply that other protein kinases and enzymes important in 
the  oxidative  burst  such  as  myeloperoxidase,  are  also  activated  in  the  presence  of the 
bacteria so that the absence of p38 M A P K  makes very little difference to the final outcome.
In  conclusion, the p38 M A P K  signaling pathway  is  important in  ammonia-induced 
impairment  of neutrophil  phagocytosis.  Ammonia  reduces  the  ability  of neutrophils  to 
phagocytose,  as  the  neutrophil  in  no  longer  able  to  osmoregulate  and  consequently 
swells;  this  can  be  overcome  by  adding  a  p38‘M A P K   agonist.  Inhibition  of  p38"M A P K  
however,  also  reduces  the  number  of neutrophils  undergoing  spontaneous  respiratory
261burst which has been shown to increase in the presence of ammonia. Therefore, ammonia 
is  also  likely  to  separately  activate  key  oxidative  enzymes  such  as  myeloperoxidase 
within 90 minutes (as shown in chapter 6), which have more of an  immediate influence 
on the spontaneous neutrophil respiratory burst rate than p38'M A P K  activation, which leads 
to the transcription of inflammatory genes e.g. TNF-a maximal at 24 hours (150; 151). It 
is possible that these mechanisms may, in part, account for the increased susceptibility to 
infection found in patients with cirrhosis.
262Chapter 7
Jin investigation into the 
influence of inflammation on 
ammonia uptake in muscCe
2637.1  BACKGROUND
If inflammation modulates the cerebral effects of ammonia, then a key question to 
answer is how is the metabolism of ammonia affected by the presence of inflammation or 
infection?  The  muscle  is  an  important  organ  in  total  body  ammonia  metabolism.  As 
described earlier, the muscle may be an important site for ammonia detoxification and a 
potential therapeutic target for ammonia reduction in liver disease. By exploring how the 
muscle  metabolism  of ammonia  is  modulated  by  inflammation,  it  was  anticipated  that 
potential  mechanisms might be  further elucidated.  The hypothesis to be tested  was that 
muscle metabolism of ammonia is modulated by inflammation.
Studies were performed using chick embryo primary muscle cell cultures and later 
with  cultures  of  the  immortilized  murine  myofibroblast  cell  line  C2C12  exploring 
whether  ammonia  metabolism,  as  measured  by  stable  amino  acid  isotopes,  could  be 
altered by the addition of an inflammatory stimulus such as lipopolysaccharide.
2647.2 METHODS
7.2.1 MUSCLE CELL CULTURE
7.2.1.1 CHICK EMBRYO PRIMARY MUSCLE CELLS
All  the  following  methods  were  performed  in  a  Laminar  Airflow  Cabinet 
(Microflow Biological Safety) to maintain sterility, adhering to a strict aseptic technique.
7.2.1.2 COLLAGEN PREPARATION FROM RAT TAILS (262)
1.  Rat tails were washed in 70% ethanol for 30 minutes.
2.  The  skin  was  stripped  away  and  the  tendons  removed.  The  tendons  were  then
placed in sterile 0.1% ethanoic acid solution at 4 °C for at least 24 hours.
3.  The resulting suspension was centrifuged at  18,000G  for  1   hour, the  supernatant
was decanted and diluted 1:5 with sterile ddELO and stored at 4 °C until required.
7.2.1.3 CHICK EMBRYO EXTRACT (CEE)
This  was  prepared  by  squeezing  9-12  day  old  chick  embryos  through  a  50  ml 
syringe  followed by the addition  of an  equal  volume  of Earle’s  Balanced  Salt  Solution 
(EBSS) [Table 7.1]. (263)
265F.Wt mM g/litre
NaCl
KC1
Glucose
M gS04
NaH2P04
NaHC03
CaCl2
58.44
74.55
180.2
246.5
137.99
84.01
147
116.35
5.4
5.55
0.81
0.9
26
1.2
6.80
0.40
1.00
0.20
0.124
2.184
0.176
Table 7.1
Earle’s Balance Salt Solution
After standing for 2 hours at room temperature (20 -  22 °C), the extract was either 
centrifuged immediately or stored at -20 °C. Centrifugation was carried out for  1   hour at 
4 °C and 18,000G and the supernatant was stored at -20 °C until use.
7.2.1.4 PREPARATION OF TRYPSIN SOLUTION
This was prepared in a calcium and magnesium-free EBSS to a concentration  of
0.1% and sterilised by filtration.
7.2.1.5 PREPARATION OF CULTURE MEDIUM
Eagle’s  minimum  essential  growth  medium  (MEM)  (264)  [Dulbecco’s  Eagle’s 
MEM with glutamax I (L-alanyl-L-glutamine) without sodium pyruvate with 4500 mg/L 
glucose with pyridoxine (GibcoBRL)] was used for culturing chick skeletal muscle cells 
and the following was added to 500 ml:
•  75 mis horse sera (Invitrogen; UK)
•  25 mis CEE
266•  5 mis glutamine (Sigma; UK)
•  500 meg penicillin G (Sigma; UK)
•  125 meg streptomycin (Sigma; UK)
7.2.1.6  TISSUE CULTURE OF CHICK EMBRYO SKELETAL MUSCLE
Chick skeletal  muscle myotubes were grown according to the procedures of Harvey 
and Dryden (265) in which single cell suspensions of myoblasts were obtained using the 
method  of Konigsberg  et  al.  (266)  Chick  embryos  of  10-12  days  incubation  age  were 
used for all cultures.
1.  After  removal  of the  embryo  from  the  egg  and  immediate  decapitation,  extra- 
embryonic  membranes  and  gross  debris  were  removed,  the  legs  were  severed 
from the body at the level of the ischial crests.
2.  The skin was then peeled away from both legs. The muscle tissue was then teased 
away from the bone and connective tissue and minced with a pair of fine scissors.
3.  The pulped muscle tissue was then placed in 10 ml of 0.1% trypsin solution for 30 
minutes at 37 °C and shaken every 10 minutes for 5 seconds.
4.  The  enzymatic  reaction  was  stopped  by  the  addition  of  10  mis  of cold  MEM 
containing fetal calf sera (Invitrogen; UK).
5.  Dissociation of cell aggregates was aided by sucking the solution 3 or 4 times in 
and out of a  10 ml pipette. The cell suspension was then filtered through 2  layers 
of cotton gauze to remove large cell and remaining tissue aggregates.
2676.  The  filtrate  was  then  centrifuged  for  15  minutes  at  516  g.  The supernatant was 
then  decanted  and  the  myoblasts  resuspended  in  10  mis  of whole  MEM.  The 
number of cells was then counted using a haemocytometer.
7.  Cultures were grown  in  35  mm plastic  Petri  dishes (Sterilin;  UK) that had been 
pre-coated with 1   ml of collagen solution and dried overnight in an oven at 50 °C.
8.  Cells were plated out with a density of 5  x  106 cells/ml, with 2 mis media being 
added to each plate.
9.  The cultures were then incubated at 37 °C  in a humid atmosphere of 5% CO2 in 
air. The medium was then changed every 2 to 3 days.
10. Cultures  were  treated  with  whole  MEM  media  containing  cytosine  arabinoside 
(Sigma;  UK)  10  5   after  4  to  5  days  for  24  hours  after  the  beginning  of rapid 
myoblast  fusion.  (267).  In  muscle  cells  DNA  synthesis  ceases  after  fusion 
(266;268),  therefore  this  treatment  greatly  reduces  contamination  with  actively 
replicating cells, such as fibroblasts, which could otherwise overgrow the cultures.
11. Once treated with cytosine arabinoside, the cultures were allowed to settle for 24 
to  48  hours  before  being  challenged.  A  picture  of the  cultured  muscle  cells  is 
shown in Figure 7.1.
268Figure 7.1
A scanning light micrograph of a chick embryo primary muscle cell culture (x 200 
magnification; Biorad Radiance 2000; UK)
2697.2.2  CHALLENGE  OF  CULTURED  MUSCLE  CELLS  WITH  AMMONIA, 
GLUTAMATE AND LOLA
The muscle cells were pre-incubated  for  1   hour with 2  mis of media  containing 
either  10  mM  glutamate (147  mg  in  100  mis)  (Sigma;  UK),  10  mM  LOLA  (530  pL  in 
100 mis) (Merz Pharmaceuticals,  Frankfurt,  Germany)  and 3H  Glutamate (1  pCurie/ml) 
(Amersham;  UK). The plates were then washed with 2 mis of MEM and then incubated 
for  2  hours  with  0,  25,  50  or  100  pM  NH4CI  (Sigma;  UK)  in  2  mis  MEM.  The 
supernatant was then collected and frozen at -80 °C and the culture plates were stored at - 
80 °C for later analysis.
7.2.3 MEASUREMENT OF 3H- GLUTAMATE IN CELL LYSATES
The cells  were  lysed  with  150  pL  cell  lysis buffer (300  pL  of 0.1%  triton  w/v 
(Sigma; UK) in 30 mis PBS) and scraped from the Petri dishes using a cell scraper. The 
lysis mixture was centrifuged at lOOOg for 15 mins at 4  C before 5 pL of the supernatant 
was  loaded  onto  a  silica  thin  layer  chromatography  (TLC)  (Kieselgel  60,  Merck, 
Darmstadt, Germany) plate and run to separate the glutamine from the glutamate. Non- 
radiaoactive  glutamate  and  glutamine  was  spotted  onto  the  sample  spot  (2  pL,  ImM 
solutions)  for  identification  purposes.  The  solvent  eluent  mixture  consisted  of 5  mis 
formic  acid,  15  mis  methanol,  25  mis  acetaldehyde  and  10  mM  hexanesulphonic  acid 
(Sigma, UK). The plates were then developed in a fume cupboard using Ninhydrin spray 
reagent (0.5% ninhydrin in butanol,  Sigma;  UK) and dried. The spot was then scratched 
off and added  to  8  mis of scintillation  fluid  (™Ultimo Gold,  Packard  Bioscience,  UK). 
The  count  was  then  measured  on  a  Liquid  Scintillation  Analyser  (Tri-Carb  2100  TR,
270Hewlett Packard Bioscience, UK;  Program 3). An example of a developed TLC plate is 
shown in Figure 7.2.
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Figure 7.2
A diagram showing a picture of a typical developed TLC plate for 6 samples of muscle 
cell lysate as compared with glutamate and glutamine controls on either side.
2717.2.4 CULTURE OF C2C12 MURINE MYOFIBROBLAST CELL LINE
Unfortunately,  there  was  no  evidence  of  the  presence  of  either  glutamate  or 
glutamine  in  the  muscle  cell  lysate  as  the  radioactivity  of the  different  spots  was  very 
low.  This  suggested  that  glutamine  synthetase  was  absent  or  expressed  at  very  low 
concentrations, with the glutamate instead being taken up and incorporated in muscle cell 
protein.  This  was  likely  as  the  counts  for  the  pelleted  materials  obtained  after 
centrifugation  were  relatively  high.  Furthermore,  ammonia  measured  in  the  supernatant 
and  lysates  incubated with glutamate or LOLA  did  not differ.  Moreover,  there  were  no 
differences between the muscle cells incubated with varying ammonia concentrations and 
3H-glutamate.  From  this  we  concluded  that  the  glutamine  synthetase  in  these  chick 
embryo  muscle cells  may  not be  expressed  at  this  stage of development or the cultures 
lack  the  relevant  stimuli  in  order  for  it  to  become  expressed.  In  fact  according  to  the 
literature,  the  basal  expression  of glutamine  synthetase  is  very  low  in  rat  muscle  but 
remarkably  enhanced  by  glucocorticoid  hormones  during  trauma  and  catabolic  states. 
(269) Glucocorticoids potentiate the transcription of glutamine synthetase in chick day  6 
embryonic retina cells (270) and the expression of glutamine synthetase is induced in rat 
skeletal  muscle  cells  in  response  to  treatment  with  the  inflammatory  cytokine  TNF-a. 
(271) Therefore, we attempted to stimulate the muscle cells with  50 nM  dexamethasone 
(Sigma;  UK)  added  to  the  culture  medium  from  day  7  onwards  to  encourage  the 
expression  of glutamine synthetase, prior to challenging them  with ammonia and amino 
acids.  Despite  attempting  this  on  several  occasions,  it  was  still  not  possible  to 
demonstrate  any  convincing  evidence  that  any  substantial  glutamine  synthetase  activity 
was present in the muscle cells.
272Following  the  disappointing  results  obtained  from  the  initial  pilot  experiments 
using  the  chick  embryo  muscle  cell  cultures,  we  reverted  to  culturing  an  established 
muscle cell line to see if the resultant myotubes were more likely to or could be induced 
to  express  glutamine  synthetase.  These  cells  were  obtained  from  Dr  Jim  Owen  at  the 
Institute for Liver Studies at the Royal Free Hospital.
7.2.4.1 CULTURE METHOD
Cells  were  grown  in  75  ml  vented  sterile  culture  flasks  (Fisher  Scientific)  in 
25mls  Eagle’s  minimum  essential  growth  medium  (MEM)  (264)  [Dulbecco’s  Eagle’s 
MEM with glutamax I (L-alanyl-L-glutamine) without sodium pyruvate with 4500 mg/L 
glucose with pyridoxine (GibcoBRL)] and the following was added to 500 ml:
•  10% fetal calf serum (Invitrogen; UK)
•  5 mis glutamine (Sigma; UK)
•  500 meg penicillin G (Sigma; UK)
•  125 meg streptomycin (Sigma; UK)
1.  Cells were grown  in an  incubator at 37 °C  in a humid atmosphere of 5% CO: in 
air  until  they  became  confluent  [Figure  7.3],  The  medium  was  then  changed  every  24 
hours.
2.  Cultures  were  treated  with  whole  MEM  media  containing  cytosine  arabinoside 
(Sigma,  UK)  10  5  for  24  hours  as  before  to  reduce  the  number  of  fibroblasts  and 
encourage the growth  of myotubes.  Once  treated with  cytosine arabinoside, the cultures 
were allowed to settle for 24 before being challenged.
2733.  Some  muscle  cultures  were  treated  with  50nM  dexamethasone  added  to  the 
culture medium  from day 7 onwards to see if this would further stimulate the expression 
of glutamine synthetase. (270)
4.  Tctrodotoxin (120  pL of 100 nM)  [Alomone  Labs;  Jerusalem,  Israel]  was added 
to  every  200  mis  of culture  medium  from  day  7  onwards  to  prevent  contraction  of the 
myotubes away from the culture flask.
5.  Myotubes  were cultured  with  5  mM  glutamate-enriched  culture  media  or 5  mM 
LOLA-enriched media or plain media for 24 hours prior to challenge with ammonia.
6 .  At this point there was a move away from using radioactive glutamate and toward 
2  15N- stable nitrogen isotope containing glutamate.
274Figure 7.3
A scanning light micrograph of C2C12 myotubes (x 200 magnification; Biorad Radiance 
2000; UK)
2757.2.5 CHALLENGE OF CULTURED MUSCLE CELLS WITH AMMONIA AND 2  
,5N-GLUTAMATE
1.  Twelve  flasks of myotubes  were  then  incubated  for  6 hours with  100  pM  2 l:,N- 
glutamate  (obtained  from  N.E.P  Deutz,  Academic  Department  of  Surgery, 
Maastricht University, The Netherlands) and  100 pM glutamate (Sigma; UK ) +/- 
500  pM  NH4CI  +/-  3  mM  methionine  sulfoxime  (an  inhibitor  of  glutamine 
synthetase) [Sigma; UK].
2.  Four  flasks  containing  media  only  (no  myotubes)  were  used  as  controls.  Five 
hundred  microlitre  aliquots  of supernatant  were  removed  at  t  =  0  hrs  and  then 
hourly for a total of 6 hours.
3.  Eighty microlitres of 33% w/v sulphosalicylic acid was added to each aliquot and 
the  samples  were  then  stored  at  -80  °C  for  later  determination  of amino  acid 
concentration  by  high-performance  liquid  chromatography  and  liquid 
chromatography mass spectrometry (Pharmacia, Woerden, The Netherlands). This 
was performed at The Department of Surgery, Maastricht University, Maastricht, 
The Netherlands by Dr H. van Eijk and Dr N.E.P Deutz. (191)
4.  Fifty microlitres of supernatant was also removed at each time point for ammonia 
determination using the method detailed in section 3.1.3.2.
5.  Following challenge, cells were washed 3 times with PBS and then removed from 
the  tlasks  using  a  cell  scraper and  lyscd  with  cell  lysis  buffer (300  pL  of 0.1% 
triton w/v in 30 mis PBS; pH 7.4) and stored at -80 °C for later analysis.
2767.2.6 GLUTAMINE SYNTHETASE ACTIVITY ASSAY
Glutamine synthetase  catalyses  the  formation  of L-Glutamine  from  L-Glutamate 
and NH4+  This enzyme also exerts a glutamyl-transferase activity that produces gamma- 
glutamyl-hydroxamate  from  glutamine  and  hydroxylamine.  This  gamma-glutamyl- 
transfer reaction can be used to determine glutamine  synthetase activity by  colorimetric 
assay (272). All chemicals used were from Sigma; UK.
1.  Muscle lysate was homogenised  in  ice-cold Tris buffer (pH  7.0) and centrifuged 
at 4500 g at 4 °C for 20 minutes.
2.  A  reaction  mix  including  0.05  M  imidazole,  0.05  M  imidazole-L-glutamine,  25 
mM  sodium  arsenate,  2  mM  manganese  chloride,  0.16  mM  adenosine 
diphosphate and 25 mM hydroxylamine was mixed and pre-warmed to 37 °C.
3.  Fifty  microlitres  of  the  lysate  was  added  to  25  pL  of  the  reaction  mix  and 
incubated for 30 minutes at 37 °C.
4.  The  reaction  was  stopped  by  the  addition  of  2.42%  ferric  chloride,  1.45% 
trichloroacetate and  1.2% hydrochloric acid.
5.  The  reaction  product  gamma-glutamyl-hydroxamate  forms  a  purplish  brown 
complex  in  the  presence  of trivalent  ion.  The  increase  in  optical  density  was 
followed kinetically at 540 nm using a spectrophotometer over 30 minutes.
6.  The  experiment  was  then  repeated  in  the  presence  of  3  mM  methionine 
sulphoxamine.
2777.3 RESULTS AND DISCUSSION
Once  again, the data obtained  from the repeat studies performed  on  the  C2C12 
murine  myofibroblast  line  did  not  show  any  convincing  evidence  of any  detectable 
glutamine  synthetase  activity.  Figure  7.4  below  shows  that  at  most  there  was  20% 
glutamine synthetase activity which was not inhibited by methionine sulphoxamine.
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Figure 7.4
A  graph  showing  the  percentage  glutamine  generated  from  a  colorimetric  glutamine 
synthetase  activity  assay  with  (pink  line)  and  without  methionine  sulfoxamine  (MSO) 
[dark blue line] over 30 minutes.
278Furthermore,  there  was  no  evidence  of incorporation  of glutamate  (as  measured
^  I  s by  high  performance  liquid chromatography)  or  N-glutamate  (as  measured  by  liquid 
chromatography mass spectrometry), or the production of glutamine at 6 hours as shown 
in  Figure  7.5.  Likewise,  there  was  no  drop  seen  in  ammonia  concentration  over  time 
[Figure 7.6].  Surprisingly, an increase  in ammonia concentration was seen  in the muscle 
cells grown in a LOLA-enriched media. A possible explanation for this could come from 
the fact that the muscle cells were able to take up the ornithine and convert it to glutamate 
and subsequently glutamine.  If sufficient glutamine is generated, then it may breakdown 
via the enzyme glutminase back  into ammonia.  However,  one  would  also expect to  see 
changes  in  the  concentrations  of glutamate  and  glutamine,  which  are  not  seen  in  these 
studies.
In conclusion,  it  is unclear as to why the activity of glutamine synthetase was so 
low  in  these  2  very  different  muscle  cell  cultures.  However,  we  already  know  that 
glutamine synthetase activity in skeletal muscle is low (158), and it is mainly by virtue of 
its  mass  relative  to  other glutamine  synthetase containing organs,  that  muscle  is one  of 
the  principle  glutamine  synthesizing  organs.  If one  did  find  a  way  to  upregulate  the 
expression  of this  enzyme,  then  this  in  vitro  model  could  represent  a  potential  way  to 
study  the  role  of ammonia  in  the  modulation  of muscle  ammonia  metabolism  in  the 
future.
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Figure 7.5
Bar graphs to show the change in concentration of glutamate (GLU) [top] and glutamine (GLN) 
[bottom] at 6 hours in the C2C12 muscle cell lysates cultured alone (blue), in glutamate-enriched 
media (red) or LOLA-enriched media (green), with or without the presence of 500 pM NH4C 1 
and/or 3 mM methionine sulfoxamine (MSO).
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Figure 7.6
Line graphs to show the change in concentration of ammonia over 8 hours in the C2C12 muscle cell supernatant cultured alone (blue), 
in glutamate-enriched media (red) or LOLA-enriched media (green), without ammonia (top left), with 500 pM NH4Cl (top right), with 
3 mM methionine sulfoxamine (MSO) [bottom left] or both (bottom right)
2817.4 CONCLUDING REMARKS
While  the  culture  of both  primary  chick  skeletal  muscle  myotubes  and  C2C12 
murine-derived  myotubes  was  a  potentially  interesting  direction  to  take  the  metabolic 
aspects  of  the  overall  study,  it  was  unfortunate  that  the  resulting  experimental  data 
demonstrated  a  low  glutamine  synthetase  activity  in  both  systems.  The  cultures 
themselves  were  robust  and  demonstrated  skeletal  muscle  cell  striations.  They  were 
contractile, and indeed, it was necessary to use tetrodotoxin to maintain an intact lawn of 
myotubes  on  the  culture  plate.  With  extra  time  and  resources  it  would  have  been 
interesting  and  potentially  rewarding,  from  an  understanding of metabolic  processes  in 
muscle,  to  attempt  to  transfect  the  cells  with  the  glutamine  synthetase  gene.  This  may 
remain a direction  for future work on the metabolism of ammonia by skeletal  muscle  in 
the presence and absence of a range of agonists and antagonists.Chapter 8 
Summary
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Hypothesis
Each of the 3 hypotheses illustrated above has now been explored and tested.
Question  1:  Inflammation and infection are important in the pathogenesis of hepatic 
encephalopathy IChapter31.
The  data  presented  from  the  clinical  studies  have  confirmed  the  importance  of 
ammonia  in  the  pathogenesis  of  hepatic  encephalopathy,  but  suggests  that  the 
inflammatory  response may  be  important in determining the neuropsychiatric effects of 
ammonia rather than the severity of underlying liver disease or hyperammonemia. Also, 
it  has  been  shown  for  the  first  time  that  those  patients  that  have  abnormal 
neuropsychiatric  tests  have  more  likelihood  of  further  deterioration  with  induced 
hyperammonemia.  Furthermore,  it  has  been  shown  that  hyperammonemia  induced  by 
administration of an amino acid solution to patients with cirrhosis, results in deterioration 
in  neuropsychological  function  in  the  presence  of a  systemic  inflammatory  response. 
Following resolution of the systemic  inflammatory response, there was no deterioration 
in neuropsychological function despite equivalent severity of induced hyperammonemia.
284Therefore,  these data provide  supportive evidence  suggesting that  inflammation  plays a 
crucial  role  in  the  neuropsychological  effects  of  hyperammonemia  in  patients  with 
cirrhosis.
Question  2:  Ammonia  and  inflammation/infection  act  svnergistically  in  the 
pathogenesis of hepatic encephalopathy IChapter 41
Ammonia and inflammation were shown to be synergistic in the bile duct ligated 
(BDL)  rat  which  showed  increased  brain  water  and  astrocyte  swelling  exacerbated  by 
endotoxin  and  accompanied by  a  rise  in  nitric  oxide  and brain  nitrotyrosine,  but  not  in 
plasma  ammonia,  suggesting  nitric  oxide  may  play  an  important  synergistic  role  in  the 
pathogenesis  of  hepatic  encephalopathy.  The  BDL  rats  administered  LPS  showed 
universal  deteriorating  levels  of consciousness  (to  pre-coma  and  coma  stages).  In  the 
BDL/sham  operated  rats  administered  saline  and  the  sham-operated  rats  administered 
LPS,  no  change  in  conscious  level  occurred.  This  is  despite  the  LPS  treated  sham- 
operated rats and saline BDL rats showing some evidence of brain swelling and astrocyte 
oedema.  It is therefore possible that in the BDL rats hyperammonemia in some way acts 
syncrgistically  with  the  systemic  inflammatory  response  to  alter  the  level  of 
consciousness.  This  concept  fits  with  the  observation  in  cirrhotic  patients,  where 
induction  of  hyperammonemia  resulted  in  neuropsychological  deterioration  when  the 
patients  were  infected  and  showed  evidence  of an  inflammatory  response.  Following 
resolution of infection, similarly induced hyperammonemia did not result in an alteration 
in  neuropsychological  function  supporting  the  hypothesis  that  ammonia  and 
inflammation  may  be  synergistic.  Furthermore,  the  suggestion  of  synergy  between
285hyperammonemia and inflammation is supported by the recent observation that BDL rats 
that  were  fed  a  high  ammonia  diet  (and  which  showed  evidence  of a  low  level  of 
inflammation), developed increases in brain water (240).
Question 3: Ammonia impairs neutrophil function IChapters 5 and 61
The data obtained  from the studies  incubating normal  neutrophils with  ammonia 
concentrations  typically  found  in  cirrhotic  patients  showed  that  ammonia  impaired 
neutrophil phagocytosis and induced spontaneous oxidative burst. The p38'N 1A P K  signaling 
pathway  has  been  shown  to  play  an  important  role  in  ammonia-induced  impairment  of 
neutrophil  phagocytosis.  Ammonia  reduced  the  ability  of neutrophils  to  phagocytose, 
possibly  because  the  neutrophil  was  no  longer  able  to  osmoregulate  and  consequently 
swelled;  this  can  be  overcome  by  adding  a  p38'M A P K   agonist.  Inhibition  of p38"M A P K  
however,  also  reduced  the  number  of neutrophils  undergoing  spontaneous  respiratory 
burst which has been shown to increase in the presence of ammonia. Therefore, ammonia 
is  also  likely  to  separately  activate  key  oxidative  enzymes  such  as  myeloperoxidase 
within  90  minutes,  which  have  more  of an  immediate  influence  on  the  spontaneous 
neutrophil respiratory burst rate than p38‘M A P K  activation, which leads to the transcription 
of inflammatory genes e.g. TNF-a maximal at 24 hours (150; 151). It is possible that these 
mechanisms  may,  in  part,  account  for the  increased  susceptibility  to  infection  found  in 
patients with cirrhosis.
286Question 4: An investigation into the influence of inflammation on ammonia uptake
in muscle  (Chapter 7)
By  exploring  how  the  muscle  metabolism  of  ammonia  is  modulated  by 
inflammation,  it  was  hoped  that  potential  mechanisms  might  be  further  elucidated. 
Studies were performed using chick embryo primary muscle cell cultures and  later with 
cultures of a C2C12  murine myoblast cell  line exploring whether ammonia metabolism, 
as  measured  by  stable  amino  acid  isotopes,  could  be  altered  by  the  addition  of  an 
inflammatory  stimulus  such  as  lipopolysaccharide.  Unfortunately,  there  were  severe 
methodological failures in these studies in that the muscle cell cultures had low levels of 
activity of the enzyme glutamine synthetase, essential to the conversion of glutamate and 
ammonia  into  glutamine.  Despite  attempts  to  upregulate  this  enzyme  with 
dexamethasone,  levels  of  the  enzyme  were  insufficient  to  assess  the  metabolism  of 
ammonia  into glutamine  within the muscle cell making  it extremely difficult to explore 
whether ammonia metabolism could be modulated in the presence of inflammation.
In  conclusion,  this  thesis  has  illustrated  I  believe,  the  important  factors  that 
modulate the manifestation of symptoms of hepatic encephalopathy in cirrhosis, the most 
important  of which  is  the  synergistic  role  of inflammation  and  ammonia.  Furthermore, 
the  ammonia-induced  impairment  of neutrophil  function  may,  in  part,  account  for  the 
increased susceptibility to infection found in cirrhotic patients.
287PERSPECTIVES FOR THE FUTURE
This  thesis  has  explored  the  synergistic  relationship  between  ammonia  and 
inflammation  in  the molecular pathogenesis of hepatic  encephalopathy.  The  importance 
of the  role  of ammonia  has  been  previously  highlighted  with  respect  to  both  its  direct 
neurotoxicity  and  on  brain  swelling  through  its  detoxification  to  glutamine  in  the 
astrocyte,  the cell  most often  implicated  in  the pathogenesis of hepatic encephalopathy. 
Therefore,  one  might  say  that  the  key  to  understanding  the  pathogenesis  of  hepatic 
encephalopathy  is  to  explore  the  story  of  the  ‘sick  astrocyte’.  This  thesis  has 
demonstrated  factors  that  are  critical  in  modulating  the  manifest  symptoms  of hepatic 
encephalopathy,  the  most  important  of which  is the  synergistic  role of inflammation  in 
modulating  the  cerebral  effects  of ammonia.  Furthermore,  the  production  of reactive 
oxygen species and  increased protein  tyrosine nitration  may alter astrocyte  function  and 
contribute  or  precipitate  episodes  of hepatic  encephalopathy.  However,  little  is  really 
understood  about  the  underlying  mechanisms  which  control  ammonia  handling  in  the 
brain in an inflammatory milieu.
One aspect of the  findings of this thesis that  is worthy of further attention  is the 
origin of the nitric oxide, shown to be important in mediating the synergistic relationship 
between of ammonia and inflammation. Future studies which could include Western blots 
of homogenized brain tissue would allow the identification of tissue nitric oxide synthase 
isoforms; defining the relative amounts of inducible, endothelial and neuronal nitric oxide 
synthase.  Furthermore,  immunohistochemistry  performed  on  the  sections  obtained  for
288high  resolution  light  microscopy  would  indicate  the  location  of  these  nitric  oxide 
synthases within the brain.
Another avenue  of investigation  should  be  the  study  of the  blood  brain  barrier. 
Although  the  brain  tissue  sections  visualized  under  light  microscopy  arc  highly 
informative  and  clearly  demonstrate  astrocyte  swelling,  it  would  be  even  better  if the 
blood brain barrier could be visualized by electron microscopy in these animal models in 
the  presence  and  absence  of endotoxaemia.  Contact  and  communication  between  the 
neurovascular unit, which  is a dynamic structure consisting of vascular endothelial cells, 
pericytes, and closely juxtaposed astrocytes and neurons, modulates cerebral blood  flow 
and influences the permeability properties of the blood brain barrier. Electron microscopy 
utilizing  intravascular ionic  tracers  such  as  lanthanum  nitrate,  would  allow detection  of 
blood brain barrier integrity to paracellular movement and  would  allow  visualization  of 
the  tight junctions  which  may  allow  the  study  of the  effect  of hyperammonemia  and 
inflammation on the tight junction proteins such as claudin and occludin.
Finally, perhaps a really novel study to undertake would be to investigate the role 
of p38'M A P K  in ammonia-induced astrocyte swelling. p38'M A P K  has already been shown to 
be  important  in  glutamine-induced  hepatocyte  swelling  and  these  Findings  have  been 
mirrored in the neutrophil which has been shown to swell following ammonia incubation, 
an  observation  which  is  prevented  by  a  specific  p38‘M A P K  agonist  isoproterenol.  Novel 
strategies  such  as  utilising  p38 M A F K   agonists  in  therapies  for  hepatic  encephalopathy 
might also be explored in the future.
We have so far only uncovered the tip of the iceberg in terms of understanding the 
operative mechanisms involved in the pathogenesis of hepatic encephalopathy but I  very
289much  look  forward to seeing this exciting area of research  move  forward  over the next 
few years.
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